Clinical trial NCT04832971
Conditions: Mixed Dyslipidemia
Sponsor: Arrowhead Pharmaceuticals
Start date: 2021-06-28; Completion date: 2024-09-25
Enrollment: 204 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.

Detailed description:

Arms: arm 1: Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. arm 2: Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. arm 3: Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. arm 4: Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Interventions: intervention 1: ARO-ANG3 intervention 2: Placebo
Intervention descriptions: intervention 1: ARO-ANG3 Injection intervention 2: Sterile Normal Saline (0.9% NaCl)

Protocol documents:
Prot_000.pdf: 
 
 
 
 
 
 
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and 
Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia 
Protocol Number: AROANG3-2001 
Original Protocol: 07JAN2021 
Protocol Amendment 1: 12 MAR 2021 
Protocol Amendment 2: 11 NOV 2021 
Protocol Amendment 3: 22 NOV 2022 
 
Product Number: 
ARO-ANG3 
Indication: 
Mixed Dyslipidemia 
IND Number:  
151756 
EudraCT Number: 
To be determined 
Sponsor:  
Arrowhead Pharmaceuticals, Inc. 
177 East Colorado Boulevard, Suite 700 
Pasadena, CA 91105 
USA 
Sponsor’s Responsible Medical 
Monitor: 
Arrowhead Pharmaceuticals, Inc. 
177 East Colorado Boulevard, Suite 700 
Pasadena, CA 91105 
This study will be performed in compliance with the protocol, the principles of Good Clinical 
Practices (GCP), and all applicable regulatory requirements and guidelines. 
 
 
 
 
 
 
 
 
Confidentiality Statement: Information contained in this protocol should not be disclosed, other 
than to those directly involved in the execution or ethical review of the study, without written 
authorization from Arrowhead Pharmaceuticals, Inc. It is, however, permissible to provide 
information to a participant to obtain consent. 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 2 of 85 
1 
PROTOCOL SYNOPSIS 
TITLE OF STUDY:  
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of 
ARO-ANG3 in Adults With Mixed Dyslipidemia  
PROTOCOL NUMBER:  
AROANG3-2001     
PHASE OF DEVELOPMENT: 
Phase 2b 
STUDY SITES:    
Approximately 25 sites globally 
STUDY TREATMENTS:  
There will be 2 study treatments: 1 active (Test Formulation) and 1 placebo (Reference 
Formulation).  
Test Formulation: 
The Test Formulation is active ARO-ANG3 Injection (also referred to as ARO-ANG3). The active 
pharmaceutical ingredient contained in ARO-ANG3 is a synthetic, double-stranded, small 
interfering ribonucleic acid (siRNA) duplex conjugated to an N-acetyl-galactosamine-targeting 
ligand to facilitate hepatocyte delivery. 
Reference Formulation:  
The Reference Formulation is placebo: normal saline (0.9%) administered subcutaneously (SC), 
volume-matched to the corresponding ARO-ANG3 dose volume. 
Doses and Number of Doses per Treatment:  
Three dose levels of ARO-ANG3 will be evaluated against placebo in participants with mixed 
dyslipidemia, who had low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (1.8 mmol/L) OR 
non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (2.59 mmol/L) AND mean 
fasting triglycerides (TG) ≥ 150 mg/dL (≥ 1.69 mmol/L) but < 499 mg/dL (5.61 mmol/L) at 
Screening.  
A total of approximately 180 participants will be enrolled in the study. All dose cohorts will enroll 
in parallel with 60 participants per cohort randomly assigned in a 3:1 ratio to receive ARO-ANG3 
or placebo. During the Double Blind Treatment Period, each participant will receive SC injection 
on Day 1 and Week 12 for a total of 2 injections as follows: 
• 
ARO-ANG3 50 mg (n=45) or volume-matched placebo (n=15) at Day 1 and Week 12;  or 
• 
ARO-ANG3 100 mg (n=45) or volume-matched placebo (n=15) at Day 1 and Week 12; or 
• 
ARO-ANG3 200 mg (n=45) or volume-matched placebo (n=15) at Day 1 and Week 12. 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 3 of 85 
After completing the Week 36 Visit in the Double Blind Treatment Period, participants may opt to 
continue receiving ARO-ANG3 in the 24-month Open-Label Extension (OLE) Treatment Period.  
Participants in the OLE Treatment Period will be dosed quarterly (Q3M) and except for subjects in 
the 200 mg dose group, all others will be assigned to receive the same dose level to which they 
were randomized in the Double Blind Treatment Period.  Participants in the 200 mg dose group 
who are entering OLE and those previously assigned to the 200 mg dose group in the OLE period 
will be transitioned to the 100 mg dose group at the next dosing visit. Once a single dose has been 
selected by the Sponsor, all participants will be transitioned to the selected dose level. 
STUDY OBJECTIVE:  
The primary objective of the study is to evaluate the safety and efficacy of ARO-ANG3 in adults 
with mixed dyslipidemia and to select a dosing regimen for later stage clinical studies in this 
patient population.  This study will also evaluate the efficacy, safety, and tolerability of long-term 
dosing of ARO-ANG3 in a 24-month OLE Treatment Period following the Double Blind 
Treatment Period. 
STUDY DESIGN: 
This is a randomized, double-blind, placebo-controlled, Phase 2b clinical study with an OLE 
Treatment Period. After informed consent and at least 2 weeks on a stable diet, at least 4 weeks on 
a stable optimal statin regimen (unless the participant is confirmed to be statin intolerant, refer to 
Section 8.4) and confirmation of stable background medications, the participant will be assessed 
for eligibility. Participants who have met all the protocol eligibility criteria during Screening will 
be randomly assigned to treatment in a double-blind fashion in a 3:1 ratio to receive 1 of 3 
ARO-ANG3 dosing regimens (50, 100, or 200 mg) or matched placebo (see Study Schema). 
During the Double-Blind Treatment Period, each participant will receive a total of 2 SC injections: 
1 on Day 1 and 1 at Week 12. All dose cohorts will enroll in parallel. Enrolled participants will be 
counseled to remain on stable background medications and on the specified diet throughout the 
study, as recommended by the Investigator in accordance with local standard of care. The specifics 
of the diet will be at the discretion of the Investigator based on each individual’s diagnosis and 
medical needs. 
Blinding will be preserved to the extent possible; however, investigational product (IP) unblinding 
may occur, at the Investigator’s or Medical Monitor’s discretion, where deemed necessary for 
treatment of an adverse event (AE), for a safety-related decision, or a decision to be made 
regarding study continuation in an individual participant.  
After completing the 36-week Double-Blind Treatment Period, participants will be eligible and 
invited to continue in the 24-month OLE Treatment Period to evaluate the efficacy, safety, and 
tolerability of long-term dosing of ARO-ANG3 in participants with mixed dyslipidemia.  
Participants assigned to the 50 and 100 mg dose cohorts in the Double Blind treatment period will 
continue to receive ARO-ANG3 at the same dose level in the OLE Treatment Period. The 
ARO-ANG3 200 mg dose cohort will be discontinued from the AROANG3-2001 open-label 
treatment period. Participants currently assigned to the 200 mg dose group will be transitioned to 
the 100 mg dose group at the next dosing visit.  Participants in the OLE Treatment Period will be 
dosed quarterly (Q3M) at their assigned dose until a single dose has been selected by the Sponsor. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 4 of 85 
Study Schema 
 
 
Abbreviations: N = number of participants; W = week 
 
Abbreviations: N = number of participants; Q3M = every 3 months. 
*The 200 mg ARO-ANG3 dose will be discontinued in the OLE period; all participants originally receiving 
the 200 mg dose or volume-matched placebo control in the 36-Week Blinded Treatment period will be 
assigned to 100 mg dose. 
0
Month
ARO-ANG3 100 mg Q3M (N=120)*
End of Study
Matching Placebo
(N=15)
24
ARO-ANG3 200 mg
(N=45)
Matching Placebo
(N=15)
ARO-ANG3 100 mg
(N=45)
AROANG3-2001
36-Week Blinded
Treatment Period
AROANG3-2001
24-Month Open-Label Extension Period
[OLE Period]
ARO-ANG3 selected dose Q3M (N=180)
Selection of Single ARO-ANG3 Dose
Rollover to
OLE Period
ARO-ANG3 50 mg Q3M (N=60)
Matching Placebo
(N=15)
ARO-ANG3 50 mg
(N=45)


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 5 of 85 
Adverse Event Monitoring 
Safety assessments will include AEs and serious AEs (SAEs), physical examinations, vital sign 
measurements (blood pressure, heart rate, temperature, and respiratory rate), electrocardiograms 
(ECGs), clinical laboratory tests, concomitant medications/therapy, and reasons for IP 
discontinuation. Safety assessments will be performed at specified time points and up to study 
completion.  
The AE/SAE reporting period for an enrolled participant begins when the participant provides 
informed consent. Treatment-emergent AEs (TEAEs) and SAEs are defined as those that occur 
following IP administration or are a pre-existing condition exacerbated by IP. The TEAE reporting 
period begins after the first dose and extends until the End-of-Study visit is complete. All SAEs 
that occur during the reporting period, in addition to reporting via electronic case report forms 
(eCRFs), must also be reported to the Sponsor via the SAE report form within 24 hours of being 
notified. All AEs/SAEs will be followed until resolution, until the condition stabilizes, until the 
event causality is otherwise explained, or until the participant is lost to follow-up. If the 
Investigator learns of any SAE, including a death, at any time after a participant has been 
discharged from the study, and he/she considers the event reasonably related to the IP, the 
Investigator will promptly notify the Sponsor. Laboratory or diagnostic assessment (eg, ECG) 
abnormalities will be reported as AEs if considered clinically significant (CS) by the Investigator. 
Laboratory or diagnostic assessment abnormalities not reported as AEs are not to be reported as CS 
in the study database. 
TREATMENT STOPPING RULES:  
A decision to pause/suspend dosing in an individual participant may be indicated based on any of 
the following:  
• 
Any confirmed pregnancy in the study will lead to permanent discontinuation of IP 
dosing of that participant; or 
• 
A need for apheresis or other emergent interventions indicated to lower TG; or 
• 
In participants with normal (per central laboratory reference range) aspartate 
aminotransaminase (AST) or alanine aminotransferase (ALT) on Day 1, treatment-
emergent elevations >3× upper limit of normal (ULN) at least possibly related to IP 
per study Investigator, must be confirmed by repeat blood draw within 72 hours of 
initial results. Refer to Appendix 1 for specific guidelines regarding treatment 
discontinuation or interruption for participants with any of the below findings:  
o 
AST or ALT >5× ULN will lead to permanent discontinuation of IP dosing of that 
participant per Appendix 1.  The participant will remain on study follow-up visits 
until EOS as per the Schedule of Assessments (SOA) (refer to Table 1 and Table 
2). 
o AST or ALT  >3× ULN with a total bilirubin >2× ULN 
o AST or ALT >3× ULN with the new appearance of fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever, rash, or eosinophilia (>5%) 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 6 of 85 
o AST or ALT >3× ULN with a treatment-emergent international normalized ratio 
(INR) >1.5 (must be confirmed on repeat) and which is not explained by another 
plausible cause. 
• 
Some participants enrolling into this study may have baseline elevations in 
transaminases.  In participants with elevated (per central laboratory reference range) 
AST or ALT on Day 1, treatment-emergent elevations >2× baseline or ≥300 U/L 
(whichever occurs first) at least possibly related to IP per study Investigator, as 
specified below, must be confirmed by repeat blood draw within 72 hours of initial 
results.  Refer to Appendix 1 for specific guidelines regarding treatment 
discontinuation or interruption for participants with any of the below findings: 
o AST or ALT >3× baseline or ≥300 U/L (whichever occurs first)  
o AST or ALT >2× baseline or ≥300 U/L (whichever occurs first) with the new 
appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, 
fever, rash, or eosinophilia (>5%) 
o AST or ALT >2×baseline or ≥300 U/L with a total bilirubin >2× ULN 
o AST or ALT >2× baseline or ≥300 U/L or with a treatment-emergent INR >1.5 
(must be confirmed on repeat) and which is not explained by another plausible 
cause. 
Treatment modification guidelines for participants with elevated AST or ALT are provided in 
Appendix 1. 
STUDY DRUG DISCONTINUATION CRITERIA FOR INCREASED HbA1c 
• 
Participants should discontinue IP if they meet the following criteria (Appendix 3): 
o HbA1c measurement >10% (or >86 mmol/mol International Federation of Clinical 
Chemistry [IFCC] units) at the last visit prior to the next dose; or  
o An increase from baseline HbA1c >2% (or >17 mmol/mol IFCC units) at the last 
visit prior to the next dose; or  
o For participants with a baseline HbA1c >7.5% (or >58 mmol/mol IFCC units), an 
increase in HbA1c from baseline >1% (or >8.6 mmol/mol IFCC units) at repeat 
study visits with the last one being the visit prior to the next dose. 
Participants who discontinue IP due to the above criteria will be followed for 6 months 
after their last dose per the Schedule of Assessments. 
The Sponsor or Investigator can discontinue any participant at any time.  
DATA SAFETY COMMITTEE: 
An independent Data Safety Committee (DSC) will review safety data after half of the total 
number of participants planned for enrollment have received at least 1 dose of IP. The DSC 
meetings may also occur on an ad hoc basis to review safety data and to make recommendations 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 7 of 85 
related to the study if needed. Details of DSC structure, processes, and possible actions are 
provided in the DSC charter. 
The DSC may recommend to the Sponsor to pause additional dosing in the study to allow for time 
to evaluate safety data and recommend the action to be taken.  
STUDY DURATION (PLANNED):  
The duration of the Double-Blind Treatment Period is approximately 42 weeks (10.5 months) from 
Screening to the Week 36 examination.  
The Screening period will last up to approximately 6 weeks (Day -42 through Day -1). Lipid values 
assessed during the Screening period for eligibility and throughout the study will be collected from 
participants in a fasted state.  
After completing the Week 36 Visit in the Double-Blind Treatment Period, participants may opt to 
continue receiving ARO-ANG3 in the 24-month OLE Treatment Period.  Therefore, the total 
duration of the study is approximately 35 months. 
All placebo participants who opt to continue in the OLE Treatment Period will initially receive 
ARO-ANG3. The ARO-ANG3 200 mg dose cohort will be discontinued from the AROANG3-
2001 open-label treatment period. Participants who were previously assigned ARO-ANG3 50 mg, 
100 mg, or placebo in the Double-Blind Treatment Period, will receive ARO-ANG3 at the 
corresponding dose level in the OLE Treatment Period. Subjects previously assigned to the 200 mg 
dose group will be transitioned to the 100 mg dose group at the next dosing visit. After the last 
subject in the Double Blind Treatment Period completes the Week 36 Visit and a final dose has 
been selected by the Sponsor, all subjects in the OLE Treatment Period will be transitioned to 
receive ARO-ANG3 at the selected dose for the remainder of their duration in the OLE Treatment 
Period. 
STUDY POPULATION / NUMBER OF PARTICIPANTS PLANNED:  
This study will be conducted in adults with mixed dyslipidemia (LDL-C ≥ 70 mg/dL [1.8 mmol/L] 
OR non-HDL-C ≥ 100 mg/dL [2.59 mmol/L], after at least 4 weeks of stable optimal statin 
therapy, AND mean fasting TG ≥ 150 mg/dL [≥ 1.69 mmol/L] but < 499 mg/dL [5.61 mmol/L] at 
Screening). A total of approximately 180 participants will be enrolled in the study.  
STUDY ELIGIBILITY: 
Inclusion Criteria:  
To be eligible for enrollment, participants must meet all the following inclusion criteria: 
1. Males or nonpregnant (who do not plan to become pregnant), nonlactating females 
≥ 18 years of age; 
2. Based on medical history, prior evidence of TG ≥ 150 mg/dL (≥ 1.69 mmol/L) but 
< 499 mg/dL (5.61 mmol/L );  
3. Fasting levels at Screening of LDL-C ≥ 70 mg/dL (1.8 mmol/L) OR non-HDL-C 
≥ 100 mg/dL (2.59 mmol/L) after at least 4 weeks of stable diet and stable optimal statin 
therapy (unless documented as statin intolerant per Section 8.4); 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 8 of 85 
4. A mean fasting TG level of ≥ 150 mg/dL (≥ 1.69 mmol/L) and <499 mg/dL (5.61 mmol/L) 
collected at two separate and consecutive visits and at least 7 days apart and no more 17 
days apart during the Screening period; 
5. Able and willing to provide written informed consent prior to the performance of any study 
specific procedures;  
6. Willing to follow diet counseling and maintain a stable diet as per Investigator judgment 
based on local standard of care;  
7. Participants of childbearing potential must agree to use highly-effective contraception, 
during the study and for at least 24 weeks from last dose of IP. Males must not donate 
sperm during the study and for at least 24 weeks following the last dose of IP; 
8. Women of childbearing potential on hormonal contraceptives must be stable on the 
medication for >2 menstrual cycles prior to Day 1; 
9. Participants must be on at least 4 weeks of stable optimal statin therapy (unless statin 
intolerant as per Section 8.4). Participants taking any of the following medications must be 
on a stable regimen for the specified duration prior to collection of Screening visit (S2) 
laboratory tests and for the duration of study participation.   
Medication 
Time on stable regimen prior to collection 
of Screening visit (S2) laboratory tests  
Lipid lowering therapies (including statins) 
≥ 4 weeks 
Beta-blockers, thiazide diuretics 
 ≥ 4 weeks 
Fibrates 
≥ 6 weeks 
PCSK9 inhibitors 
≥ 8 weeks 
Retinoids 
≥ 8 weeks 
Atypical antipsychotics  
≥ 12 weeks 
Diabetes mellitus medications 
≥ 12 weeks 
Anticoagulation therapy 
≥ 12 weeks 
Thyroid hormone replacement therapy 
≥ 12 weeks 
Testosterone replacement therapy 
≥ 16 weeks 
Oral estrogens, tamoxifen, raloxifene 
≥ 16 weeks 
Immunosuppressants 
≥ 24 weeks 
NOTE: All laboratory tests used as inclusion criteria will be assessed by a central laboratory 
and may be repeated once and the repeat value may be used for inclusion purposes. Local 
laboratory testing may be permitted in limited circumstances and only with prior Sponsor 
approval. 
Exclusion Criteria:  
1. Current use or use within the last 365 days from Day 1 of any hepatocyte targeted siRNA 
or antisense oligonucleotide molecule; 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 9 of 85 
2. Active pancreatitis within 12 weeks prior to Day 1; 
3. Any planned bariatric surgery or similar procedures to induce weight loss during the period 
starting at consent through the end of the study; 
4. History of major surgery within 12 weeks of Day 1 or planned major surgery during the 
study; 
5. Planned coronary intervention (such as stent placement or heart bypass) during the study; 
6. History of acute coronary syndrome event within 24 weeks of Day 1; 
7. New York Heart Association (NYHA) Class II, III, or IV heart failure or last known 
ejection fraction of <30%; 
8. Uncontrolled hypertension (sitting blood pressure > 160/100 mmHg at Screening), 
participant may be re-screened once hypertension is controlled;  
9. History of hemorrhagic stroke within 24 weeks of Day 1; 
10. History of bleeding diathesis or coagulopathy;  
11. Current diagnosis of nephrotic syndrome; 
12. Any of the following laboratory values at Screening: 
a. Hepatic: ALT or AST > 2× ULN at Screening;  
b. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (using the 
Modification of Diet in Renal Disease [MDRD] equation) at Screening;  
c. Glycated hemoglobin (HbA1c) > 9.0% (or > 75 mmol/mol International 
Federation of Clinical Chemistry [IFCC] units) at Screening; 
d. Spot urine protein/spot urine creatinine ratio >3 grams per day; 
e. Clinically significant abnormality in PT, aPTT, or INR; 
13. Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or 
planned use during the study (stable doses of testosterone replacement therapy >16 weeks 
prior to Screening (visit S2) is permitted for a documented history of hypogonadism [low 
testosterone] as verified in subject health records);  
14. Blood donation of 50 to 499 mL within 4 weeks of Screening (visit S2) or of > 499 mL 
within 8 weeks of Screening (visit S2) laboratory collection; 
15. Known history of human immunodeficiency virus infection; 
16. Seropositive (hepatitis B surface antigen [HBsAg] +) for hepatitis B virus (HBV) or 
hepatitis C virus (HCV) (HCV seropositivity requires positive test for antibodies 
confirmed with positive test for HCV RNA); 
17. Clinical evidence of uncontrolled hypothyroidism or hyperthyroidism as per Investigator’s 
judgment; 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 10 of 85 
18. History of malignancy within the last 2 years prior to the date of consent requiring 
systemic treatment except for adequately treated basal cell carcinoma, squamous cell skin 
cancer, superficial bladder tumors, or in situ cervical cancer. Currently receiving systemic 
cancer treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer; 
19. Use of an investigational agent or device within 30 days or within 5 half-lives, based on 
plasma pharmacokinetics (PK) (whichever is longer) prior to Day 1 or current participation 
in an interventional investigational study. Participants previously exposed to ARO-ANG3 
or ARO-APOC3 will require a washout period of at least 1 year from last dose; or 
20. Unwilling to limit alcohol consumption to within moderate limits for the duration of the 
study, as follows: not more than 14 units per week (1 unit = 80 mL of wine, 200 mL of 
beer, or 25 mL of 40% alcohol); 
21. Any concomitant medical, psychiatric condition, social situation, or any other situation 
that, in the Investigator’s judgment, would make it difficult to comply with protocol 
requirements or put the participant at additional safety risk. 
All laboratory tests used as exclusion criteria may be repeated once and the repeat value may be 
used for exclusion purposes. 
A participant will be excluded from the OLE Treatment Period of the study if any new 
conditions or worsening of any existing condition (eg, renal, hematologic, gastrointestinal, 
endocrine, cardiovascular, pulmonary, immunologic, psychiatric) or any other situation 
that, in the Investigator’s judgment, would make the subject unsuitable for enrollment, or 
which could otherwise interfere with the subject participating in or completing the study, 
or would make it difficult to comply with protocol requirements or put the participant at 
additional safety risk. 
ENDPOINTS:  
Primary Endpoint:  
The primary endpoint of the study is: 
• 
Percent change from baseline at Week 24 in fasting TG. 
Secondary Endpoints:  
The following secondary endpoints will be evaluated during 36-week double-blind study period: 
• 
Percent change from baseline in fasting TG over time through Week 36; 
• 
Percent change from baseline at Week 24 and over time through Week 36 in fasting 
non--HDL-C; 
• 
Percent change from baseline at Week 24 and over time through Week 36 in fasting total 
apolipoprotein (Apo) B; 
• 
Percent change from baseline at Week 24 and over time through Week 36 in fasting 
LDL--C using ultracentrifugation;  
• 
Percent change from baseline at Week 24 and over time through Week 36 in angiopoietin-
like protein 3 (ANGPTL3); 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 11 of 85 
• 
Percent change from baseline at Week 24 and over time through Week 36 in fasting HDL-
C; 
• 
Plasma concentrations of ARO-ANG3 over time through Week 12; and 
• 
The frequency and severity of AEs and SAEs at Week 24 and over time through Week 36. 
The following secondary endpoints will be evaluated in the OLE Treatment Period: 
• 
Percent change from baseline in fasting TG, non-HDLC, total apolipoprotein (Apo) B, 
LDL-C using ultracentrifugation, ANGPTL3, HDL-C, and plasma ARO-ANG3 at all 
visits as described in Table 2 (SOA). 
• 
The frequency and severity of AEs and SAEs through Month 24. 
 
Exploratory Endpoints:  
The following exploratory endpoints will be evaluated in this study: 
• 
Change from baseline over time during double-blind study period as well as over time 
during the OLE Treatment Period in other fasting lipid parameters (total cholesterol, 
LDL/HDL ratio, very low-density lipoprotein-cholesterol [VLDL-C], ApoB-48, 
lipoprotein [LP]a, ApoB-100, ApoC-III, ApoC-II, ApoA-I, ApoA-V, and ApoA-1) 
• 
Change from baseline to Week 24 and over time through Week 36 during double-blind 
study period as well over time in the OLE Treatment Period in fasting serum blood 
glucose, HbA1c, homeostatic model assessment for insulin resistance (HOMA-IR) and 
C- peptide  
• 
Proportion of participants requiring emergent apheresis over time during double-blind 
study period as well as during the OLE Treatment Period 
• 
Change from baseline to Week 24 in liver fat content using magnetic resonance imaging-
proton density fat fraction (MRI-PDFF; only in participants with a liver fat fraction of 
≥ 8% at Screening); and 
• 
Emergence of and levels of anti-drug antibodies to ARO-ANG3 in those receiving 
AROANG3 over time during double-blind study period as well as over time during the 
OLE Treatment Period. 
 
DATA ANALYSIS / STATISTICAL METHODS: 
Statistical Considerations:  
With a total of 180 participants randomly assigned in a 3:1 (active to placebo) ratio within each 
dosing cohort, the study will have greater than 98% power to detect at least 1 active dose cohort 
which is significantly different from placebo, and at least 95% power to detect all active dose 
cohorts which are significantly different from placebo using a two-sided test, with 5% level of 
significance, adjusted for multiplicity. These estimates are based on the assumption of 35% to 60% 
reduction from baseline in fasting TG in the 3 active dose cohorts and no change in fasting TG in 
the pooled placebo cohort. The standard deviation (SD) is assumed to be 65% in the pooled 
placebo cohort and 35% to 55% in the active treatment cohorts.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 12 of 85 
Efficacy and Pharmacodynamics Analysis:  
The primary endpoint will be evaluated using mixed model repeated measures approach with a 
minimum model terms included for treatment group, baseline value, visit, and stratification factors. 
The primary analysis will be performed will evaluate the difference in means between each ARO-
ANG3 dose group and pooled placebo groups in all randomized participants who receive at least 1 
dose of IP (Full Analysis Set). The primary estimand of interest is the difference in means of 
percent change from baseline in fasting TG at Week 24 during double-blind study period in adult 
Mixed Dyslipidemia population (as defined by the inclusion/exclusion criteria), regardless of 
treatment compliance or other intercurrent events postbaseline. When performing the primary 
analysis, the adjustment for multiplicity of testing several arms versus placebo will be carried out 
using Holm’s step-down procedure. 
All continuous secondary endpoints of double-blind study period will be analyzed in a similar 
manner to the primary endpoint, unless otherwise noted.  
Data will be summarized as applicable for the following: Serum ANGPTL3, ratio of 
LDL-C/HDL-C, ApoC-III, ApoC-II, LDL-C, total cholesterol, non-HDL-C, HDL-C, VLDL-C, 
LP(a), TG, ApoB-48, ApoB-100, total ApoB, ApoA-I, ApoA-V, HbA1c, C-peptide, HOMA-IR, 
changes in serum insulin, and changes in serum glucose.  
For primary endpoint (TG) analysis at Week 24 during double-blind study period, the laboratory 
value for endpoint analysis will be the arithmetic mean of 2 values taken during Week 24. If only 1 
value is available during Week 24, then this value will be used for endpoint analysis. For data 
analysis purposes, baseline will be defined as the arithmetic mean of Day 1 predose assessment and 
two fasting assessments during screening period. For other efficacy endpoints, only Day 1 predose 
assessment will be used as the baseline. 
After the last subject in the Double Blind Treatment Period completes the Week 36 Visit, an 
interim analysis will be conducted to review the efficacy and safety data in order to select a single 
dose level for all subjects in OLE Treatment Period and for the remainder of their participation in 
the trial. 
For efficacy variables during open-label treatment period, the measurements and changes and/or 
percent changes from baseline over time will be summarized descriptively.  
Descriptive statistics of biomarker changes will include mean, median SD, minimum, and 
maximum. Additional details will be provided in the statistical analysis plan.  
Tolerability and Safety Data:  
In general, safety analyses will be performed and the results summarized by dose cohort. 
Post-treatment safety assessments will be compared with measurements recorded at baseline. 
Treatment emergent AEs will be summarized using the latest version of the Medical Dictionary for 
Regulatory Activities (MedDRA) by System Organ Class (SOC) and Preferred Term (PT). The 
incidence and frequency of AEs, SAEs, related AEs, related SAEs, and AEs leading to 
discontinuation, will be summarized by dose cohort per SOC, PT, and severity. All AEs will also 
be presented in listings. The duration of AEs will be determined and included in listings, along 
with the action taken and outcome. The incidence of laboratory abnormalities will be assessed 
using descriptive summary statistics and shift tables. Vital sign measurements will be summarized 
at each scheduled time point using descriptive statistics. Abnormal physical examination findings 
will be summarized by time point and presented in participant listings. ECG parameters, changes 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022   
 
Confidential 
Page 13 of 85 
from baseline, and qualitative assessments will be summarized. Pregnancy and follicle-stimulating 
hormone (FSH) test results will be listed separately by time point.  
All safety and tolerability analyses will be performed using the Safety Analysis Population, defined 
as all enrolled participants who received at least 1 dose of IP.  
Pharmacokinetics:  
Plasma concentrations of ARO-ANG3 will be measured in all participants to evaluate trough and 
postdose levels throughout the study per the SOA (Table 1).  
Full PK group: In each of the dose cohorts, 16 PK participants (12 active, 4 placebo for 48 total 
participants for PK) will be enrolled at the designated PK sites. Plasma concentrations will be 
measured predose, serially postdose on Day 1 and Week 12, as per the SOA. Only samples 
collected from participants receiving active treatment will be included in the PK analysis.  
Sparse Sample PK group: All participants will provide a predose and postdose PK sample on Day 
1 and Week 12, as per the SOA.  
Immunogenicity (Anti-drug Antibodies): 
Changes from assay negative to positive will be summarized by dose and number of doses 
administered. Descriptive statistics of immunogenicity parameters will include mean, SD, 
minimum, and maximum. 
 
 






 
Protocol Number: AROANG32001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 16 of 85 
8  
At Week 24 and Week 36, whole blood for pharmacodynamic analysis of lipid parameters should be drawn on two separate occasions, separated by 2 – 7 days after a 10 hour 
fast for calculation of primary and secondary endpoints  
9  
The ECGs are to be completed predose, then 30 min (± 10 minutes) and 2 hours (± 30 minutes) postdose. The ECG will be performed prior to any invasive procedures (eg, 
venipuncture).  
10  Selected sites (where MRI-PDFF is available) will perform MRI-PDFF assessments at Screening until up to approximately 35 participants with baseline liver fat fraction ≥ 8% have 
been enrolled in each of the 3 dosing cohorts after which, MRI-PDFF will no longer be included as an evaluation. If a participant terminates prior to the Week 24 visit, an 
unscheduled MRI-PDFF assessment should be performed.  
11  Whole blood for the plasma PK samples will be drawn in 16 participants (12 active and 4 placebo) enrolled at designated PK sites in each of the 50, 100, and 200 mg dose cohorts. 
PK time points are at predose, 0.25, 1, 3, 6, and 24 hours postdose. Recommended time window for PK samples through the 6-hour time point: ± 5 minutes. Recommended time 
window for PK samples at the 24-hour time point: ± 60 minutes (see Section 10.5). If the recommended time window is missed, every attempt should be made to collect this PK 
sample as soon as possible within the same study visit. Only samples collected from participants receiving active treatment will be included in the PK analysis. For postdose samples 
that require next-day collection, participants may return to the clinical facility to have their blood drawn or they may opt to have their PK samples collected through home health. 
12  All other participants (Sparse PK participants) will have PK samples drawn predose and at no less than 15 minutes postdose on dosing days.  
 
 
 
 
 
 
 
 
 
 
 


 
Protocol Number: AROANG32001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 17 of 85 
Table 2  
Open-Label Extension Treatment Period Schedule of Assessments 
Study Visit Assessments 
24-Month Open-Label Extension Treatment Period 
 
 
OLE Months 
 
OLE  
Day 1a 
(< 30 days after 
Week 36 Visit) 
1a,b 
2 a,b 
3 a,b  
6 a,b  
9 a,b  
12 a,b  
15 a,b  
18 a,b  
21 a,b  
24/EOS/ET a 
Verify Subject Consent to OLE Treatment Period  
X 
 
 
 
 
 
 
 
 
 
 
Dietary counseling / maintain diet 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Weight 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs (BP, temperature, respiratory rate, heart rate) 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination (symptom directed) 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Single 12-Lead ECGc 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy test in women of childbearing potential (predose on 
dosing days) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Clinical laboratory tests (predose on dosing day)d 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Fasting Lipid parameters (predose on dosing days)e 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
ARO-ANG3 Administration 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant medications/therapies 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Anti-drug Antibodies 
X 
X 
 
X 
X 
 
X 
 
X 
 
 
Adverse events (including documentation of pancreatitis, abdominal 
pain or events requiring apheresis) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Abbreviations: OLE= Open-label extension; BP = blood pressure; ECG = electrocardiogram 
a Visits occur within  + 5 days until Month 3, then + 14 days 
b Assessments on dosing days are to be completed predose unless otherwise specified. 
c Performed in the semi-supine position after the participant has rested comfortably for 5 minutes.  ECGs will be collected prior to any blood draws. 
d At study visits requiring lipid parameter collection, participants will have fasted for at least 10 hours prior to blood draw. Samples collected on OLE Month 1 and 2 will be analyzed for 
HbA1c only. HbA1c will be evaluated on an ongoing basis against treatment discontinuation criteria. 
e  At study visits requiring lipid parameter collection, participants will have fasted for at least 10 hours prior to blood draw.   


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 18 of 85 
2 
TABLE OF CONTENTS 
1 PROTOCOL SYNOPSIS ....................................................................................................2 
2 TABLE OF CONTENTS ...................................................................................................18 
3 STUDY INFORMATION AND SIGNATURE ................................................................23 
4 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ......................................24 
5 BACKGROUND ...............................................................................................................27 
5.1 Overview of Mixed Dyslipidemia.............................................................................27 
5.2 Overview of ARO-ANG3 Development...................................................................29 
Mechanism of Action of ARO-ANG3 and Therapeutic Rationale ..........................29 
Preclinical Studies ....................................................................................................30 
Clinical Studies ........................................................................................................31 
5.3 Risk Assessment for Participants ..............................................................................31 
5.4 Study Rationale .........................................................................................................32 
5.5 Rationale for Dose and Schedule of Administration ................................................33 
6 STUDY OBJECTIVES ......................................................................................................34 
7 STUDY PLAN ...................................................................................................................34 
7.1 Overall Study and Design Plan .................................................................................34 
Number of Study Sites .............................................................................................37 
Number of Participants .............................................................................................37 
Estimated Study Duration ........................................................................................37 
7.2 Discussion of Study Design, Including Choice of Control Group ............................37 
8 PARTICIPANT SELECTION ...........................................................................................38 
8.1 Inclusion Criteria.......................................................................................................39 
8.2 Exclusion Criteria .....................................................................................................40 
8.3 Participant Withdrawal Criteria ................................................................................42 
8.3.1 Data Safety Committee and Treatment Stopping Rules ...........................................43 
8.4 Restrictions and Concomitant Medications ..............................................................45 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 19 of 85 
8.5 Lipid Monitoring .......................................................................................................46 
9 INVESTIGATION PRODUCT .........................................................................................47 
9.1 Description, Identification, and Dosage ....................................................................47 
9.2 Supply, Preparation, Storage and Labeling of ARO-ANG3 .....................................48 
9.3 Study Drug Handling ................................................................................................48 
9.4 Allocation to Treatment ............................................................................................49 
9.5 Study Formulation Administration ...........................................................................49 
9.6 Accountability of Study Supplies .............................................................................50 
9.7 Retention of Investigational Product Vials ...............................................................51 
9.8 Blinding and Code-Break..........................................................................................51 
10 STUDY METHODS AND PROCEDURES .....................................................................52 
10.1 Overview of Procedures ............................................................................................52 
10.2 Screening Diet Stabilization Period ..........................................................................53 
10.3 Selection and Screening ............................................................................................53 
10.4 On-Study Procedures/Assessments ...........................................................................54 
Efficacy Assessments ...............................................................................................54 
Pharmacokinetic Assessments ..................................................................................55 
General and Safety Assessments ..............................................................................55 
10.5 Timing of Treatments and Procedures ......................................................................58 
10.6 Pregnancy Testing and Contraception Requirements ...............................................59 
11 ADVERSE EVENTS .........................................................................................................59 
11.1 Definitions .................................................................................................................60 
11.2 Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events .........................................................................................................61 
11.3 Timing, Frequency, and Method of Detecting Adverse Events ................................61 
11.4 Recording of Adverse Events ...................................................................................61 
11.5 Evaluating Adverse Events .......................................................................................62 
Severity of Adverse Events ......................................................................................62 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 20 of 85 
Injection Site Reactions ............................................................................................62 
Assessment of Causality ...........................................................................................63 
Follow-up of Adverse Events ...................................................................................64 
11.6 Prompt Reporting of Serious Adverse Events ..........................................................64 
Completion and Transmission of the Serious Adverse Events Reports ...................64 
Pregnancy Reporting ................................................................................................65 
Serious Adverse Event Reports to the IRB/EC ........................................................65 
11.7 Regulatory Requirements for Reporting of Serious Adverse Events .......................65 
11.8 Poststudy Adverse Events .........................................................................................66 
11.9 Serious Adverse Events Related to Study Participation ...........................................66 
12 DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ....................................66 
12.1 Endpoints ..................................................................................................................66 
Primary Endpoint .....................................................................................................66 
Secondary Endpoints ................................................................................................66 
Exploratory Endpoints ..............................................................................................67 
12.2 Analysis Populations .................................................................................................68 
12.3 Sample Size Considerations ......................................................................................68 
12.4 Stratification ..............................................................................................................68 
12.5 Analysis Methods ......................................................................................................68 
Screening Data .........................................................................................................68 
Efficacy and Pharmacodynamics Analysis ..............................................................69 
Pharmacokinetic Analysis ........................................................................................70 
Safety/Tolerability Analysis .....................................................................................70 
Analysis of Immunogenicity (Anti-drug Antibodies) Data ......................................70 
12.6 Data Recording and Quality Control ........................................................................70 
13 STUDY APPROVAL AND CONDUCT ..........................................................................70 
13.1 Regulatory Approval .................................................................................................71 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 21 of 85 
13.2 Institutional Review Board (IRB)/Ethics Committee (EC) Approval ......................71 
13.3 Ethical Considerations ..............................................................................................71 
13.4 Written Informed Consent ........................................................................................71 
13.5 Emergency Contact with Principal Investigator .......................................................72 
13.6 Notification of General Practitioner ..........................................................................72 
13.7 Clinical Laboratory Certification and Reference Ranges .........................................72 
13.8 Protocol Deviations ...................................................................................................72 
13.9 Termination of the Study ..........................................................................................73 
14 STUDY ADMINISTRATION...........................................................................................73 
14.1 Study Monitoring ......................................................................................................73 
14.2 Quality Assurance .....................................................................................................75 
14.3 Records Retention .....................................................................................................75 
15 INFORMATION DISCLOSURE AND INVENTIONS ...................................................76 
15.1 Ownership .................................................................................................................76 
15.2 Confidentiality ..........................................................................................................76 
15.3 Publication ................................................................................................................77 
16 REFERENCES ..................................................................................................................78 
17 APPENDIX 1 .....................................................................................................................81 
18 APPENDIX 2 .....................................................................................................................84 
19 APPENDIX 3 .....................................................................................................................85 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 22 of 85 
List of Tables 
Table 1 36-Week Double-Blind Treatment Period Schedule of Assessments .......................14 
Table 2  Open-Label Extension Treatment Period Schedule of Assessments ........................17 
Table 3 Stable Therapy Regimen at Screening ........................................................................40 
Table 4 Concomitant Medications .........................................................................................46 
Table 5 Investigational Product Description............................................................................48 
Table 6 Injection Number and Volume Per Dose Cohort During Blinded Study Period ......50 
Table 7 Assessment Windows .................................................................................................58 
Table 8: Liver Related Study Modification and Follow-Up Guidelines for Participants .......81 
Table 9: Local Injection Site Reactions (LISRS) ....................................................................84 
 
List of Figures 
Figure 1 siRNA Mechanism of Action ....................................................................................30 
Figure 2 Study Schema ............................................................................................................35 
Figure 3 Study Schema (OLE) ................................................................................................36 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 23 of 85 
3 
STUDY INFORMATION AND SIGNATURE 
Protocol Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy 
and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia  
Protocol Number: AROANG3-2001 
INVESTIGATOR SIGNATURE: 
I have read and understand the information in this protocol and agree to conduct the study 
according to the protocol (participant to any amendments) and in accordance with the principles 
of Good Clinical Practice. I have read and agree to comply with the Investigator obligations 
stated in this protocol. Any changes in procedure will only be made, if necessary, to protect the 
safety, rights, or welfare of participants. I agree to conduct in person or to supervise the study. I 
agree to ensure that all who assist me in the conduct of the study are aware of their obligations. 
 
 
 
 
Signature 
Date 
 
 
Printed Name 
 
 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 24 of 85 
4 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
ACS 
Acute coronary syndrome 
AE 
Adverse event 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase  
ANGPTL3 
Angiopoietin-like protein 3 
Apo(B) 
Apolipoprotein B 
ApoB-48 
Apolipoprotein B 48 
ApoB-100 
Apolipoprotein B 100 
ApoA-I 
Apolipoprotein A-I 
ApoA-V or ApoA5 
Apolipoprotein A-V 
ApoC-II or ApoC2 
Apolipoprotein C-II 
ApoC-III or ANG3 
Apolipoprotein C-III 
ASCVD 
Atherosclerotic cardiovascular disease 
AST 
Aspartate aminotransferase 
ARO 
Arrowhead Pharmaceuticals, Inc 
ARO-ANG3 Injection 
Clinical drug product solution ready for SC injection 
ARO-ANG3 
Short name for ARO-ANG3 Injection 
BMI 
Body mass index 
CECT 
Contrast-enhanced computed tomography 
cGMP 
current Good Manufacturing Practice 
CM 
Chylomicronemia 
COVID 
Coronavirus disease 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
CS 
Clinically significant 
CTCAE 
Common Terminology Criteria for Adverse Events 
DSC  
Data Safety Committee 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Form 
eGFR 
Estimated glomerular filtration rate 
EL 
Endothelial lipase 
EOS 
End-of-Study 
ET 
Early Termination 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 25 of 85 
FAS 
Full Analysis Set 
FCS 
Familial Chylomicronemia Syndrome 
FSH 
Follicle-Stimulating Hormone 
GCP 
Good Clinical Practice 
GGT 
Gamma glutamyl transferase 
GLP 
Good Laboratory Practice 
GPIHBP1 
Glycosylphosphatidylinositol anchored high density lipoprotein binding 
protein 1 
HbA1c 
Glycated hemoglobin 
HbSAg 
Hepatitis B surface antigen 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HDL-C 
High density lipoprotein cholesterol 
HOMA-IR 
Homeostatic model assessment for insulin resistance 
HTG 
Hypertriglyceridemia 
IB 
Investigator’s Brochure 
ICH 
International Council for Harmonisation  
IDL 
Intermediate-density lipoprotein 
IFCC 
International Federation of Clinical Chemistry 
INR 
International normalized ratio 
IP 
Investigational product 
IRB 
Institutional Review Board 
ISR 
Injection Site Reaction 
IWRS 
Interactive Web Response System 
LD 
Lactate dehydrogenase 
LDL-C 
Low density lipoprotein cholesterol 
LDLR 
Low-density lipoprotein receptor 
LIPG 
Endothelial lipase 
LISR 
Local injection-site reactions 
LLN 
Lower limit of normal 
LLOQ 
Lower limit of quantification 
LMF1 
Lipase maturation factor 1 
Lp 
Lipoprotein 
LPL 
Lipoprotein lipase 
MCH 
Mean cell hemoglobin 
MCHC 
Mean cell hemoglobin concentration 
MCM 
Multifactorial chylomicronemia 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 26 of 85 
MCV 
Mean cell volume 
MDRD 
Modification of Diet in Renal Disease  
MedDRA 
Medical Dictionary for Regulatory Activities 
Mixed Dyslipidemia 
Severe hypertriglyceridemia 
MRI 
Magnetic resonance imaging 
MRI-PDFF 
Magnetic resonance imaging-proton density fat fraction 
mRNA 
Messenger ribonucleic acid 
NCEP 
National Cholesterol Education Program 
NOAEL 
No observed adverse effect level 
non-HDL-C 
Non-Low density lipoprotein cholesterol 
NYHA 
New York Heart Association 
OLE 
Open-Label Extension 
OTC 
Over the Counter 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred Term 
Q12W 
Once every 12 weeks 
RISC 
RNA-induced silencing complex 
RNA 
Ribonucleic acid 
RNAi 
RNA interference 
SAE 
Serious adverse event  
SC 
Subcutaneous(ly) 
SD 
Standard deviation 
siRNA 
Short interfering RNA oligonucleotides  
SOA 
Schedule of Assessments 
SOC 
System Organ Class 
TEAE 
Treatment-emergent adverse event 
TG 
Triglyceride(s) 
TSH 
Thyroid stimulating hormone 
TRL 
Triglyceride-rich lipoprotein 
ULN 
Upper Limit of Normal 
US 
United States 
VLDL-C 
Very-low-density lipoprotein-cholesterol 
 
Definition of Terms  
Investigational Product (IP) is defined as, “A pharmaceutical form of an active ingredient or 
placebo being tested or used as a reference in a clinical study, including a product with a 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 27 of 85 
marketing authorization when used or assembled (formulated or packaged) in a way different 
from the approved form, or when used for an unapproved indication, or when used to gain 
further information about an approved use” (from International Council on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH] Harmonised 
Tripartite Guideline E6: Guideline for Good Clinical Practice). 
5 
BACKGROUND 
Patients with mixed dyslipidemia are at high risk of atherosclerotic cardiovascular disease 
(ASCVD), the leading cause of mortality worldwide that is associated with substantial morbidity 
and healthcare costs (Barquera 2015). ASCVD is commonly associated with elevated 
concentrations of low-density lipoprotein cholesterol (LDL-C), but even in the setting of 
adequate LDL-C control, considerable residual cardiovascular disease risk remains 
(Hussain 2020) due to elevated triglycerides (TG) and TG-rich lipoprotein levels (TRLs) 
(Lawler 2017, Chapman 2011, Jorgensen 2013, Nordestgaard 2016). Evidence from a large 
prospective study of over 4,000 patients hospitalized for acute coronary syndrome (ACS) 
(PROVE-IT TIMI 22 study), indicate that the risk of death or recurrent ACS event was reduced 
by 2.3% when TG was lowered 10% during the first month of statin therapy (Miller 2008).  
5.1 
Overview of Mixed Dyslipidemia 
Dyslipidemia is a major risk factor for ASCVD (Kersten 2017). While current standard of care 
including a low-fat and low cholesterol diet, HMG-CoA reductase inhibitors (statins), ezetimibe, 
niacin, and proprotein convertase subtilisin kexin type-9 (PCSK9) inhibitors are effective at 
lowering LDL-C, a large unmet medical need for lipid lowering and risk modifying therapies 
with novel mechanisms of action persists. Despite statin use, and even when achieving LDL-C of 
less than 50 mg/dL there remains a residual risk of developing ASCVD (Giugliano 2017). Such 
residual risk is derived from additional independent risk factors other than LDL-C including 
elevated TG, lipoprotein(a) (Lp[a]), highly atherogenic remnant particles and lipoproteins such 
as apolipoprotein (Apo) C-III. Novel therapeutics designed to target the factors contributing to 
residual risk which could be used in combination with standard of care are needed.  
In the United States (US), 21% (42.0M) of adults have mixed dyslipidemia, defined as the 
presence of high LDL-C combined with at least one other lipid abnormality (ie, high LDL-C 
with either low high-density lipoprotein-cholesterol (HDL-C) and/or high TG). Nearly 6% 
(11.6M) of US adults have all 3 lipid abnormalities (Toth 2012).  
Metabolic syndrome is recognized as a multiplex risk factor for both ASCVD and type 2 
diabetes mellitus. Available evidence from meta-analyses suggests that metabolic syndrome is 
independently associated with ASCVD risk, essentially doubling the risk (Jacobson 2015). 
Although LDL-C has traditionally been the primary target of therapy in previous lipid guidelines 
and in the practice of clinical lipidology, the National Lipid Association Expert Panel’s 
consensus view is that non-HDL-C is a better primary target for modification than LDL-C. 
Non-HDL-C comprises the cholesterol carried by all potentially atherogenic particles, including 
low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), very-low-density 
lipoprotein (VLDL) and VLDL remnants, chylomicron particles and chylomicron remnants, and 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 28 of 85 
Lp (a). Epidemiologic studies have shown that non--HDL-C is a stronger predictor of ASCVD 
morbidity and mortality than LDL-C (Jacobson 2015). 
A meta-analysis demonstrated that among statin-treated patients, on-treatment levels of LDL-C, 
non-HDL-C, and ApoB were each associated with risk of future major cardiovascular events, but 
the strength of this association was greater for non-HDL-C than for LDL-C and ApoB 
(Boekholdt 2012).  
A more recent meta-regression analysis examined the association between the magnitude of non-
HDL-C, LDL-C, and TG lowering and the reduction in major vascular events across studies of 
fibrates, niacin, and marine omega-3 fatty acids, as well as statins as an established reference. 
The authors reported that in randomized controlled studies, TG lowering is associated with a 
lower risk of major vascular events, but to a lesser extent per absolute amount of reduction than 
with LDL. Additionally, they found that a reduction in non-HDL-C, a measure of atherogenic 
LDL and VLDL particles, is strongly associated with a lower risk of major vascular events 
regardless of the lipid-lowering drug class (Marston 2019).  
An emerging therapeutic target with relevance to mixed dyslipidemia (including 
hypercholesterolemia, hypertriglyceridemia) is angiopoietin like protein 3 (ANGPTL3). 
ANGPTL3 has emerged as an important regulator of plasma lipoprotein levels (including 
LDL-C, HDL-C, and VLDL-C) by inhibition of enzymes including lipoprotein lipase (LPL) and 
endothelial lipase (EL). ANGPTL3 is also involved in regulating ApoB particle containing 
synthesis and hepatocyte clearance of LDL-C through mechanisms independent of the 
low-density lipoprotein receptor (LDLR) (Xu 2018). This LDLR-independent feature makes 
ANGPTL3 inhibition interesting for LDLR-deficient hypercholesterolemic patients.  
ANGPTL3 is a primarily hepatocyte-synthesized member of the angiopoietin like family of 
proteins. It is exclusively produced in the liver and can therefore be classified as a true 
hepatokine (Conklin 1999). Serum concentrations in humans average 368 ± 168 ng/mL 
(Robciuc 2010). Its key role is as a regulator of LDL-C, HDL-C, and TG metabolism. 
ANGPTL3 acts with ANGPTL8 to inhibit LPL and is most active after feeding 
(Quagliarini 2012). LPL is responsible for TG hydrolysis in peripheral tissues (eg, adipose tissue, 
muscle). Inactivation of ANGPTL3 in mice reduces plasma TG and free fatty acid levels and 
suppresses atherosclerosis (Graham 2017). ANGPTL3 also inhibits EL-driven HDL-C 
metabolism and inhibits hepatocyte uptake of ApoB-containing lipoproteins (LDL-C and 
VLDL-C) through mechanisms at least partially independent of the LDLR (Xu 2018). Given 
ANGPTL3’s inhibitory role of various lipoproteins and TG, reduced expression and reduced 
circulating levels of ANGPTL3 would be expected to increase clearance of TGs, non-HDL-C, 
LDL-C and HDL-C.  
In humans, homozygous loss-of-function mutations in ANGTPL3 lead to very low or 
undetectable serum ANGPTL3, low plasma levels of LDL-C, HDL-C and TGs, a condition 
referred to as familial combined hypolipidemia (Musunuru 2010). Heterozygous carriers of loss-
of-function mutations in ANGPTL3 have a lower risk of coronary artery disease than non-carriers 
(Dewey 2017, Stitziel 2017). To date no adverse clinical phenotype such as hepatic steatosis, 
obesity or other metabolic derangements have been reported in ANGPTL3 -deficient subjects 
(Dewey 2017). Importantly, the low HDL-C observed in ANGPTL3 deficiency is due to 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 29 of 85 
enhanced EL activity and does not appear to increase risk of cardiovascular disease. The low 
LDL-C, TG, and reduced odds of developing cardiovascular disease seen in ANGPTL3 deficient 
subjects indicate that pharmacologic suppression of ANGPTL3 may hold considerable promise 
for the treatment and secondary prevention of ASCVD.  
ANGPTL3 inhibition may also benefit patients with diseases of intracellular TG accumulation 
with associated insulin resistance which include metabolic syndrome and nonalcoholic fatty liver 
disease/nonalcoholic steatohepatitis. Treatment of wild type mice with hepatic steatosis due to a 
high fat diet experienced and 80% reduction in liver TG when treatment with antisense 
oligonucleotides targeting ANGPTL3 expression (Graham 2017). Hepatic steatosis has been 
proposed as the first in a cascade of ‘hits’ in the development of nonalcoholic steatohepatitis 
(NASH) (Tilg 2010). Intrahepatic targeting of ANGPTL3 may lead to reductions in hepatic fat in 
these subjects, therefore potentially lowering the risk of progression to NASH. Additionally, 
ANGPTL3-deficient homozygotes show lower serum insulin, lower serum glucose and improved 
measures of insulin resistance compared to non-carriers (Robciuc 2010). 
One method of targeting serum ANGPTL3 is with a monoclonal antibody approach. Evaluations 
with evinacumab, targeting circulating ANGPTL3 in healthy volunteers (Dewey 2017) and in 
patients with familial hypercholesterolemia (Gaudet 2017), have confirmed potent reductions in 
LDL-C, HDL-C, and TG. However, an antibody approach would miss intra-hepatocyte 
ANGPTL3 which may be important for improvement of intra-hepatocyte TG accumulation and 
insulin resistance (Graham 2017). 
5.2 
Overview of ARO-ANG3 Development 
A brief overview of existing information on ARO-ANG3 is provided below; a comprehensive 
review of available data is contained in the Investigator’s Brochure (IB) provided by the 
Sponsor, which should be reviewed prior to initiating the study. 
Mechanism of Action of ARO-ANG3 and Therapeutic Rationale 
siRNA Mechanism of Action 
An RNA interference (RNAi)-based therapeutic targeting ANGPTL3 has the potential to treat 
dyslipidemias in a fundamentally different manner than current therapies. RNAi is a 
naturally -occurring phenomenon by which siRNAs trigger a sequence-specific down-
modulation of gene expression. RNAi triggers refer to synthetic siRNAs designed to target 
specific messenger ribonucleic acid (mRNA) expression. By delivering the RNAi trigger 
targeting ANGPTL3 to the liver, it is possible to silence expression of ANGPTL3 mRNA in 
hepatocytes. Since ANGPTL3 is exclusively expressed in hepatocytes, silencing of ANGPTL3 
mRNA is expected to reduce both intrahepatic and plasma ANGPTL3 protein levels. Significant 
reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead 
to the reduction of risk of coronary heart disease and cardiovascular events associated with 
hypertriglyceridemia and LDL-C in patients with persistent dyslipidemia. Targeting ANGPTL3 
may also improve insulin resistance and hepatic steatosis. The RNAi trigger molecule in 
ARO-ANG3 Injection was designed to avoid activity against other human mRNAs, microRNA 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 30 of 85 
and other non-coding RNA and to avoid acting outside of the liver. Thus, ARO-ANG3 is not 
expected to have off-target effects.  
Figure 1 
siRNA Mechanism of Action 
 
Abbreviations: mRNA = messenger ribonucleic acid; RISC = RNA-induced silencing complex; siRNA = short interfering RNA 
oligonucleotides. 
Preclinical Studies 
The Sponsor is conducting a comprehensive preclinical program to support the subcutaneous 
(SC) administration of ARO-ANG3. Studies of potential clinical significance and relevance to 
this protocol are summarized below. 
Proof-of-concept studies in animal models support the use of siRNA against ANGPTL3 as a 
potential treatment of mixed dyslipidemia. Details regarding preclinical pharmacology, 
pharmacokinetics (PK), and toxicology results are provided in the IB. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 31 of 85 
• Preclinical pharmacology of ADS-004, the active pharmaceutical ingredient in 
ARO-ANG3, shows that ADS-004 treatment in transgenic mice (TgANG3) resulted in 
dose-dependent reduction of hepatic ANGPTL3 mRNA levels, which correlated with 
reduced serum ANG3 of > 90%. Reductions in serum ANG3 were associated with 
reductions in serum lipids (maximum mean reduction of 91% in TG, 45% in total 
cholesterol, and 64% in LDL-C).  
• Similar reductions in liver and serum ANGPTL3 were also observed after ADS-004 
doses in a diet-induced dyslipidemic rhesus monkey model. ARO-ANG3 has been well 
tolerated in rats and in non-human primate toxicology studies.  
• Results of non-Good Laboratory Practice (GLP) and GLP short term and chronic 
toxicology studies are reviewed in the IB. 
Clinical Studies 
The Sponsor has initiated a Phase 1 single and multiple dose study to evaluate the safety, 
tolerability, PK, and pharmacodynamic (PD) effect of ARO-ANG3 in adult healthy volunteers 
and patients with dyslipidemia (AROANG1001). Details regarding Phase 1 study results can be 
found in the IB.  
5.3 
Risk Assessment for Participants 
• Embryo-Fetal: Limited GLP toxicology and clinical studies have been conducted. 
Accordingly, eligible participants enrolled in this study, both male and female (including 
partners), must agree to use 2 highly effective forms of contraception during the study, or 
agree to abstinence (acceptable only if this method is in alignment with the normal life 
style of the participant).  
• Liver Function: ARO-ANG3 targets the liver. siRNA literature has described alanine 
aminotransferase (ALT) changes associated with off-target effects of the siRNA seed 
region on microRNAs in the hepatocyte (Janas 2018). The siRNA sequence of the 
ARO-ANG3 sense and antisense molecules have been screened for potential mRNA and 
microRNA homology and sequences with homology were excluded from consideration. 
Thus, no such off-target effects are anticipated. In the AROANG1001 study, transient 
mild to moderate elevations in ALT were occasionally seen (Refer to IB for details) 
without accompanying elevation in international normalized ratio (INR) or total bilirubin. 
To mitigate this risk, the proposed study protocol has built in stopping rules for ALT and 
aspartate aminotransferase (AST) elevation. Blood samples will be drawn frequently to 
evaluate liver injury and liver function. The Data Safety Committee (DSC) will review all 
available safety data including laboratory data periodically.  
• Injection Site Adverse Events (AEs): Other SC administered modified siRNA drug 
candidates evaluated in clinical studies have been associated with mild to moderate 
injection site reactions (eg, pain, erythema). Generally mild and transient injection site 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 32 of 85 
AEs have been reported in the AROANG1001 study (Refer to IB for details). In this 
study, steps will be taken to minimize injection site reactions such as rotating injection 
sites and allowing the ARO-ANG3 solution to come to room temperature prior to 
injection. 
• Glycemic Control:  
An administrative analysis in the ongoing Phase 2 AROANG3-2001 clinical trial 
observed an imbalance in changes in HbA1c over time, with increased HbA1c values 
observed in subjects who had preexisting diabetes at baseline and particularly in a subset 
of subjects in the highest (200 mg) ARO-ANG3 dose group. 
 
To mitigate the risk of worsening glycemic control, investigators will be encouraged to 
evaluate diabetes status and adjust diabetes treatment according to clinical practice and 
diabetes care guidance.  
 
In addition, any subject with worsening diabetic control may return for an unscheduled 
visit for evaluation of HbA1c prior to the next planned dose to confirm continued 
treatment eligibility.  
 
For those subjects who, despite diabetes treatment adjustments, remain with elevated 
HbA1C above the protocol pre-established level, a number of criteria for study drug 
discontinuation have been established (Appendix 3). 
 
Routine monitoring of serum HbA1c and fasting glucose concentrations will be assessed 
as part of the clinical laboratory panels to monitor glycemic control, as specified in the 
SOA (Table 1 and Table 2).  
5.4 
Study Rationale 
Interim results from the Phase 1, First in Human study AROANG1001 show that in healthy 
volunteers and in patients with hypertriglyceridemia, treatment with ARO-ANG3 reduces 
hepatic production of ANGPTL3 via RNAi, leading to reductions in serum TG, non-HDL-C, 
LDL-C, and HDL-C. Thirty-five (35), 100, 200, and 300 mg all demonstrated durable PD 
activity lasting beyond Week 12. Aside from mild and transient injection site reactions and 
transient, self-limited ALT elevations, single and repeat doses of ARO-ANG3 were well 
tolerated in healthy volunteers and the safety profile based on Phase 1 warrants additional later 
stage clinical evaluation. 
Based on these results and given the unique ability of ARO-ANG3 to simultaneously lower both 
TG and LDL-C, this current study will be conducted in adults with mixed dyslipidemia, defined 
as patients who have LDL-C ≥ 70 mg/dL (1.8 mmol/L) OR non-HDL-C ≥ 100 mg/dL 
(2.59 mmol/L) AND a mean fasting TG ≥ 150 mg/dL (≥ 1.69 mmol/L) but < 499 mg/dL 
(5.61 mmol/L). The design is intended to evaluate the effects of 3 different dosing levels of ARO-
ANG3 (50, 100, or 200 mg) with 3 doses administered per dose level, against volume-matched 
placebo in lowering TG levels on top of standard of care lipid-lowering medications and dietary 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 33 of 85 
modifications. In addition, this study will evaluate whether 50, 100, or 200 mg of ARO-ANG3 
improve other lipid parameters (eg, LDL-C, non-HDL-C). Plasma concentrations of ARO-ANG3 
will also be measured over time to evaluate the PK profile. Administration of doses on Day 1 and 
Week 12 with extended follow-up  will allow complete assessment of the drug effect over a long 
duration. This study is expected to inform on dose level and dose interval selection for later stage 
clinical development.  
5.5 
Rationale for Dose and Schedule of Administration 
Rationale for the doses selected comes primarily from the single escalating and multiple 
escalating dose components of the AROANG31001 phase 1 clinical study. The 35, 100, 200, and 
300 mg dose levels were assessed in the Phase 1 study (AROANG1001). Based on efficacy and 
safety data from that study, 
 
, the dose levels of 50, 100, and 200 mg, were selected for use in this Phase 2b study. 
Overall, there was no appreciable difference in the safety profile of the 100 or 200 mg dose 
levels as described in the safety data summary provided in the IB. Furthermore, it is expected 
that the 50 mg dose level would have a safety profile that is comparable to the dose levels 
studied in Phase 1.  
In the Phase 1 study evaluating ARO-ANG3 in healthy volunteers, single doses and multiple 
doses (Days 1 and 29) of 35, 100, 200, or 300 mg consistently reduced serum TG levels through 
Week 12. Reductions in TG of greater than 50% from baseline were maintained for the 200 and 
300 mg doses at Week 12 with single doses. In the multi-dose cohorts, 100, 200, and 300 mg 
doses maintained > 60% reductions in TG through Week 16 (Day 113). A clearer dose response 
is seen with ANGPTL3 with dose-dependent decreases in ANGPTL3 demonstrated with 
increasing single doses. Summary PD data are provided in the IB. All 3 dose levels are active 
and reduce serum ANGPTL3 as well as TGs versus placebo. 
 
 
 
 
 
 
 
 
 
  
The planned dose levels of 50, 100, and 200 mg are approximately 1/30th, 1/10th, and 1/5th, 
respectively, of the no observed adverse effects level (NOAEL) (15 mg/kg) from 4 week/3 dose 
GLP toxicology studies in rat, assuming weight-based conversion and an average 70 kg subject. 
The planned dose levels of 50, 100, and 200 mg are approximately 1/600th, 1/210th, and 1/105th, 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 34 of 85 
respectively, of the NOAEL (300 mg/kg) from 4 week/3 dose GLP toxicology studies in 
monkeys, assuming weight-based conversion and an average 70 kg subject. It should be 
additionally noted that the dose frequency in this proposed study is only once every 12 weeks, 
whereas the dose frequency in chronic toxicology studies (6-month rat and 9-month monkey) 
was every 4 weeks. Therefore, there is a wide margin of safety between planned clinical doses 
and animal toxicology study NOAELs.  
The proposed study design is intended to evaluate the duration of effect after doses of 50, 100 or 
200 mg administered on Day 1 and Week 12 with follow-up through Week 36.  This design will 
inform on optimal dose and duration based on time for ANGPTL3 levels and other lipid 
parameters to return to baseline after the second dose. Details of the analyses used for dose 
selection are provided in the Statistical Analysis Plan.  After completing Week 36, participants 
will be eligible and invited to continue in a 24-month open-label extension (OLE) period during 
which all participants, including those previously assigned to placebo, will switch to 
ARO-ANG3. Participants who were previously assigned ARO-ANG3 50 mg or 100 mg or 
placebo in the 36-week Double Blind Treatment Period, will receive ARO-ANG3 at the 
corresponding dose level in the OLE Treatment Period.  However, participants previously 
assigned to the 200 mg dose group will be transitioned to the 100 mg dose group at the next 
dosing visit in the OLE.  After the last subject in the Double Blind Treatment Period completes 
the Week 36 Visit and a final dose has been selected, all subjects in the OLE Treatment Period 
will be transitioned to receive ARO-ANG3 at the selected dose for the remainder of their 
duration on the OLE. 
 
6 
STUDY OBJECTIVES 
The primary objective of the study is to evaluate the safety and efficacy of ARO-ANG3 in adults 
with mixed dyslipidemia and to select a dosing regimen for later stage clinical studies in this 
patient population. 
Following the 36-week Double-Blind Treatment Period, participants will have the option to 
receive ARO-ANG3 in a 24-month OLE Treatment Period to evaluate the efficacy, safety, and 
tolerability of long-term dosing of AROANG3.  
 
7 
STUDY PLAN 
7.1 
Overall Study and Design Plan 
This is a randomized, double-blind, placebo-controlled, Phase 2b clinical study. Participants who 
have signed an Ethics Committee (EC)/Institutional Review Board (IRB) approved informed 
consent form may initiate screening during which eligibility assessments will be completed. 
Participants must maintain a stable diet and stable lipid-lowering therapy, including statins, and 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 35 of 85 
other relevant background medications, as applicable (see Sections 8.1, 8.4, and 10.2), 
throughout the Screening Period.   
Participants who have met all the protocol eligibility criteria during the Screening Period will be 
randomly assigned to treatment in a double-blind fashion in a 3:1 ratio to receive 1 of 3 
ARO-ANG3 dosing regimens (50, 100, or 200 mg) or matched placebo (Figure 2). Each 
participant will receive a total of 2 SC injections, on Day 1 and Week 12 during the Double 
Blind Treatment Period. All dose cohorts will enroll in parallel.  
Enrolled participants will be counseled to remain on stable background medications and on the 
specified diet throughout the study, as recommended by the Investigator in accordance with local 
standard of care, see the Schedule of Assessments (SOA) (Table 1).  The specifics of the diet 
will be at the discretion of the Investigator based on each individual’s diagnosis and medical 
needs. 
Figure 2 
Study Schema 
 
 
Abbreviations: N = number of participants; W = week 
Blinding will be preserved to the extent possible (or unless otherwise specified); however, 
investigational product (IP) unblinding may occur, at the Investigator’s or medical monitor’s 
discretion, where deemed necessary for treatment of an AE or for a decision to be made 
regarding study continuation in an individual participant. 
Following completion of the Week 36 Visit, eligible participants will be invited to continue in 
the 24-month OLE Treatment Period (Figure 3). The ARO-ANG3 200 mg dose cohort will be 
discontinued from the AROANG3-2001 open-label treatment period. Participants entering the 
OLE period at the 200 mg dose group (placebo or ARO-ANG3) and participants previously 
assigned to the 200 mg dose group in the OLE period will be transitioned to the 100 mg dose 
group at the next dosing visit.  Participants in the OLE will be dosed quarterly and will receive 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 36 of 85 
the same dose level (either 50 mg or 100 mg) to which they were randomized in the Double 
Blind Treatment Period until a single dose has been selected by the Sponsor.  Once a single dose 
has been selected by the Sponsor, all subjects will be transitioned to the selected dose for the 
duration of their participation in the OLE Study Period (Figure 3).  
Figure 3 
Study Schema (OLE) 
Abbreviations: N = number of participants; 3QM = every 3 months. 
*The 200 mg ARO-ANG3 dose will be discontinued; all subjects originally receiving the 200 mg dose or 
volume-matched placebo control in the 36-Week Blinded Treatment period will be assigned to 100 mg dose in the 
OLE period. 
Adverse Event Monitoring 
Safety assessments will include: AEs and serious AEs (SAEs), physical examinations, vital sign 
measurements (blood pressure, heart rate, temperature, and respiratory rate), electrocardiograms 
(ECGs), clinical laboratory tests, concomitant medications/therapy, and reasons for IP 
discontinuation. Safety assessments will be performed at specified time points and up to study 
completion.  
The AE/SAE reporting period for an enrolled participant will begin when the participant 
provides informed consent. Treatment emergent AEs (TEAE) and SAEs are defined as AEs that 
occur following IP administration or a pre-existing condition exacerbated following IP 
administration. The TEAE reporting period begins after the first dose and extends until the 
End-of-Study visit is complete. All SAEs that occur during the reporting period, in addition to 
reporting via electronic case report forms (eCRFs), must also be reported to the Sponsor via the 
SAE report form within 24 hours of being notified. All AEs/SAEs will be followed until 
resolution, until the condition stabilizes, until the event causality is otherwise explained, or until 
0
Month
ARO-ANG3 100 mg Q3M (N=120)*
End of Study
Matching Placebo
(N=15)
24
ARO-ANG3 200 mg
(N=45)
Matching Placebo
(N=15)
ARO-ANG3 100 mg
(N=45)
AROANG3-2001
36-Week Blinded
Treatment Period
AROANG3-2001
24-Month Open-Label Extension Period
[OLE Period]
ARO-ANG3 selected dose Q3M (N=180)
Selection of Single ARO-ANG3 Dose
Rollover to
OLE Period
ARO-ANG3 50 mg Q3M (N=60)
Matching Placebo
(N=15)
ARO-ANG3 50 mg
(N=45)


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 37 of 85 
the participant is lost to follow-up. If the Investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from the study, and he/she considers the event 
reasonably related to the IP, the Investigator will promptly notify the Sponsor. Laboratory or 
diagnostic assessment (eg, ECG) abnormalities will be reported as AEs if considered clinically 
significant (CS) by the Investigator. Laboratory or diagnostic assessment abnormalities not 
reported as AEs are not to be reported as CS in the study database. 
Number of Study Sites 
Approximately 25 centers globally. 
Number of Participants 
Approximately 180 participants.  
Estimated Study Duration 
The total estimated duration of the study, including the Double Blind Treatment Period and the 
OLE Treatment Period is approximately 35 months.  
 
The total duration of the Double Blind Treatment Period is approximately 42 weeks (10.5 
months) from Screening to the Week 36 Visit in the Double Blind Treatment Period.   
The Screening period will last approximately up to 6 weeks (Day -42 through Day -1) consisting 
of dietary stabilization and other required eligibility assessments. Lipid parameter values 
assessed to determine eligibility during the Screening period and throughout the study will be 
collected from participants in a fasted state as specified in the SOA (Table 1 and Table 2). 
After completing the Week 36 visit, participants will be eligible and invited to continue in the 
24-month OLE Treatment period (Table 2) and will receive the dose corresponding to their study 
treatment dose as assigned in the Double Blind Treatment Period. Participants who had 
previously received ARO-ANG3 50 mg or100 mg, or volume-matched placebo, will continue to 
receive the corresponding dose level of ARO-ANG3 in the OLE Treatment Period. However, 
participants previously assigned to the 200 mg dose group (Placebo or ARO-ANG3) will be 
transitioned to the 100 mg dose group at the next dosing visit in the OLE.  After the last 
participant in the Double-Blind Treatment Period completes the Week 36 Visit and a single dose 
has been selected by the Sponsor, all participants in the OLE will receive the selected 
ARO-ANG3 dose Q3M for the remainder of their participation in the study.  
7.2 
Discussion of Study Design, Including Choice of Control Group 
The primary objective of the study is to select 1 dose and dosing regimen for later stage clinical 
studies based on evaluation of the safety and efficacy of 3 doses of ARO-ANG3 in participants 
with mixed dyslipidemia. Patients with mixed dyslipidemia is the key planned patient population 
for later stage clinical studies.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 38 of 85 
Participants confirmed to be on a stable diet, a stable optimal statin regimen (unless documented 
history of statin intolerance as per Section 8.4), and stable background medications, (see 
Sections 8.1, and 10.2) will complete all remaining eligibility assessments within 6 weeks (Day -
42 to Day -1) prior randomization on Day 1 as specified in the SOA (Table 1). The Double Blind 
Treatment Period will begin on Day 1 and will continue for 36 weeks. Dietary counseling will 
commence at the start of the Screening Period and will be reinforced at intervals throughout the 
study. This approach is necessary to minimize the potential effects of dietary changes that can 
alter TG levels and confound interpretation of study results. 
A placebo-controlled design was chosen because it would have been impractical to maintain 
blinding with an active control. Compared with the potent effect of ARO-ANG3 in lowering TG 
levels, other first-line therapies have modest effects on TGs. For example, patients with severe 
hypertriglyceridemia receiving omega-3 fatty acid only had a 33% placebo-adjusted reduction in 
TG (Bays 2011) and patients with mild TG elevations receiving gemfibrozil had a 31% reduction 
in TG (Rubins 1999). Thus, additional TG and lipid lowering effect is expected when 
ARO-ANG3 is used on top of optimal lipid lowering therapy. In this Phase 2 study, stable 
concomitant optimal statin therapy is required for all participants. Concomitant use of other 
prescription or over-the-counter (OTC) lipid management regimens (eg, nicotinic acid/niacin, 
omega-3 fatty acids) will be permitted as long as the participant has maintained a stable regimen 
for the specified timeframe (refer to Section 8.1) prior the collection of Screening lipid parameter 
laboratory tests and will agree to stay on this baseline regimen during the Double Blind 
Treatment Period (refer to Section 8.4).  
The duration of the treatment is intended to ensure adequate exposure to ARO-ANG3 to evaluate 
the safety and efficacy for its long-term use, and to facilitate selection of a lowest effective dose 
to maximally lower TG. The primary analysis will be at Week 24. Additional analysis at various 
time points from Week 24 over time through Week 36 will assess the durability of the treatment 
effect, additional efficacy outcomes, and long-term safety. The OLE study will determine the 
long term safety and efficacy of the study drug.  
 
8 
PARTICIPANT SELECTION 
The proposed participant population is adults with mixed dyslipidemia, defined as LDL-C 
≥ 70 mg/dL (1.8 mmol/L) OR non-HDL-C ≥ 100 mg/dL (2.6 mmol/L), after at least 4 weeks of 
stable optimal statin therapy (unless participant has a documented history of statin intolerance as 
documented in medical records as per Section 8.4), AND mean fasting TG ≥ 150 mg/dL 
(≥ 1.69 mmol/L) but < 499 mg/dL (5.61 mmol/L). Patients with mixed dyslipidemia are at high 
risk of ASCVD, the leading cause of mortality worldwide that is associated with substantial 
morbidity and healthcare costs (Barquera 2015). ASCVD is commonly associated with elevated 
concentrations of LDL-C, but even in the setting of adequate LDL-C control, considerable 
residual cardiovascular disease risk remains (Hussain 2020) due to elevated TG and TRLs 
(Lawler 2017, Chapman 2011, Jorgensen 2013, Nordestgaard 2016). Evidence from a large 
prospective study of over 4,000 patients hospitalized for ACS (PROVE-IT TIMI 22 study), 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 39 of 85 
indicate that the risk of death or recurrent ACS event was reduced by 2.3% when TG was 
lowered 10% during the first month of statin therapy (Miller 2008). To ensure that appropriate 
participants are selected, the inclusion and exclusion criteria are provided in Section 8.1 and 
Section 8.2. 
Information about the study population size is provided in Section 12.3. 
8.1 
Inclusion Criteria 
To be eligible for enrollment, participants must meet all the following inclusion criteria: 
1. Males or non-pregnant (who do not plan to become pregnant), non-lactating females 
≥ 18 years of age; 
2. Based on medical history, prior evidence of TG ≥ 150 mg/dL (1.69 mmol/L) and 
< 499 mg/dL (5.61 mmol/L)  
3. Fasting levels at Screening of LDL-C ≥ 70 mg/dL (> 1.8 mmol/L) OR non-HDL-C 
≥ 100 mg/dL (> 2.6 mmol/L) after at least 4 weeks of stable diet and stable optimal statin therapy 
(unless documented as statin intolerant per Section 8.4); 
4. A mean fasting TG level at Screening of ≥ 150 mg/dL (≥ 1.69 mmol/L) and < 499 mg/dL 
(5.61 mmol/L) collected at two separate and consecutive visits at least 7 days apart and no 
more than 17 days apart during the Screening period; 
5. Able and willing to provide written informed consent prior to the performance of any study 
specific procedures; 
6. Willing to follow diet counseling and maintain a stable diet as per Investigator judgment 
based local standard of care;  
7. Participants of childbearing potential must agree to use highly-effective contraception, during 
the study and for at least 24 weeks from last dose of IP. Males must not donate sperm during 
the study and for at least 24 weeks following the last dose of IP. 
8. Women of childbearing potential on hormonal contraceptives must be stable on the 
medication for >2 menstrual cycles prior to Day 1;  
9. Participants must be on at least 4 weeks of stable optimal statin therapy (unless statin 
intolerant as documented in medical records per section 8.4).  Participants taking any of the 
following medications must be on a stable regimen for the specified duration prior to 
collection of Screening visit (S2) laboratory tests and for the duration of study participation.   


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 40 of 85 
Table 3 Stable Therapy Regimen at Screening 
Medication 
 
Time on stable regimen prior 
to collection of Screening visit 
(S2) laboratory tests 
Lipid lowering therapies (including 
 
≥ 4 weeks 
Beta-blockers, thiazide diuretics 
 
≥ 4 weeks 
Fibrates 
 
≥ 6 weeks 
PCSK9 inhibitors 
 
≥ 8 weeks 
Retinoids 
 
≥ 8 weeks 
Atypical antipsychotics  
 
≥ 12 weeks 
Diabetes mellitus medications 
 
≥ 12 weeks 
Anticoagulation therapy 
 
≥ 12 weeks 
Thyroid hormone replacement 
 
≥ 12 weeks 
Testosterone replacement therapy 
 
≥ 16 weeks 
Oral estrogens, tamoxifen, raloxifene 
 
≥ 16 weeks 
Immunosuppressants 
 
≥ 24 weeks 
NOTE: All laboratory tests used as inclusion criteria will be assessed by a central laboratory 
and may be repeated once and the repeat value may be used for inclusion purposes. Local 
laboratory testing may be permitted in limited circumstances and only with prior Sponsor 
approval (see Table 1). 
 
8.2 
Exclusion Criteria 
Individuals who meet any of the following exclusion criteria will not be eligible to participate in 
the study: 
1. Current use or use within the last 365 days from Day 1 of any hepatocyte targeted siRNA or 
antisense oligonucleotide molecule; 
2. Active pancreatitis within 12 weeks prior to Day 1; 
3. Any planned bariatric surgery or similar procedures to induce weight loss during the period 
starting at consent through the end of the study; 
4. History of major surgery within 12 weeks of Day 1 or planned major surgery during the 
study; 
5. Planned coronary intervention (such as stent placement or heart bypass) during the study. 
6. History of acute coronary syndrome event within 24 weeks of Day 1; 
7. New York Heart Association (NYHA) Class II, III, or IV heart failure or last known ejection 
fraction of < 30%; 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 41 of 85 
8. Uncontrolled hypertension (sitting blood pressure > 160/100 mmHg at Screening), 
participant may be re-screened once hypertension is controlled; 
9. History of hemorrhagic stroke within 24 weeks of  Day 1; 
10. History of bleeding diathesis or coagulopathy; 
11. Current diagnosis of nephrotic syndrome; 
12. Any of the following laboratory values at Screening: 
a. Hepatic: ALT or AST > 2× upper limit of normal (ULN) at Screening ; 
b. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (using the 
Modification of Diet in Renal Disease [MDRD] equation) at Screening, or 
c. Glycated hemoglobin (HbA1c) > 9.0% (or > 75 mmol/mol International Federation of 
Clinical Chemistry [IFCC] units) at Screening; 
d. Spot urine protein/spot urine creatinine ratio > 3 grams per day 
e. Clinically significant abnormality in PT, aPTT or INR; 
13. Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or planned 
use during the study (stable doses of testosterone replacement therapy >16 weeks prior to 
Screening (visit S2) is permitted for a documented history of hypogonadism [low 
testosterone] as verified in subject health records); 
14. Blood donation of 50 to 499 mL within 4 weeks of Screening (visit S2) or of > 499 mL 
within 8 weeks of Screening (visit S2) laboratory collection;  
15. Known history of human immunodeficiency virus infection; 
16. Seropositive (hepatitis B surface antigen [HBsAg] +) for hepatitis B virus (HBV) or hepatitis 
C virus (HCV) (HCV seropositivity requires positive test for antibodies confirmed with 
positive test for HCV RNA); 
17. Clinical evidence of uncontrolled hypothyroidism or hyperthyroidism as per Investigator’s 
judgment; 
18. History of malignancy within the last 2 years prior to the date of consent requiring systemic 
treatment except for adequately treated basal cell carcinoma, squamous cell skin cancer, 
superficial bladder tumors, or in situ cervical cancer. Currently receiving systemic cancer 
treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer; 
19. Use of an investigational agent or device within 30 days or within 5 half-lives, based on 
plasma PK (whichever is longer) prior to Day 1 or current participation in an interventional 
investigational study. Participants previously exposed to ARO-ANG3 will require a washout 
period of at least 1 year from last dose; or 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 42 of 85 
20. Unwilling to limit alcohol consumption to within moderate limits for the duration of the 
study, as follows: not more than 14 units per week (1 unit = 80 mL of wine, 200 mL of beer, 
or 25 mL of 40% alcohol); 
21. Any concomitant medical or psychiatric condition or social situation or any other situation 
that, in the Investigator’s judgment, would make it difficult to comply with protocol 
requirements or put the participant at additional safety risk. 
NOTE: All laboratory tests used as exclusion criteria will be assessed by a central laboratory 
and may be repeated once and the repeat value may be used for inclusion purposes. Local 
laboratory testing may be permitted in limited circumstances and only with prior Sponsor 
approval (see Table 1). 
A participant will be excluded from the OLE Treatment Period of the study if any new 
conditions or worsening of any existing condition (eg, renal, hematologic, gastrointestinal, 
endocrine, cardiovascular, pulmonary, immunologic, psychiatric) or any other situation that, in 
the Investigator’s judgment, would make the subject unsuitable for enrollment, or which could 
otherwise interfere with the subject participating in or completing the study, or would make it 
difficult to comply with protocol requirements or put the participant at additional safety risk; 
8.3 
Participant Withdrawal Criteria 
Participants will be advised that they are free to withdraw from the study at any time for any 
reason or, if necessary, the Investigator, medically trained designee, or Sponsor may withdraw a 
participant from the study, per the following criteria, to protect the participant's health: 
• the need to take medication which may interfere with study measurements; 
• intolerable/unacceptable adverse experiences; 
• major violation of or deviation from study protocol procedures; 
• noncompliance of participant with protocol; 
• participant unwilling to proceed and/or consent is withdrawn; or 
• withdrawal from the study if, in the Investigator’s judgment, it is in the participant’s best 
interest. 
The reasons for withdrawal will be recorded on the eCRF and included in the final clinical study 
report, along with any AEs and any necessary medical treatment.  
If a participant is withdrawn from the study due to significant AE or SAE, the Investigator, or 
medically trained designee, will evaluate the urgency of the event. If the situation warrants, the 
Investigator, or medically trained designee, will take appropriate diagnostic and therapeutic 
measures. If the situation is not an immediate emergency, the Investigator, or medically trained 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 43 of 85 
designee, at the clinical study facility will attempt to contact the Medical Monitor or medically 
qualified designee for consultation. No medical help, diagnosis, or advice will be withheld from 
the participant due to an inability to contact the Medical Monitor. The participant will be 
encouraged to remain available for follow-up medical monitoring. The Sponsor will be notified 
as soon as possible of any participant withdrawals. 
8.3.1 Data Safety Committee and Treatment Stopping Rules 
An independent DSC will be assembled to review safety data after half of the total number of 
participants planned for enrollment have received at least 1 dose of IP. This group may also be 
asked by the study Sponsor to meet on an ad hoc basis to review safety data and make 
recommendations related to the study. Planned safety reviews will include evaluations for 
imbalances between active and placebo groups for AEs and SAEs. The DSC may be asked to 
review safety data at additional unscheduled meetings should a potential safety signal be 
detected. The DSC may also make recommendations to the Sponsor for modifying, stopping, or 
continuing the study as planned. Blinded data will be reviewed initially and if there are any 
concerns or unblinded review is warranted based on blinded review, the DSC may review 
unblinded data in a closed session. Details of DSC structure, processes, and possible actions are 
provided in the DSC charter. 
The DSC may recommend to the Sponsor to pause additional dosing to allow for time to 
evaluate safety data and recommend the action to be taken. The DSC’s recommendation may 
include, but is not limited to, one of the following: 
• The study may continue without modifications  
• The study may continue with modifications 
• The study should be terminated 
• The study should be temporarily suspended 
• Other changes 
Sponsor or Investigator can discontinue any participant at any time.  
A decision to modify the study or pause/suspend dosing in an individual participant, group of 
participants or to halt enrollment temporarily or permanently may be indicated based on any of 
the following:  
• Any confirmed pregnancy in the study will lead to permanent discontinuation of IP 
dosing of that participant.  
• A need for apheresis or other emergent interventions indicated to lower TG; or 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 44 of 85 
• In participants with normal (per central laboratory reference range) aspartate 
aminotransaminase (AST) or alanine aminotransferase (ALT) on Day 1, treatment-
emergent elevations >3× ULN at least possibly related to IP per study Investigator, must 
be confirmed by repeat blood draw within 72 hours of initial results. Refer to Appendix 1 
for specific guidelines regarding treatment discontinuation or interruption for participants 
with any of the below findings:  
o AST or ALT >5× ULN will lead to permanent discontinuation of IP dosing of that 
participant per Appendix 1. The participant will remain on study follow-up visits until 
EOS as per the Schedule of Assessments (SOA) (refer to Table 1 and Table 2). 
o AST or ALT  >3× ULN with a total bilirubin >2× ULN 
o AST or ALT >3× ULN with the new appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, or eosinophilia (>5%) 
o AST or ALT >3× ULN with a treatment-emergent INR >1.5 (must be confirmed on 
repeat) and which is not explained by another plausible cause. 
• Some participants enrolling into this study may have baseline elevations in 
transaminases.  In participants with elevated (per central laboratory reference range) AST 
or ALT on Day 1, treatment-emergent elevations >2× baseline or ≥300 U/L (whichever 
occurs first) at least possibly related to IP per study Investigator, as specified below, must 
be confirmed by repeat blood draw within 72 hours of initial results.  Refer to Appendix 
1 for specific guidelines regarding treatment discontinuation or interruption for 
participants with any of the below findings: 
o AST or ALT >3× baseline or ≥300 U/L (whichever occurs first)  
o AST or ALT >2× baseline or ≥300 U/L (whichever occurs first) with the new appearance 
of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia (>5%) 
o AST or ALT >2×baseline or ≥300 U/L with a total bilirubin >2× ULN 
o AST or ALT >2× baseline or ≥300 U/L or with a treatment-emergent INR >1.5 (must be 
confirmed on repeat) and which is not explained by another plausible cause 
Please see protocol Appendix 1 for treatment modification guidelines in participants 
with elevated AST or ALT. 
Study drug discontinuation criteria for increased HbA1c 
• Participants should discontinue IP if they meet the following criteria (refer to 
Appendix 3): 
o HbA1c measurement >10% (or >86 mmol/mol International Federation of 
Clinical Chemistry [IFCC] units) at the last visit prior to the next dose; or  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 45 of 85 
o An increase from baseline HbA1c >2% (or > 17 mmol/mol IFCC units) at the last 
visit prior to the next dose; or  
o For participants with a baseline HbA1c >7.5% (or >58 mmol/mol IFCC units), an 
increase in HbA1c from baseline >1% (or >8.6 mmol/mol IFCC units) at repeat 
study visits with the last one being the visit prior to the next dose. 
Participants who discontinue IP due to the above criteria will be followed for 6 months 
after their last dose per the Schedule of Assessments. 
8.4 
Restrictions and Concomitant Medications 
1. Fasting: On the day of dosing or on other days with blood draws for lipid parameter 
measurement, participants will have fasted from food for at least 10 hours prior to IP 
administration or blood draw unless otherwise specified. 
2. Recreational Drugs & Alcohol: Participants will be instructed to abstain from consuming 
alcohol for at least 48 hours prior to their clinic visit on dosing days and during the clinic 
visit. In addition, participants will be instructed to refrain from regular use of alcohol (ie, 
more than 14 units per week [1 unit = 80 mL of wine, 200 mL of beer, or 25 mL of 40% 
alcohol]) for the study duration. Participants must abstain from use of recreational drugs 
throughout the study. 
3. Concomitant Medications: Unless a participant has a documented history of statin 
intolerance, all participants must be on a stable optimal statin regimen for at least 4 weeks 
prior to Screening (S2 visit) laboratory assessments and throughout the study is required 
of all participants.  Participants not receiving a statin must have documented evidence of 
statin intolerance to at least two different statins, one at the lowest starting daily dose and 
another at any daily dose.  In cases where a participant is taking lower than the 
recommended statin dose (as defined by local standard of care) the reason will be clearly 
documented in the eCRF by the Investigator.  
Participants taking any of the concomitant medications specified in Table 4 (below) must 
be on a stable regimen for the minimum duration specified below prior to collection of 
Screening (visit S2) laboratory blood tests and for the duration of the study. In cases 
where any concomitant medication specified in Table 4 is initiated after Day 1, continued 
participation in the study must be approved by the Sponsor’s Medical Monitor. 
Adjustments to background medication specified in Table 4 during the study, are only 
allowed if, at the discretion of the Investigator, this is needed to provide adequate 
supportive care. These changes must be documented in the eCRF no later than at the next 
study visit. Participants will be instructed to inform the Investigator of the details 
(indication, dose and dates of administration) if they do take any medication, and these 
details will be recorded in the eCRF.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 46 of 85 
Table 4 
Concomitant Medications 
Background Medications 
Time on stable regimen prior to 
collection of Screening visit (S2) 
laboratory tests and throughout 
study duration 
Lipid lowering therapies (including statins) 
 > 4 weeks 
Fibrates 
> 6 weeks 
PCSK9 inhibitors 
> 8 weeks 
Beta-blockers, Thiazide diuretics 
> 4 weeks 
Retinoids 
> 8 weeks 
Atypical antipsychotics 
> 12 weeks 
Diabetes Mellitus medications 
> 12 weeks 
Anticoagulation therapy 
>12 weeks 
Thyroid hormone replacement therapy 
>12 weeks 
Testosterone replacement therapy 
>16 weeks 
Oral estrogens, tamoxifen, raloxifene 
> 16 weeks 
Immunosuppressants  
> 24 weeks 
 
4. Local laboratory lipid testing: Central laboratory results of fasting serum ANGPTL3, as 
well as TG and other lipid parameters (LDL-C, total cholesterol, non-HDL-C, HDL-C, 
VLDL-C, ApoB-48, Lp(a), ApoB-100, total ApoB, ApoC-III, ApoC-II, ApoA-I and 
ApoA-V), will not be reported to the Investigator during the Double-Blind Treatment 
Period as these results may potentially unblind IP assignment. After Day 1, Investigators 
should not perform local non-protocol testing of these analytes for the duration of the 
Double Blind Treatment Period and through Day 1 of the OLE Treatment Period.    
Beginning with the second OLE study visit (Month 1 Visit, refer to Table 2), lipid 
parameters from the central laboratory will be reported to the Investigator for the 
remainder of the OLE Treatment Period. 
8.5 
 Lipid Monitoring 
Following the Week 24 visit, in cases where a participant with a baseline LDL-C >130 mg/dL 
(>3.37 mmol/L) experiences an increase from baseline >25% on two consecutive visits, LDL-C 
values for this subject will be unblinded for the remainder of the study, and the central laboratory 
will notify the Investigator and Medical Monitor for medical follow-up. Appropriate medical 
follow-up will include dietary and medication compliance counseling, which may also include 
modification to the participant’s lipid-lowering regimen to lower LDL-C according to 
country-specific guidelines (eg, initiate statin therapy or increase the statin dose for patients who 
are already on treatment). 
Following the Week 24 visit, in cases where a participant with a baseline LDL-C <130 mg/dL 
(<3.37 mmol/L) subsequently experiences an increase to >130 mg/dL (>3.37 mmol/L) on two 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 47 of 85 
consecutive visits, LDL-C values for this subject will be unblinded for the remainder of the 
study, and the central laboratory will notify the Investigator and Medical Monitor for appropriate 
medical follow-up. Appropriate medical follow-up will include dietary and medication 
compliance counseling, which may also include modification to the participant’s lipid-lowering 
regimen to lower LDL-C according to country-specific guidelines (eg, initiate statin therapy or 
increase the statin dose for patients who are already on treatment).  
In cases where any participant has TG > 2000 mg/dL (> 22.6 mmol/L) at any postbaseline visit, 
the central laboratory will notify the Investigator and Medical Monitor. A fasting TG repeat test 
will be requested. If the retest confirms TG > 2000 mg/dL (> 22.6 mmol/L), the Investigator and 
Medical Monitor will be informed so that appropriate medical follow-up can be initiated. The 
Investigator will contact the participant to provide appropriate medical follow-up including 
dietary and medication compliance counseling, which may include modification to the 
participant’s lipid lowering regimen. 
9 
INVESTIGATION PRODUCT 
9.1 
Description, Identification, and Dosage 
The Sponsor is responsible for the supply of active drug supplies together with detailed 
instructions (in a Pharmacy Manual) describing preparation of ARO-ANG3. Placebo (normal 
saline 0.9%) will be supplied by the clinical site. 
Accordingly, ARO-ANG3 will be supplied as single sterile 2-mL vials containing ARO-ANG3, 
with the correct dose of ARO-ANG3 prepared by the Pharmacy prior to dosing participants. 
Placebo will be 0.9% normal saline administered SC.  
Doses administered per Dose Level:  
Each dose of either active drug (ARO-ANG3) or placebo (normal saline 0.9%), will be 
administered by SC injection by the Investigator or appropriately trained and qualified clinical 
staff designated by the Investigator. Injections will be made into the SC tissue at an appropriate 
site (eg, abdomen, thigh, upper arm, etc.) using a 25 to 30 gauge, ½ inch needle. The abdomen is 
the preferred site. Injection site is to be varied (no multiple injections into the same exact site. 
Alternating various locations on the abdomen is acceptable). Injection site location is to be 
recorded in the eCRF. Prior to IP administration, the ARO-ANG3 vial must be allowed sufficient 
time to come to room temperature. Do not inject into areas of active skin disease or injury such 
as sunburns, skin rashes, inflammation or skin infections. Injection volume per site should not 
exceed approximately 1.0 mL. 
There will be no dose escalation or dose reduction (ie, the same drug dose will be administered 
to each participant within dose cohort) during the Double-Blind Treatment Period.  During the 
OLE Treatment Period, participants assigned to 50 mg or 100 mg of ARO-ANG3 or placebo 
during the Double-Blind Treatment Period will receive ARO-ANG3 at the same dose.  
Participants assigned to receive 200 mg of ARO-ANG3 or placebo during the Double-Blind 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 48 of 85 
Treatment Period will be assigned to receive 100 mg during the OLE Treatment Period. 
Participants will continue on their assigned dose in the OLE Treatment Period until the Sponsor 
has selected a single dose at which point all subjects will transition to the selected dose. 
9.2 
Supply, Preparation, Storage and Labeling of ARO-ANG3 
ARO-ANG3 will be supplied as a sterile Type-1 glass 2.0-mL vial (1.2 mL nominal volume, 
1.0 mL withdrawable volume).  
Table 5 Investigational Product Description 
Strength  
200 mg/mL 
Appearance 
Clear, colorless to light yellow solution 
Inactive ingredients 
0.5 mM sodium phosphate monobasic, 0.5 mM sodium phosphate dibasic 
in water for injection 
Shipment and Storage 
Refrigerated, 2ºC to 8ºC 
 
ARO-ANG3 will be prepared, per the Pharmacy Manual, by a pharmacist or qualified staff at the 
clinical sites. Aseptic technique will be used to ensure sterility of the solution to be injected. The 
time of preparation for active drug must be documented and tracked to demonstrate 
administration within prepared drug stability boundaries. Please refer to the Pharmacy Manual 
for more detailed instructions. 
The IP vials will be labeled per current Good Manufacturing Practice (cGMP)/Good Clinical 
Practice (GCP).  
Investigational product supplies will be stored at clinical sites securely under the appropriate 
conditions. 
9.3 
Study Drug Handling 
The Sponsor will provide the Investigator with a sufficient quantity of clinical drug supplies. The 
Investigator must ensure that deliveries of IP from the Sponsor are correctly received by a 
responsible person, that all receipts of drug shipments are recorded on the appropriate Drug 
Accountability forms prepared by the pharmacy at the clinical site and that the products are 
stored in a secure area under recommended storage conditions. It is also the responsibility of the 
Investigator to ensure that the integrity of packaged study product not be jeopardized prior to 
dispensing.  
Only participants enrolled in the study may receive IP, in accordance with all applicable 
regulatory requirements. Only authorized site staff may supply or administer IP. The IP must be 
stored in a secure area with access limited to the Investigator and authorized staff and under the 
physical conditions that are consistent with the IP-specific requirements.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 49 of 85 
An authorized and trained staff member at each clinical study site will dispense the IP per 
predefined drug dispensing requirements. The dispensing will be verified by a second member of 
site staff.  
ARO-ANG3 will be supplied by the Sponsor and labeled with the drug name, batch number, 
expiration date (as applicable) and storage conditions. The IP will be dispensed by clinical study 
site staff members on the day of dosing and recorded in the drug accountability records. A 
Pharmacy Manual will be prepared to define the procedures for dispensing. 
9.4 
Allocation to Treatment 
All potential participants who sign an informed consent at Screening will receive a unique 
identifier (ie, a Screening Number). For participants who are deemed eligible, this unique 
screening number will become the participant’s permanent study identification number. 
Eligible participants will be allocated a unique randomization number, in accordance with the 
randomization schedule. Each participant will be randomly assigned 3:1 to either active 
(ARO-ANG3) treatment in 1 of 3 dose groups (50, 100, or 200 mg) or to placebo treatment. 
Treatments will be administered per the randomized sequence generated by an Interactive Web 
Response System (IWRS). The allocation of active treatment or placebo will be performed using 
a block randomization algorithm. 
After completing the Week 36 Visit, eligible participants may opt to enroll into the OLE 
Treatment Period (Table 2)  and will receive the dose corresponding to their study treatment dose 
as assigned in the Double Blind Treatment Period. Participants who had previously received 
ARO-ANG3 50 mg or100 mg, or volume-matched placebo, will continue to receive the 
corresponding dose level of ARO-ANG3 in the OLE Treatment Period. However, participants 
previously assigned to the 200 mg dose group will be transitioned to the 100 mg dose group at 
the next dosing visit in the OLE.  After the last participant in the Double-Blind Treatment Period 
completes the Week 36 Visit and a single dose has been selected by the Sponsor, all participants 
in the OLE will receive the selected ARO-ANG3 dose Q3M for the remainder of their 
participation in the study. 
9.5 
Study Formulation Administration 
Appropriately trained employees of the clinical site will administer the IP. Each dose will be 
administered as a single SC injection. The site of injection will be marked and mapped for later 
observation. The preferred site of injection is the abdomen. Optional additional sites are the 
upper arms and thighs. Injection site is to be varied (no multiple injections into the same exact 
site. Alternating various locations on the abdomen is acceptable). 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 50 of 85 
Table 6 
Injection Number and Volume Per Dose Cohort During Blinded Study 
Period 
ARO-ANG3 
Dose 
Concentration 
Total 
Injection 
Volume 
Number of 
Injections per 
Planned Dose 
Total Number 
of Study 
Injections 
(Blinded 
Period) 
Total Number 
of Study 
Injections 
(OLE 
Treatment 
Period) 
50 mg 
200 mg/mL 
0.25 mL 
Single 
2 
8 
100 mg 
200 mg/mL 
0.50 mL 
Single 
2 
8 
200 mg* 
200 mg/mL 
1.00 mL 
Single 
2 
8 
*The 200 mg ARO-ANG3 dose will be discontinued in the OLE period; all participants originally receiving the 
200 mg dose or volume matched placebo control in the 36-Week Blinded Treatment period will be assigned to 
100 mg dose. 
Placebo injections of normal saline will be volume matched during Double Blind Treatment Period. 
 
9.6 
Accountability of Study Supplies 
All material supplied is for use only in this clinical study and should not be used for any other 
purpose. The Investigator is responsible for the IP accountability, reconciliation and record 
maintenance at the investigational site. In accordance with all applicable regulatory 
requirements, the Investigator or designated site staff must maintain IP accountability records 
throughout the course of the study. This person will document the amount of IP received from 
the Sponsor and the amount administered to participants. A nonblinded Clinical Research 
Associate (CRA) will perform initial and ongoing IP accountability. The nonblinded CRA will 
protect the integrity of the assignment blind and will not participate in data review for study 
participants. Used vials of ARO-ANG3 will be retained sequestered per participant and cohort 
(where allowable by local policy) and made available to the nonblinded CRA during IP and 
placebo reconciliation.  
A Drug Dispensing Log must be kept current and will contain the following information: 
• the identification of the participant to whom the drug was dispensed; and 
• the date(s) and quantity of the drug dispensed to the participant. 
The date and time of dose preparation and release will be maintained to support administration of 
IP. The authorized pharmacist or qualified staff will be unblinded to IP assignment (ie, active or 
placebo). The pharmacy will dispense the IP and the study center will administer the IP only to 
participants included in this study following the procedures set out in the study protocol. Each 
participant will be given only the IP as assigned by the IWRS. Investigational product 
administration will be documented and recorded on the eCRFs. The inventory must be available 
for inspection by the nonblinded monitor during the study. Drug supplies will either be collected 
at the end of the study by the study monitor or returned by the Investigator or designee to the 
Sponsor or the designated Sponsor-approved depot.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 51 of 85 
9.7 
Retention of Investigational Product Vials 
For this study, used and partially used IP vials will be retained for an adequate period to allow 
accountability by the nonblinded CRA. No additional IP samples will be retained. 
9.8 
Blinding and Code-Break 
Treatment assignment (active vs placebo) is blinded in this clinical study.  Dose group 
assignment is not blinded, due to required injection volume differences dictated by the respective 
dose group.  Therefore, during the Double Blind Treatment Period, participants will receive an 
injection of either active or placebo volume matched to the assigned dose group (Table 1). In 
order to mask for slight color differences between active and placebo, syringes will be blinded in 
the Pharmacy with translucent wrapping to mask the blinded staff and participants to the 
treatment assignment in accordance with instructions provided in the Pharmacy Manual 
Blinding of IP/placebo assignment is critical to the integrity of this clinical study. It is expected 
that in most cases, AEs can be properly managed without the need for unblinding. However, in 
the event of a medical emergency in which knowledge of an individual participant’s assignment 
is considered critical to the participant’s well-being and management, the Investigator or 
documented designated treating physician or the Sponsor medical monitor can unblind the IP 
assignment. If the situation is not an immediate emergency, the Investigator should contact the 
responsible Medical Monitor to discuss the participant and circumstances requiring the 
unblinding. The blind will be broken only for the specific participant under discussion. The 
unblinding will be documented in the electronic data capture system. The study monitor should 
be informed promptly. 
The randomization assignments will be maintained under controlled access. The personnel 
involved in the dispensing of IP will be accountable for ensuring compliance to randomization 
assignment. The nonblinded CRA will review the randomization assignment in comparison to 
the dispensing log to verify correct randomization.  
If the Investigator considers an AE to be of such severity as to require immediate specific 
knowledge of the identity and dose of the relevant product, unblinding will be completed via 
IWRS system. Medical emergency unblinding in IWRS is only accessible to the designated 
unblinded Pharmacist, Investigator, and Subinvestigator. The Medical Monitor should be 
informed promptly. 
If a participant requires emergency unblinding (with or without a discussion between the 
Investigator and the Medical Monitor preceding the unblinding), the Investigator may also be 
required to complete a ‘Drug Safety Unblinding Request/Notification Form’ to document the 
medical rationale necessitating the unblinding. This form is then forwarded to the Medical 
Monitor. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 52 of 85 
10 STUDY METHODS AND PROCEDURES  
10.1 Overview of Procedures 
The SOA is provided in Table 1 (Double Blind Treatment Period) and Table 2 (OLE Treatment 
Period). Potential participants will visit the site to provide informed consent and start the 
Screening Period.  At the Investigator’s discretion and if permitted by local requirements, the 
first and second Screening visit (S1 and S2) assessments may be conducted concurrently within 
the S2 visit window (Day -35 to Day -21) as long as the participant meets stable diet, stable 
background medications, and fasting requirements as outlined in Sections 8.1, 8.4, and 10.2.  The 
third Screening visit (S3) must occur at least 7 days but no more than 17 days after the second 
Screening (S2) visit.   
Participants who successfully pass the requirements at the Screening visit will be enrolled into 
the study. All dose cohorts will enroll in parallel with participants randomized 3:1 to receive 
ARO-ANG3 or placebo. Each participant will receive 1 SC injection on Day 1, and Week 12, for 
a total of 2 injections during the Double Blind Treatment Period as follows:  
• ARO-ANG3 50 mg (n=45) or volume-matched placebo (n=15) on Day 1 and Week 12; 
• ARO-ANG3 100 mg (n=45) or volume-matched placebo (n=15) on Day 1 and Week 12; 
or 
• ARO-ANG3 200 mg (n=45) or volume-matched placebo (n=15) on Day 1 and Week 12. 
All participant Screening visits and dosing visits during the Double Blind Treatment Period and 
OLE Treatment Period must be conducted at the clinical study site. At the discretion of the 
Investigator and with prior Sponsor approval, utilization of home health care services to conduct 
other study assessment visits is permissible when pandemic restrictions or other logistical 
disruptions occur in order to avoid missed visits.  Utilization of home health services is 
contingent upon compliance with local laws and regulations; the capability of the Investigator to 
adequately monitor participant safety. In cases where home health care services are to be 
utilized, this approach, and any specific risks associated with it must be clearly outlined in the 
EC/IRB approved informed consent form.  
All participants will have predose and postdose PK samples collected at Day 1 and Week 12 as 
specified in the SOA. In a subset of participants undergoing full PK (12 active, 4 placebo in each 
dose cohort), PK will be measured predose and postdose on Day 1 and Week 12 as per the SOA 
(Table 1). Pharmacokinetic time points are at predose, 0.25, 1, 3, 6, and 24 hours postdose. 
Recommended time window for PK sample through the 6-hour time point: ± 5 minutes. 
Recommended time window for PK sample at the 24-hour time point: ± 60 minutes. If the 
recommended time window is missed, every attempt should be made to collect this PK sample as 
soon as possible within the same study visit. Only samples collected from participants receiving 
active treatment will be included in the PK analysis. For postdose samples that require next-day 
collection, participants may return to the clinical facility to have their blood drawn or they may 
opt to have their PK samples collected through home health.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 53 of 85 
Parameters to be assessed and the timing of assessments are provided in the SOA in Table 1 and 
Table 2. At regular intervals during the study, participants will undergo the following 
evaluations: medical history review, physical examinations, vital sign measurements (blood 
pressure, temperature, heart rate, respiratory rate), weight measurement, AEs monitoring, ECGs, 
pregnancy test (females of childbearing potential), laboratory assessments, and concomitant 
medication review. Blood samples will be collected predose for non-HDL-C, HDL-C, LDL-C, 
VLDL-C, TG, and other specified lipid or metabolic parameters, hematology, serum lipase and 
insulin, HbA1c, C-peptide, coagulation, chemistry analysis, and urinalysis. Blood samples will 
also be collected for PK and immunogenicity analysis. Participants will have fasted for at least 
10 hours prior to blood sample collection. 
Clinically significant changes including AEs will be followed until resolution is achieved or 
considered medically stable.  
10.2 Screening Diet Stabilization Period 
Confirmation of ≥ 2 weeks diet stabilization will precede lipid parameter laboratory assessments 
collected at Screening visits (S2 and S3).  Enrolled participants will be counseled to remain on 
the specified diet throughout the study, as recommended by the Investigator in accordance with 
local standard of care. For example, in the US, Investigators may refer to the guidelines 
established by the American Heart Association/American College of Cardiology 
(Van Horn 2016). The specifics of the diet will be at the discretion of the Investigator based on 
each individual’s specific diagnosis and medical needs. Dietary assessment and counseling will 
begin during the Screening Period with dietary counseling performed throughout the study to 
facilitate compliance as per the SOA (Table 1 and Table 2).  
This diet may vary at the Investigator’s discretion and certain populations may require more 
strict dietary regimens. 
10.3 Selection and Screening 
Prior to commencement of any screening procedures, the Investigator or designee will inform the 
participant about the nature and purpose of the study, including the risks and benefits involved, 
possible AEs, the fact that their participation is voluntary and provide a copy of the 
IRB/EC-approved Informed Consent Form for review. Each participant will acknowledge receipt 
of this information by giving written informed consent for their involvement in the study in the 
presence of the Investigator or designee, who will also sign and date the Informed Consent Form. 
Time of consent will be recorded in the site’s source document for each participant. The original 
signed consent form will be retained by the Investigator and a copy of the original will be given 
to the participant.  
Informed consent will be performed per the Principles of the ICH GCP procedures. 
Documentation of the participant’s fulfillment of the entry criteria, for all participants considered 
for the study and subsequently included or excluded, is to be completed by the Investigator, or 
medically qualified designee. Documentation of screening failure details will be recorded using 
eligibility screening forms or a participant screen failure log. Procedures outlined in the SOA 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 54 of 85 
(Table 1 and Table 2) will be performed. Timing will abide by fasting restrictions outlined in 
Sections 8.1, 8.4, and 10.2. 
No study assessment or procedure will occur before the participant has signed the informed 
consent.  
10.4 On-Study Procedures/Assessments 
Efficacy Assessments 
Serum Triglycerides and Other Lipid Parameters 
Fasting serum TG, LDL-C, and non-HDL-C, will be collected at the Screening after a 10-hour 
fast in order to evaluate lipid parameters. In order to determine the average (arithmetic mean) TG 
level during Screening, two fasting serum TG levels will be collected separately and 
consecutively at least at least 7 days but no more than 17 days apart in accordance with the SOA 
(Table 1).    
Fasting serum TG will be measured as per the SOA (Table 1, Table 2) and assessed by a central 
laboratory standard method. LDL-C will be measured as per the SOA and assessed by a central 
laboratory.  During Screening, either ultracentrifugation methodology or Martin -Hopkins 
methodology may be used to determine eligibility.  In the event of logistical disruptions (eg, 
coronavirus disease [COVID]-related) where a participant does not have direct access to the site, 
laboratory samples may be collected at alternative location (eg, home health, local laboratory) 
using the central laboratory kit and shipped to central laboratory for analysis.  
Fasting TG and other lipid metabolism parameters (LDL-C, total cholesterol, non-HDL-C, 
HDL-C, VLDL-C, ApoB-48, LP(a), APOB-100, total ApoB, ApoC-III, ApoC-II, ApoA-I, 
ApoA-V, and ANGPTL3) will be collected on Day 1 prior to dosing after a 10-hour fast.   
 Glucose Metabolism 
Beginning on Day 1 and for the remainder of the treatment period, glucose metabolism analytes 
will be collected after at least 10 hours of fasting and predose on dosing days. Fasting serum 
blood glucose, HbA1c, homeostatic model assessment for insulin resistance (HOMA-IR), and 
C-peptide will be measured as per the SOA and assessed by a central laboratory. 
 Magnetic Resonance Imaging 
Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for the evaluation of 
percentage liver fat will be conducted at Screening, after completion of the S2 visit, and at 
Week 24 as outlined in the SOA (Table 1) and in accordance with procedural standards detailed 
in the Imaging Acquisition Manual. Selected sites (where MRI-PDFF is available) will perform 
MRI-PDFF assessments at Screening until approximately 35 participants with baseline liver fat 
fraction ≥ 8% have been enrolled in each of the 3 dosing cohorts after which, MRI--PDFF will 
no longer be included as an evaluation. The MRI protocol used should be consistent across all 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 55 of 85 
individual participant visits (same MRI imaging technique/protocol will be used predose and at 
Week 24 on a participant-by-participant basis). Please refer to the Imaging Acquisition Manual 
for further instructions. 
 Blood Sampling for Pharmacodynamic Analysis 
Blood samples will be collected from participants through an indwelling cannula or through a 
fresh vein puncture. The actual blood collection time will be recorded in the source documents. 
All deviations outside the range allowed above will be documented as protocol deviations. In all 
such cases, appropriate time corrections, for the actual time of sample collection will be 
incorporated at the time of data analysis. Blood samples will be collected at time points outlined 
in the SOA (Table 1, Table 2).  
The actual sample times (times samples taken) will be recorded in the eCRF and will be entered 
at the time of or as soon as possible after sampling. All times must be recorded in the 24-hour 
format. An explanation must be given for any blood sample taken outside of the set sampling 
times. 
Pharmacokinetic Assessments 
Plasma samples for analysis of circulating ARO-ANG3 will be obtained in a subset of 
participants at time points following IP administration as outlined in the SOA (Table 1). Blood 
samples will be collected from participants through an indwelling cannula or through a fresh vein 
puncture.  For postdose samples that require next-day collection, participants may return to the 
clinical facility to have their blood drawn or they may opt to have their PK samples collected 
through home health.  Sparse sampling PK blood draws and analysis will also be conducted on 
all participants not included in the specified PK group as per the SOA. 
Sample Processing and Analysis for Pharmacokinetic Samples 
Whole blood will be collected and processed per the Laboratory Manual. Plasma samples will be 
assayed by a validated hybridization-ligation method. The criteria for repeat analysis, as defined 
in the respective in-house procedure, will be followed. The validation study conducted by the 
appointed bioanalytical laboratory to establish validity including accuracy, precision, 
reproducibility, specificity, recovery and frozen stability of the analytical method will be 
appended to the final report. 
General and Safety Assessments 
General assessments include optional genotype, medical history, and demographics. Safety will 
be evaluated by the incidence, frequency, and severity of AEs and SAEs, including injection site 
reactions. 
The safety of ARO-ANG3 will also be evaluated by the collection of the following 
measurements performed at time points specified in the SOA as well as CS changes from 
baseline to scheduled time points:  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 56 of 85 
• Monitoring of AEs/SAEs 
• Physical examinations 
• Vital signs 
• ECG measurements 
• Clinical laboratory assessments (hematology, chemistry, HbA1c, coagulation, amylase, 
lipase, urinalysis) 
• Concomitant medications/therapy 
• Reasons for IP discontinuation due to toxicity. 
The AE/SAE reporting period for an enrolled participant will begin when the participant 
provides informed consent. Treatment-emergent AEs/SAEs will be those defined as following IP 
administration. All AEs/SAEs that occur during the AE reporting period specified in the protocol 
must be reported to the Sponsor, regardless of the relationship of the AE to IP. Any known 
untoward event that occurs beyond the AE reporting period that the Investigator considers an 
SAE and possibly related to IP will be reported to the Sponsor. 
 Demographics and Medical History 
Participant demographics (eg, date of birth, race and ethnicity, sex) and medical history will be 
collected during the Screening period. Medical History will include medication use over the 
previous 30 days, including vitamins, OTC medications, prescription drugs, recreational drugs or 
supplements and alcohol and tobacco use. 
Optionally, participants will be invited to consent for pharmacogenetic analyses. Participants 
who consent will have a blood sample drawn for these analyses.  
 Physical Examination 
A complete physical examination will be performed at Screening and as per SOA (Table 1, Table 
2). At Screening, height (centimeters, without shoes) and weight (kilograms, without shoes) will 
be measured. At all other time points outlined in the SOA, a symptom-directed physical 
examination will be performed if indicated.  
 Vital Signs 
Systolic/diastolic blood pressure (mmHg), temperature (°C), heart rate (beats/minute), 
respiratory rate (breaths/minute) will be obtained at time points outlined in the SOA (Table 1, 
Table 2) after the participant is sitting for at least 3 minutes. Vitals signs will be obtained prior to 
venipuncture and other invasive procedures.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 57 of 85 
Electrocardiogram 
A single 12-lead ECG measurement will be obtained at time points outlined in the SOA (Table 1, 
Table 2) after the participant is semi-supine for at least 3 minutes. Any abnormal and CS ECGs, 
as per the Investigator’s medical judgment, will be repeated in triplicate, with each measurement 
approximately 1 minute apart. ECGs will be performed prior to venipuncture and other invasive 
procedures.  
Clinical Laboratory Tests for Safety 
Blood and urine samples will be collected at the site and shipped to the central laboratory for 
analysis. In the event of logistical disruptions (eg, COVID-related) where a participant does not 
have direct access to the site, laboratory samples may be collected at an alternative location (eg, 
home health, local laboratory) using the central laboratory kit and shipped to central laboratory 
for analysis. If central laboratory kit collection is not available, local laboratory safety testing 
may only be permitted in limited circumstances and only with prior Sponsor approval.  
In accordance with the SOA (Table 1) blood and urine samples will be collected for the 
laboratory tests detailed below to establish baseline data and eligibility for enrollment. One 
repeat Screening lab draw is allowed per assessment to establish eligibility. The results will be 
assessed by the Investigator or medically qualified designee before study enrollment. Any 
abnormality in laboratory values (that are confirmed on repeat) deemed CS by the Investigator, 
or medically qualified designee (ie, those that would jeopardize the safety of the participant or 
impact on the validity of the study results), will result in exclusion of that participant. Clinical 
laboratory tests will be performed on participants’ blood and urine at specified time-points listed 
in the SOA (Table 1, Table 2).  Refer to the laboratory manual for additional details on clinical 
laboratory tests. 
Biochemistry: Sodium, potassium, chloride, bicarbonate, glucose, urea, creatinine, calculated 
eGFR, creatine kinase, uric acid, phosphate, total calcium, anion gap, cholesterol, albumin, 
globulins, protein, total bilirubin, amylase, lipase, HbA1c, serum insulin, C-peptide, conjugated 
bilirubin, gamma glutamyltransferase (GGT), alkaline phosphatase (ALP), ALT, AST, lactate 
dehydrogenase (LD), TG, C-reactive protein, thyroid stimulating hormone, and free T4 
Hematology: Hemoglobin, red blood cell count (RBC), hematocrit, mean cell volume (MCV), 
mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), platelets, white 
cell count, neutrophils, lymphocytes, monocytes, eosinophils and basophils.  
Coagulation: Partial thromboplastin time, prothrombin time with INR and fibrinogen. 
Urinalysis: Leukocytes, nitrites, urobilinogen, protein, pH, blood, specific gravity, ketone, 
bilirubin and glucose.  
Microscopic urinalysis will be performed if indicated: White blood cells, RBC, epithelial cells, 
bacteria. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 58 of 85 
Spot urine protein and spot urine creatinine: will be performed at screening only in order to 
determine the spot urine protein/spot urine creatinine ratio. 
Serology: HBsAg and hepatitis C antibody screen. If necessary, participants will be counseled by 
the Investigator, or medically trained designee, concerning the blood tests for hepatitis B surface 
antigen, and hepatitis C antibody, and their subsequent results.  
Follicle-stimulating hormone (FSH): Postmenopausal status at screening will be supported 
based on FSH level consistent with postmenopausal state. 
Immunogenicity: Participants will be assessed for anti-drug antibodies.  
The Day 1 value will be used as each participant’s baseline value for data analysis purposes or as 
otherwise specified. If Day 1 or as otherwise specified values are erroneous or not available and 
repeat blood draw is not possible, the Screening value may be used as baseline. 
Early Termination Procedures 
If a participant discontinues from the study prematurely, every reasonable effort will be made to 
perform the Early Termination Visit within 30 days of the decision to terminate a participant’s 
study participation. The reason for Early Termination will be documented in source documents 
and eCRF. Procedures as outlined in the SOA (Table 1, Table 2) will be completed. Participants 
who discontinue ARO-ANG3 due to SAE will be encouraged to remain available for follow-up 
for medical monitoring until resolution. 
Follow-Up Procedures 
Contact will be made to each participant and documented to verify AEs occurring over the 
24 hours following doses at Day 1 and at Week 12 (Table 1) during the Double Blind Treatment 
Period and following doses administered Q3M (Table 2) during the OLE Treatment Period. 
10.5 Timing of Treatments and Procedures  
Actual times of procedures for each participant will vary depending on scheduling and will be 
recorded in the eCRF. 
In the event of multiple procedures scheduled at the same time, noninvasive procedures (ie, vital 
signs, ECGs, AE assessment) will be conducted prior to invasive procedures (ie, blood sample 
collection). Timing of activities may be adjusted slightly to accommodate all procedures. 
The following windows are allowed for study assessments/visits: 
Table 7 Assessment Windows 
Predose 
Any time during the study visit, and before 
first dose  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 59 of 85 
Plasma PK1 up to 6-hour sampling time point 
± 5 minutes 
Plasma PK1 24-hour sampling time point  
± 60 minutes 
Day 1 
Not Applicable 
Postbaseline visits 
± 5 days 
Abbreviation: PK = pharmacokinetic. 
1Only for Full PK assessments.  
10.6 Pregnancy Testing and Contraception Requirements 
Female participants of childbearing potential will have urine pregnancy tests at each Screening 
visit, Day 1 (baseline), and at subsequent study visits as indicated in Table 1 and Table 2. 
Females not of childbearing potential must be either surgically sterile or postmenopausal 
(defined as cessation of regular menstrual periods for at least 12 months) with supportive FSH 
consistent with postmenopausal state based on laboratory reference ranges. 
If a participant’s urine pregnancy test is positive, the participant will be referred to their primary 
care provider for follow-up. Female participants with a positive pregnancy test during the 
Screening Period or on Day 1 predose will not be enrolled in the study.  
All participants (female participants of childbearing potential with male partners and male 
participants with female partners of childbearing potential) must consent to use highly effective 
contraception during the study and for at least 24 weeks following the last dose of IP.  
• Using twice the normal protection of birth control by using a condom AND one other 
form of contraception; either birth control pills (The Pill), or injectable birth control, birth 
control patch, vaginal contraceptive ring,  or contraceptive implant associated with 
inhibition of ovulation, or intrauterine device. 
• Surgical sterilization as a single form of birth control: ie, tubal ligation, hysterectomy, 
bilateral oophorectomy, vasectomy or equivalently effective surgical form of birth 
control. 
• True sexual abstinence for the duration of the study and for at least 24 weeks following 
the last dose of IP, is acceptable only when in line with the preferred and usual lifestyle 
of the participant. Periodic abstinence (calendar, symptothermal, postovulation methods), 
withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods 
are not considered “true” abstinence and are not acceptable methods of contraception. 
11 ADVERSE EVENTS 
The Investigator and clinical facility staff are responsible for detection, recording, and reporting 
of events that meet the criteria and definition of various AEs as listed below. AEs will be 
recorded from time of signed consent through to end of the study; only AEs that occur postdose 
will be considered treatment emergent. The Investigator and clinical facility staff are responsible 
for detection, recording, and reporting of pregnancy and appropriate follow-up. Information 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 60 of 85 
regarding any reported pregnancy should be collected for up to 1 year after birth or until the end 
of the pregnancy. 
11.1 Definitions 
An AE is any untoward medical occurrence in a patient or clinical investigation participant 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding or diagnostic test), symptom, or disease temporally 
associated with the use of a medicinal (investigational/experimental) product, whether related to 
this product or not. (Refer to International Council for Harmonisation [ICH] E2a: Clinical Safety 
Data Management: Definitions and Standards for Expedited Reporting, 27 October 1994). 
Treatment-emergent AEs will be defined as AEs with onset after administration of the IP, or 
when a preexisting medical condition increases in severity or frequency after IP administration.  
Adverse events will not include: 
• A medical or surgical procedure such as surgery, endoscopy, tooth extraction, or 
transfusion (although the condition that leads to the procedure may be an AE); 
• A preexisting disease or condition present at the start of the study that does not worsen 
during the study; 
• Any situation where an untoward medical occurrence has not occurred (eg, 
hospitalizations for cosmetic elective surgery or “social” admissions); or 
• An overdose of either the IP or a concurrent medication without any resulting signs or 
symptoms. 
An SAE is an AE that: 
• Results in death; 
• Is life-threatening, (NOTE: The term ‘life-threatening’ in the definition of ‘serious’ refers 
to an event/reaction in which the participant was at immediate risk of death at the time of 
the event/reaction; it does not refer to an event/reaction which hypothetically might have 
caused death, if it were more severe); 
• Requires inpatient hospitalization or prolongation of an existing hospitalization;  
• Results in persistent or significant disability/incapacity;  
• Is a congenital anomaly/birth defect; or 
• Is a medically important event or reaction. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 61 of 85 
Medical and scientific judgment should be exercised in deciding whether other situations, should 
be considered serious such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but might jeopardize the participant or might 
require medical or surgical intervention to prevent one of the other serious outcomes listed in the 
above definition. These should also be considered serious. Examples of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency or drug 
abuse. 
11.2 Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse 
Events 
Abnormal assessments (eg, ECGs and vital signs) that are judged by the Investigator as CS or 
result in clinical sequelae should be recorded as AEs. Laboratory abnormalities should be 
reported by the Investigator as AEs if the abnormality is considered CS or result in clinical 
sequelae. Laboratory abnormalities not reported as AEs are not to be reported as CS in the study 
database. 
Clinically significant abnormal laboratory findings or other CS abnormal assessments that are 
detected during the study or are present at baseline and significantly worsen following the start 
of the study will be reported as AEs.  
The Investigator (or medically qualified designee) will exercise his or her medical and scientific 
judgment in deciding whether an abnormal laboratory finding, or other abnormal assessment is 
CS. 
11.3 Timing, Frequency, and Method of Detecting Adverse Events 
Any pre-existing conditions or signs and/or symptoms present in a participant prior to the start of 
the study (ie, before informed consent) should be recorded as Medical/Surgical History.  
All AEs occurring after informed consent and on or before the final visit must be reported as 
AEs; only AEs that occur postdose will be considered treatment emergent. All AEs must be 
recorded irrespective of whether they are considered drug related. 
At each visit/assessment in the period defined above, AEs will be evaluated by the Investigator 
(or medically qualified designee) and recorded in the medical notes and eCRF. 
11.4 Recording of Adverse Events 
When an AE occurs, it is the responsibility of the Investigator or medically qualified designee to 
review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) 
relative to the event. The Investigator or medically qualified designee will then record the AE on 
the AE CRF. Additional reporting requirements for an AE meeting any serious criterion are 
discussed in Section 11.5. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 62 of 85 
The Investigator or medically qualified designee will attempt to establish a diagnosis of the event 
based on signs, symptoms, and/or other clinical information. In all cases, when available, the 
diagnosis should be reported as the event and not the individual signs/symptoms. It is not 
acceptable for the Investigator to send photocopies of the participant’s medical records to the 
Sponsor in lieu of completion of the appropriate AE eCRF pages. 
11.5 Evaluating Adverse Events 
Severity of Adverse Events 
The Investigator or medically qualified designee will assess the severity for each AE reported 
during the study. The assessment will be based on the Investigator’s (or medically qualified 
designee’s) clinical judgment. The severity of all AEs will be graded using the latest version of 
the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0: 
If an AE cannot be graded using the CTCAE criteria, it should be graded as mild, moderate, 
severe, life-threatening, or death using the following definitions: 
• Mild: An event that is easily tolerated by the participant, causing minimal discomfort, and 
not interfering with everyday activities. Medical intervention not indicated.  
• Moderate: An event that is sufficiently discomforting to interfere with normal everyday 
activities. Noninvasive medical intervention indicated. 
• Severe: An event that prevents normal everyday activities but not immediately 
life-threatening. 
• Life-threatening: An event that places the participant at immediate risk of death or is 
disabling. 
• Death: An event that results in death. 
An AE that is assessed as severe should not be confused with a SAE. Severity is a category 
utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe. 
An event is defined as ‘serious’ when it meets one of the predefined outcomes as described in 
Section 11.1. 
Injection Site Reactions 
For purposes of data analysis, a local injection site reaction (LISR) is defined as an adverse 
reaction (usually immunologic) developing at the site of injection and lasting at least 48 hours 
which must be based on the specified Medical Dictionary for Regulatory Activities (MedDRA) 
Preferred Times as provided in Appendix 2. For data analysis purposes, AEs at the injection site 
with reported terms of bruising or hematoma will not be considered LISRs. Injection site 
reactions are graded based on CTCAE.  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 63 of 85 
• Grade 1: Tenderness with or without associated symptoms (eg, warmth, erythema, 
itching). 
• Grade 2: Pain; lipodystrophy; edema; phlebitis. 
• Grade 3: Ulceration or necrosis; severe tissue damage; operative intervention indicated. 
• Grade 4: Life-threatening consequences; urgent intervention indicated. 
• Grade 5: Results in death. 
Assessment of Causality 
The Investigator (or medically qualified designee) is obligated to assess the relationship between 
IP and the occurrence of each AE. The Investigator (or medically qualified designee) will use 
clinical judgment to determine the relationship. Alternative causes, such as natural history of the 
underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the 
event to the IP will be considered and investigated. The Investigator (or medically qualified 
designee) will also consult the IB in the determination of his/her assessment. 
There may be situations when an SAE has occurred and the Investigator has minimal information 
to include in the initial SAE report. However, it is very important that the Investigator (or 
medically qualified designee) always assess causality for every event prior to transmission of the 
SAE report form. The Investigator (or medically qualified designee) may change his/her opinion 
of causality considering follow-up information, amending the SAE report form accordingly. The 
causality assessment is one of the criteria used when determining global regulatory reporting 
requirements. 
The Investigator (or medically qualified designee) will provide the assessment of causality 
utilizing 3 possible categories: Not Related, Possibly Related, and Probably Related. 
An AE will be considered “not related” to the use of the product if any of the following tests are 
met: 
• An unreasonable temporal relationship between administration of the product and the 
onset of the AE (eg, the event occurred either before, or too long after administration of 
the product for it to be considered product-related); 
• A causal relationship between the product and the AE is biologically implausible (eg, 
death as a passenger in an automobile accident); 
• A clearly more likely alternative explanation for the AE is present (eg, typical adverse 
reaction to a concomitant drug and/or typical disease-related event). 
An AE will be considered “Possibly related” when there is a reasonable possibility that the 
incident, experience, or outcome may have been caused by the product under investigation. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 64 of 85 
An AE will be considered “Probably related” when there are facts, evidence, or arguments to 
suggest that the event is related to the product under investigation. 
Follow-up of Adverse Events 
After the initial AE, the Investigator is required to proactively follow each participant and 
provide further information on the participant’s condition as deemed appropriate.  
All AEs will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up. Once resolved, the appropriate 
AE eCRF page and SAE report form (if event is serious) will be updated. The Investigator or 
medically qualified designee will ensure that follow-up includes any supplemental investigations 
as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include 
additional laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals. In the event of a fatal outcome in an SAE, the Investigator or 
medically qualified designee will attempt to obtain postmortem findings, including 
histopathology, and provide all additional information in a follow-up SAE report. 
New or updated information regarding an SAE will be recorded on a new SAE report form 
marked as follow-up with the appropriate follow-up number added to the report. The follow-up 
report will be signed and dated by the Investigator. 
11.6 Prompt Reporting of Serious Adverse Events 
Any AEs meeting serious criteria MUST be reported promptly to the designated 
Pharmacovigilance Contract Research Organization (CRO), and the IRB/EC.  
Completion and Transmission of the Serious Adverse Events Reports 
Once an Investigator becomes aware that an SAE has occurred in a study participant, he/she will 
report the information on an SAE report form to the designated Pharmacovigilance CRO within 
24 hours. The SAE report form will always be completed as thoroughly as possible with all 
available details of the event and signed by the Investigator (or medically qualified designee). If 
the Investigator does not have all information regarding an SAE, he/she will not wait to receive 
additional information before reporting the event. The SAE report form will be updated when 
additional information is received. 
The Investigator (or medically qualified designee) will always provide an assessment of causality 
at the time of the initial report as described in Section 11.5. 
Electronic transmission of the SAE report form are the preferred methods to transmit this 
information to the designated Pharmacovigilance CRO. In rare circumstances, notification by 
telephone is acceptable, with a copy of the SAE report sent by overnight mail. Initial notification 
via the telephone does not replace the need for the Investigator, or medically qualified designee, 
to complete and sign the SAE report form within the outlined time frames. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 65 of 85 
The Sponsor will provide a list of project contacts for SAE receipt, fax numbers, telephone 
numbers, and mailing addresses. Any event that in the opinion of the Investigator may be of 
immediate or potential concern for the participant’s health or well-being will be reported to the 
Sponsor emergency contact listed below.  
Sponsor Emergency Contact 
 
Pregnancy Reporting  
Pregnancy occurring in a participant or in the female partner of a male participant during the 
study must be reported on a pregnancy reporting form or on an SAE form to the designated 
Pharmacovigilance CRO within 24 hours of initially becoming aware of the pregnancy by the 
Investigator. 
Pregnancies are not SAEs. However, pregnancy data will be collected at the initial notification, 
birth/termination of pregnancy, and for up to 1 year after birth or until the end of the pregnancy.  
Any SAE that occurs during pregnancy (eg, serious maternal complications, therapeutic abortion, 
ectopic pregnancy, stillbirth etc.) must be reported in accordance with the procedure for 
reporting SAEs. 
Serious Adverse Event Reports to the IRB/EC 
The Investigator, or responsible person per local requirements, will comply with the applicable 
local regulatory requirements related to the reporting of SAEs to regulatory authorities and the 
EC.  
11.7 Regulatory Requirements for Reporting of Serious Adverse Events 
The Investigator or medically qualified designee will promptly report all SAEs in accordance 
with the procedures detailed in Section 11.6. Prompt notification of SAEs by the Investigator is 
essential so that the Sponsor may comply with its regulatory obligations. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 66 of 85 
Any SAEs requiring expedited reporting will be reported the Sponsor to relevant regulatory 
authorities, Investigators and IRBs/ECs in accordance with the Sponsor’s procedures and local 
regulatory requirements. 
11.8 Poststudy Adverse Events 
A poststudy AE is defined as any event that occurs outside of the AE detection period defined in 
Section 11.3. 
Investigators are not obligated to actively seek AEs in former study participants. However, if the 
Investigator learns of any SAE, including a death, at any time after a participant has been 
discharged from the study, and he/she considers the event reasonably related to the IP, the 
Investigator will promptly notify the Sponsor.  
11.9 Serious Adverse Events Related to Study Participation 
An SAE considered related to study participation (eg, procedures, invasive tests, a change in 
existing therapy), even if it occurs during the pretreatment or post-treatment period, will be 
reported promptly (refer Section 11.7). 
12 DATA ANALYSIS AND STATISTICAL CONSIDERATIONS 
Statistical analyses and descriptive summaries will be presented for primary, secondary and 
exploratory endpoints using appropriate methods. Any proposed amendments to the Statistical 
Analysis Plan will only occur prior to database lock. Descriptive statistics will be presented for 
all analyses unless otherwise specified. For continuous variables, data will be presented as 
number (n), mean, median, standard deviation (SD), minimum, and maximum. Discrete variables 
will be presented as frequencies and proportions or percent. Data will be analyzed by treatment 
groups of ARO-ANG3 50, 100, and 200 mg and placebo. 
Additional details of all planned analyses will be provided in the Statistical Analysis Plan. 
12.1 Endpoints 
Primary Endpoint 
The primary endpoint in this study is: 
• Percent change from baseline at Week 24 in fasting TG during. 
Secondary Endpoints 
The following secondary endpoints will be evaluated during 36-week double blind study period: 
• Percent change from baseline in fasting TG over time through Week 36 
• Percent change from baseline at Week 24 and over time through Week 36 in fasting 
non−HDL-C 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 67 of 85 
• Percent change from baseline at Week 24 and over time through Week 36 in fasting total 
apolipoprotein (Apo) B 
• Percent change from baseline at Week 24 and over time through Week 36 in fasting 
LDL-C using ultracentrifugation; 
• Percent change from baseline at Week 24 and over time through Week 36 in 
angiopoietin-like protein 3 (ANGPTL3)  
• Percent change from baseline at Week 24 and over time through Week 36 in fasting 
HDL-C;  
• Plasma concentrations of ARO-ANG3 over time through Week 12; and  
• The frequency and severity of AEs and SAEs at Week 24 and over time through 
Week 36. 
The following secondary endpoints will be evaluated in the OLE portion of the study: 
• Percent change from baseline in fasting TG, non−HDLC, total apolipoprotein (Apo) B, 
LDL-C using ultracentrifugation, ANGPTL3, HDL−C, and plasma ARO-ANG3 at all 
visits as described in Table 2 (SOA).  
• The frequency and severity of AEs and SAEs through Month 24.  
 
Exploratory Endpoints 
The following exploratory endpoints will be evaluated in this study: 
• Change from baseline over time during double-blind study period as well as open-label 
treatment period in other fasting lipid parameters (total cholesterol, LDL/HDL ratio, very 
low-density lipoprotein-cholesterol (VLDL-C), ApoB-48, lipoprotein (LP)(a), ApoB-
100, ApoC-III, ApoCII, ApoA-I, ApoA-V, and ApoA-1 
• Change from baseline to Week 24 and over time through Week 36 during the double-
blind study period as well as over time in the open-label treatment period in fasting 
serum blood glucose, HbA1c, homeostatic model assessment for insulin resistance 
(HOMA-IR) and C-peptide; 
• Proportion of participants requiring emergent apheresis over time during the double-
blind study period as well as during the OLE treatment period; 
• Change from baseline to Week 24 in liver fat content using magnetic resonance imaging-
proton density fat fraction (MRI-PDFF; only in participants with a liver fat fraction of 
≥ 8% at Screening); and 
• Emergence of and levels of anti-drug antibodies to ARO-ANG3 in those receiving 
ARO-ANG3 over time during the double-blind study period as well as over time during 
the open-label treatment period. 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 68 of 85 
12.2 Analysis Populations 
The following study populations are defined for 36-week double blind study period and OLE 
Treatment Period in this study, respectively: 
• Full Analysis Set (FAS): All randomized participants who receive at least 1 dose of IP 
during the study period. All efficacy analyses will be performed using FAS. Participants 
will be analyzed according to the treatment assigned at randomization. 
• Safety Analysis Set: All participants who receive at least 1 dose of IP during the study 
period. All safety and tolerability analyses will be performed using this set. Participants 
will be analyzed according to the treatment they actually received. 
• PK Analysis Set: All FAS participants who have sufficient plasma concentration data to 
facilitate determination of PK parameters. 
12.3 Sample Size Considerations 
With a total of 180 participants randomly assigned to treatment in a 3:1 (active to placebo) ratio 
within each dosing cohort, the study will have greater than 98% power to detect at least 1 active 
treatment dose cohort which is significantly different from placebo, and at least 95% power to 
detect all treatment dose cohorts which are significantly different from placebo using a two-sided 
test, with 5% level of significance, adjusted for multiplicity. These estimates are based on the 
assumption of 35% to 60% reduction from baseline in fasting TG in the 3 active treatment dose 
cohorts and no change in fasting TG in the pooled placebo cohort. The SD is assumed to be 65% 
in the pooled placebo group and 35% to 55% in the active treatment groups (Graham 2017).  
12.4 Stratification 
Enrollment will be stratified into placebo and active groups based on: 
• Level of LDL-C at Screening ≥ 100 versus < 100 mg/dL (≥ 2.59 versus < 2.59 mmol/L). 
Prespecified subgroup analyses will be conducted for: 
• Participants with reported history of ASCVD (coronary artery disease, symptomatic 
peripheral artery disease, Stroke/transient ischemic attack). 
12.5 Analysis Methods 
Screening Data 
Demographics will be tabulated by participant and summarized by for each dose level and for 
pooled placebo. Eligibility assessments at baseline, including medical/surgical history data and 
physical examination data (including height and weight), will be listed for each participant. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 69 of 85 
Medical history will be summarized and listed by participant. Medical history will be coded 
using the MedDRA. Prior and Concomitant Medications will be coded using the World Health 
Organization Drug Dictionary into drug class (Anatomical Therapeutic Chemical level 4) and 
PT. Preferred terms will be summarized and listed, and verbatim terms will be listed by 
participant. 
Efficacy and Pharmacodynamics Analysis 
The primary analysis will be performed using a mixed-model repeated measures approach with 
treatment, study visit, stratification factor, and baseline TG level included as model terms. The 
model will also include treatment by visit and treatment by baseline interaction terms. The 
primary estimate of interest will be the difference in means between each active treatment dose 
group and pooled placebo group, evaluated at Week 24 during double-blind study period. When 
performing the primary analysis, the adjustment for multiplicity of testing several arms versus 
placebo will be carried out using Holm’s step-down procedure.  
All continuous secondary endpoints during double-blind study period will be analyzed in a 
similar manner to the primary endpoint, unless otherwise noted. Descriptive statistics of 
biomarker changes will include mean, median SD, minimum, and maximum. The frequency and 
severity of AEs and SAEs at Week 24 and over time through Week 36 during double-blind study 
period will be summarized with descriptive statistics.  
For efficacy variables during open label treatment period, the measurements and changes and/or 
percent changes from baseline over time will be summarized descriptively. 
Data will be summarized as applicable for the following: serum ANGPTL3, ApoC-II, ApoCIII, 
LDL-C, total cholesterol, non-HDL-C, HDL-C, VLDL-C, LDL-C/HDL-C, LP(a), TG, ApoB-48, 
ApoB-100, total ApoB, ApoA-I, ApoA-V, HbA1c, C-peptide, changes in serum insulin, 
HOMAIR, and changes in serum glucose.  
For primary endpoint (TG) analysis at Week 24 during double-blind study period, the laboratory 
value for endpoint analysis will be the arithmetic mean of 2 values taken during Week 24. If only 
1 value is available during Week 24, then this value will be used for endpoint analysis. For data 
analysis purposes, baseline will be defined as the arithmetic mean of Day 1 predose assessment 
and two fasting assessments during screening period. For other efficacy endpoints, only Day 1 
predose assessment will be used as the baseline. 
After the last subject in the Double Blind Treatment Period completes the Week 36 Visit, an 
interim analysis will be conducted to review the efficacy and safety data in order to select a 
single dose level for all subjects in OLE Treatment Period and for the remainder of their 
participation in the trial. 
For efficacy variables during open-label treatment period, the measurements and changes and/or 
percent changes from baseline over time will be summarized descriptively. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 70 of 85 
Pharmacokinetic Analysis 
Plasma concentrations of ARO-ANG3 will be measured in all participants to evaluate trough and 
postdose levels through the study (see SOA in Table 1).  
Full PK group: In each of the dose cohorts, 16 PK participants (12 active, 4 placebo for a total 
of 48 participants for PK) will be enrolled at the designated PK sites. Plasma concentrations will 
be measured predose and serially postdose on Day 1 and Week 12 as per the SOA. Only samples 
collected from participants receiving active treatment will be included in the PK analysis. 
Sparse Sample PK group: All other participants at all sites will provide a predose PK sample 
and 1 additional sample >15 minutes postdose on Day 1 and Week 12 as per the SOA.   
Safety/Tolerability Analysis 
In general, safety analyses will be performed and the results summarized by treatment groups. 
Post-treatment safety assessments will be compared with measurements recorded at baseline. 
Treatment-emergent AEs will be summarized using the latest version of the MedDRA by System 
Organ Class (SOC) and PT. The incidence of AEs, SAEs, related AEs, related SAEs, and AEs 
leading to discontinuation, will be summarized by treatment group and by dose level per SOC, 
PT, and severity. All AEs will also be presented in listings. The duration of AEs will be 
determined and included in listings, along with the action taken and outcome. The incidence of 
laboratory abnormalities will be assessed using descriptive summary statistics and shift tables. 
Vital sign measurements will be summarized at each scheduled time point using descriptive 
statistics. Abnormal physical examination findings will be summarized by time point and 
presented in listings. The ECG parameters, changes from baseline, and qualitative assessments 
will be summarized. Pregnancy and FSH test results will be listed separately by time point.  
Analysis of Immunogenicity (Anti-drug Antibodies) Data 
Changes from assay negative to positive will be summarized by dose and number of doses 
administered. Descriptive statistics of immunogenicity parameters will include mean, SD, 
minimum, and maximum. 
12.6 Data Recording and Quality Control 
Source documents must be maintained for each participant in the study, consisting of all 
demographic and medical information, including clinical laboratory data, etc. A copy of the 
signed informed consent form must be retained. All information on the eCRFs must be traceable 
to these source documents in the participant's file.  
Data recorded in all participants’ eCRFs will be subjected to a quality control review.  
13 STUDY APPROVAL AND CONDUCT 
The following conditions will be met. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 71 of 85 
13.1 Regulatory Approval 
The requirements for the conduct of clinical studies in accordance with local applicable 
regulations will be met before commencement of this study. 
13.2 Institutional Review Board (IRB)/Ethics Committee (EC) Approval 
Prior to initiation of the study, written IRB/EC approval of the Protocol and Informed Consent 
Forms, based on the principles of ICH GCP, will be received. A copy of the signed and dated 
letter of approval will be provided to the clinical site and Sponsor prior to study commencement. 
Any written information and/or advertisements to be used for participant recruitment will be 
approved by the IRB/EC prior to use. A list of the IRB/EC voting members, their titles or 
occupations, FWA number (where applicable) and their institutional affiliations will be requested 
before study initiation.  
Protocol modifications that may impact participant safety or the validity of the study will be 
approved by the IRB/EC, following written agreement from the Sponsor. 
13.3 Ethical Considerations 
This study will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory 
requirement(s). The protocol will be submitted for approval to the IRB/EC, and written approval 
obtained before participants are enrolled. The composition of the IRB/EC will also be provided 
to the Sponsor. If approval is suspended or terminated by the IRB/EC, the Investigator will 
notify the Sponsor immediately. 
Where applicable, the clinical site and Sponsor agree to abide by the local compensation 
guidelines for injury resulting from participating in a company-Sponsored research project. 
Compensation will only be provided on the understanding that the provision of compensation 
does not amount to an admission of legal liability and is subject to the proposed recipient signing 
a full and complete release of the company from all claims, damages and costs. 
13.4 Written Informed Consent 
Informed consent will be obtained before the participant can participate in the study. The 
contents and process of obtaining informed consent will be in accordance with all applicable 
regulatory requirements. Study participation includes all screening procedures, as well as any 
wash-out of excluded medications. 
It is the responsibility of the Investigator or medically qualified designee to obtain a written 
informed consent from everyone participating in this study after adequate explanation of the 
aims, methods, objectives, and potential hazards of the study. The Investigator or medically 
qualified designee must also explain to the participants that they are completely free to refuse to 
enter the study or to withdraw from it at any time. Appropriate forms for documenting a written 
consent will be provided by the Investigator or by the Sponsor. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 72 of 85 
For this study, each eligible participant will be required to provide written informed consent 
before participation in the study.  
All eligible participants will have the study explained by the Investigator or designee. They will 
receive a full explanation, in lay terms, of the aims of the study, the discomforts, risks and 
benefits in taking part as well as of insurance and other procedures for compensation in case of 
injury. It will be explained that the study is for research purposes only and is not expected to 
provide any therapeutic benefit to the individual. It will be pointed out that they can withdraw 
from the study at any time without prejudice. Each participant will acknowledge receipt of this 
information by giving written informed consent for participation in the study. The participant 
will be given a copy of the signed Informed Consent Form to retain. 
13.5 Emergency Contact with Principal Investigator 
Suitable arrangements will be made for participants to contact the Investigator or medically 
trained designee in the event of an emergency. 
13.6 Notification of General Practitioner 
It is the responsibility of the Investigator or designee, to notify, where applicable, with the 
consent of the participant, the general practitioner of the participant’s participation in the study, 
by sending a letter stating the nature of the study, treatments, expected benefits or AEs and 
concomitant drugs to be avoided. 
13.7 Clinical Laboratory Certification and Reference Ranges 
Before the initiation of this study, the Investigator or designee will obtain a copy of the 
certification form, with certification number and expiration date for all clinical laboratories 
(excluding central laboratories) used in the study. Reference ranges for each clinical laboratory 
test used in this study will be obtained from the appropriate central laboratory, which will 
perform the test for the study. In the event of major logistical disruptions (eg, COVID-related) 
where a participant does not have direct access to the site and central laboratory kit collection is 
not available, local laboratory safety testing with associated local lab reference ranges may only 
be permitted in limited circumstances and only with prior Sponsor approval.  
13.8 Protocol Deviations 
A protocol deviation is defined as any intentional or unintentional change to, or noncompliance 
with, the approved protocol procedures or requirements. The Investigator will conduct the study 
in compliance with the approved protocol and will not implement any deviation from or changes 
to the protocol, except where necessary to eliminate an immediate hazard to study participants. 
Deviations may result from the action or inaction of the participant, Investigator, or site staff. 
Examples of deviations include, but are not limited to: 
• Failure to adhere to study exclusion and inclusion criteria; 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 73 of 85 
• Failure to comply with dispensing or dosing requirements; 
• Use of medications, food, drink, herbal remedies, or supplements that are specifically 
prohibited in the protocol; 
• Missed or out-of-window visits; 
• Drug dosing not administered within the time frame specified in the protocol; 
• Failure to adhere to test requirements, including vital signs, laboratory tests, physical 
examinations, PK blood draws, medical history, etc. – either tests not done, incorrect tests 
done, or not done within the time frame specified in the protocol; and 
• Procedural deviations such as incorrect storage of IP, failure to update the Informed 
Consent Form when new risks become known, failure to obtain IRB/EC approvals for the 
protocol and Informed Consent Form revisions. 
Protocol deviations impacting participant safety or eligibility will be reported to the Sponsor or 
CRO within 2 business days of occurrence and to the IRB/EC/competent regulatory authority per 
local regulatory requirements.  
The Investigator is responsible for ensuring that any known protocol deviations are recorded and 
reported as agreed. The nature and reasons for protocol deviations will be recorded. 
13.9 Termination of the Study 
The Sponsor reserves the right to discontinue the study at any time. Reasons will be provided in 
the event of this happening.  The circumstances under which the study may be terminated 
include:  
• 
Discontinuation of the study is in the interest of the health of trial participants;  
• 
Continuation of the clinical trial no longer serves a scientific purpose.   
The Investigator reserves the right to discontinue the study for safety reasons at any time in 
collaboration with the Sponsor. 
14 STUDY ADMINISTRATION 
14.1 Study Monitoring 
The Sponsor is responsible for assuring the proper conduct of the study about protocol adherence 
and validity of the data recorded on the eCRFs. Participant confidentiality will be maintained. 
In accordance with applicable regulations, GCP and Sponsor procedures, the Sponsor will be 
responsible for assigning a study monitor (CRA) who will contact the site to organize a visit 
prior to participant enrollment to review the protocol and data collection procedures with site 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 74 of 85 
staff. In addition, the assigned study monitor will periodically contact the site, including 
conducting on-site and remote monitoring visits. The extent, nature and frequency of visits will 
be based on such considerations as the study objective and/or endpoints, the purpose of the 
study, study design complexity and enrollment rate. 
During special circumstances (eg, COVID-19 restrictions) the specific guidance from local 
public health and other competent authorities regarding the protection of individuals’ welfare 
must be applied. For the duration of such special circumstances, remote monitoring may be 
implemented to adhere to study specifications. 
During these site visits, the study monitor will: 
• Check the progress of the study; 
• Review study data collected; 
• Conduct source document verification; 
• Identify any issues and address their resolution; 
• Check IP accountability; and 
• Review blood and urine samples and ensure they are labeled and stored correctly. 
This will be done to verify that the: 
• Data are authentic, accurate and complete; 
• Safety and rights of participants are being protected; and 
• Study is conducted in accordance with the currently approved protocol (and any 
amendments), GCP and all applicable regulatory requirements. 
The Investigator agrees to allow the monitor direct access to all relevant documents and to 
allocate his/her time and the time of his/her staff to the monitor to discuss findings and any 
relevant issues. 
At study closure, a study monitor will conduct the following activities in conjunction with the 
Investigator or site staff as appropriate: 
• Return of all study data to the Sponsor; 
• Data queries; 
• Accountability, reconciliation and arrangements for unused IP(s); 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 75 of 85 
• Inventory and final disposition (eg, destruction, shipping to repository, etc.); and 
• Review of site study records for completeness. 
14.2 Quality Assurance 
To ensure compliance with GCP and all applicable regulatory requirements, the Sponsor may 
conduct a quality assurance audit of the study site. Regulatory agencies may also conduct a 
regulatory inspection of this study. Such audits/inspections can occur at any time during or after 
completion of the study. If an audit or inspection occurs, the Investigator and clinical site agree 
to notify Sponsor as soon as possible following awareness of an impending regulatory 
inspection. The Investigator and clinical site agree to allow the auditor/inspector direct access to 
all relevant documents and allocate his/her time and the time of his/her staff to the 
auditor/inspector to discuss findings and any relevant issues. 
14.3 Records Retention 
Following closure of the study, the Investigator must maintain all site study records in a safe and 
secure location. The records must be maintained to allow easy and timely retrieval, when needed 
(eg, audit or inspection) and whenever feasible, to allow any subsequent review of data in 
conjunction with assessment of the facility, supporting systems and staff. When permitted by 
local laws/regulations or institutional policy, some of these records can be maintained in a format 
other than hard copy (eg, microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is taken. The Investigator must assure that all reproductions are 
legible and are a true and accurate copy of the original and meet accessibility and retrieval 
standards, including re-generating a hard copy, if required. Furthermore, the Investigator must 
ensure there is an acceptable back-up of these reproductions and that an acceptable quality 
control process exists for making these reproductions. 
The Sponsor will inform the Investigator of the time period for retaining these records to comply 
with all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by any institutional requirements or local 
laws or regulations, or Sponsor standards/procedures; otherwise, the retention period will default 
to 15 years. 
The material to be stored shall include, but is not limited to, the following: 
• Signed and dated copy of the final study protocol and any amendments; 
• Signed and dated letter of IRB/EC approval, letter of constitution of the IRB/EC and 
copies of any other correspondence relevant to the study with the IRB/EC or regulatory 
authorities; 
• The IRB/EC approved informed consent form; 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 76 of 85 
• Current curriculum vitae (signed and dated) of the Principal Investigator and co-workers 
with major responsibilities in the study; 
• Site Signature and Delegation of Responsibility Log; 
• Food and Drug Administration Form 1572 (where applicable); 
• Financial Disclosure Form(s); 
• Blank CRF/eCRF; 
• Signed participant informed consent forms; 
• Laboratory reference ranges (signed and dated); 
• The completed Clinical Trial Notification Application Form (where applicable); and 
• Clinical raw data including the Source Data Forms, all clinical laboratory report forms, 
participant CRFs, drug accountability forms, and dispensing records, etc. 
 
15 INFORMATION DISCLOSURE AND INVENTIONS 
15.1 Ownership 
 
 
 
 
 
 
 
 
15.2 Confidentiality 
 
 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 77 of 85 
 
 
 
15.3 Publication 
 
 
 
 
 
 
  
 
 
 
 
 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 78 of 85 
16 REFERENCES 
Barquera S, Pedroza-Tobias A, Medina C, Hernandez-Barrera L, Bibbins-Domingo K, Lozano 
R, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch 
Med Res. 2015;45(5):328-38. 
Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, and Soni PN. 
Eicosapentaenoic Acid Ethyl Ester (Amr101) Therapy in Patients with Very High Triglyceride 
Levels (from the Multi-Center, Placebo-Controlled, Randomiz. Am J Cardiol. 
2011;108(5)682-90. 
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of 
LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of 
Cardiovascular Events Among Patients Treated with Statins - A Meta-analysis. JAMA. 
2012;307(12):1302-09. 
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. 
Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High 
Risk of Cardiovascular Disease: Evidence and Guidance for Management. Eur Heart J, 
2011;32(11):1345-61. 
Conklin D, Gilbertson D, Taft DW, Maurer MF, Whitmore TE, Smith DL, et al. Identification of 
a mammalian angiopoietin-related protein expressed specifically in liver. Genomics. 
1999;62(3);477-82. 
Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic 
and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 
2017;377(3):211-21. 
Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 Inhibition in 
Homozygous Familial Hypercholesterolemia. N Engl J Med. 2017;377(3):296-7. 
Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, et al. Clinical 
Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary 
Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a 
Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2017;2(12):1385-91. 
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. 2017. Cardiovascular and 
Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 
2017;377(3):222-32. 
Hussain, A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD Risk Reduction: 
Recent Insights and Future Directions. Curr Atheroscler Rep 2020;22(7):25. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 79 of 85 
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al.National Lipid 
Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 - Full 
Report. J Clin Lipidol. 2015;9(2):129-69. 
Janas, MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, et al. The 
Nonclinical Safety Profile of Galnac-Conjugated RNAi Therapeutics in Subacute Studies. 
Toxicol Pathol. 2018;46(7):735-45. 
Jorgensen, AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. 
Genetically Elevated Non-Fasting Triglycerides and Calculated Remnant Cholesterol as Causal 
Risk Factors for Myocardial Infarction. Eur Heart J 2013;34(24):1826-33. 
Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 
2017;13(12):731-9. 
Lawler PR, Akinkuolie AO, Chu AY, Shah SH, Kraus WE, Craig D, et al. Atherogenic 
Lipoprotein Determinants of Cardiovascular Disease and Residual Risk among Individuals. 
J Amer Heart Assoc. 2017;6. 
Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, et al. 
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across 
Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression 
Analysis of Randomized Controlled Trials. Circulation. 2019;140(16):1308-17. 
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of Triglyceride 
Levels Beyond Low-Density Lipoprotein Cholesterol after Acute Coronary Syndrome in the 
Prove It-Timi 22 Trial. J Am Coll Cardiol. 2008;51(7):724-30.  
Musunuru, K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et. al. Exome 
sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 
2010;363(23):2220-7. 
Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: 
New Insights from Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547-63. 
Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, et al. Atypical 
angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 
2012;109(48):19751-6. 
Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, et al. Consensus: 
guidelines: best practices for detection, assessment and management of suspected acute drug-
induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment 
Pharmacol Ther. 2019;49(6):702-13. 
Robciuc MR, Tahvanainen E, Jauhiainen M, Ehnholm C. Quantitation of serum angiopoietin-
like proteins 3 and 4 in a Finnish population sample. J Lipid Res. 2010;51(4):824-31. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 80 of 85 
Rubins, HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the 
secondary prevention of coronary heart disease in men with low levels of high-density 
lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention 
Trial Study Group. N Engl J Med. 1999;341(6):410-8. 
Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. 2017. ANGPTL3 
Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol. 
2017;69(16):2054-2063. 
Tilg H, Moschen AR. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The 
Multiple Parallel Hits Hypothesis. Hepatology. 2010;52(5):1836-46. 
Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: The National 
Health and Nutrition Examination Survey 2003–2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325-30. 
Van Horn L, Carson JA, Appel LJ, Burke LE, Economos C, Karmally W, et al. Recommended 
Dietary Pattern to Achieve Adherence to the American Heart Association/American College of 
Cardiology (AHA/ACC) Guidelines: A Scientific Statement from the American Heart 
Association. Circulation. 2016;134(22):e505-29. 
Xu YX, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, et al. Role of angiopoietin-like 3 
(ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 
2018;268:196-206. 
 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 81 of 85 
17 Appendix 1 
Table 8: 
Liver Related Study Modification and Follow-Up Guidelines for Participants 
Treatment-Emergent 
AST or ALT 
Treatment-
Emergent Total 
Bilirubin (TBL)  
Liver Symptoms  
Action  
Normal baseline: AST   
or ALT >3× ULN  
Elevated baseline: AST 
or ALT >2× baseline or 
>300 U/L (whichever 
occurs first) 
Normal 
Participants with 
Gilbert’s 
syndrome or 
hemolysis- no 
change in baseline 
TBL 
None 
Confirm AST, ALT, ALP, TBL 
within 72 hours. Initiate close 
observation and workup for 
competing etiologies1 
Follow-up for symptoms. 
Normal baseline: AST 
or ALT >5× ULN 
Elevated baseline: AST 
or ALT >3× baseline or 
≥300 U/L (whichever 
occurs first) 
Normal  
Participants with 
Gilbert’s 
syndrome or 
hemolysis- no 
change in baseline 
TBL 
None  
Discontinue IP.  
Confirm AST, ALT, ALP, TBL 
within 72 hours. Initiate close 
observation and workup for 
competing etiologies1 
Refer to guidelines for close 
observation below.  Follow-up 
for symptoms. 
Normal baseline: AST   
or ALT >3× ULN  
Elevated baseline: AST 
or ALT >2× baseline or 
>300 U/L  
(whichever occurs first)  
Normal  
Participants with 
Gilbert’s 
syndrome or 
hemolysis- no 
change in baseline 
TBL 
 Symptoms of 
clinical hepatitis – 
severe fatigue, 
nausea, vomiting, 
right upper 
quadrant pain or; 
immunologic 
reactions (eg rash, 
>5% eosinophilia) 
Interrupt IP.  Confirm AST, 
ALT, ALP, TBL within 72 
hours. Initiate close observation 
and workup for competing 
etiologies.1  
IP can be restarted only if an 
alternative etiology is identified 
and liver enzymes return to 
baseline. IP cannot be restarted 
if hepatic decompensation 
occurred. 
Refer to guidelines for close 
observation below. Follow-up 
for symptoms. 
Normal baseline: AST 
or ALT >3× ULN  
Elevated baseline: AST 
or ALT >2× baseline or 
≥300 U/L (whichever 
occurs first)  
TBL >2× ULN  
or increased INR 
to >1.5 
In participants 
with Gilbert’s 
syndrome or 
hemolysis- 
doubling of direct 
None  
Interrupt IP.  
Confirm AST, ALT, ALP, TBL 
within 72 hours. Initiate close 
observation and workup for 
competing etiologies.1  


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 82 of 85 
Treatment-Emergent 
AST or ALT 
Treatment-
Emergent Total 
Bilirubin (TBL)  
Liver Symptoms  
Action  
bilirubin if 
baseline 
>0.5 mg/dL  
Initiate close observation and 
workup for competing 
etiologies.1 
IP can be restarted only if an 
alternative etiology is identified 
and liver enzymes return to 
baseline. IP cannot be restarted 
if hepatic decompensation 
occurred. 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; IP = investigational product; TBL = total bilirubin; ULN = upper limit of 
normal.  
1 Competing etiologies include: acute and chronic viral hepatitis (hepatitis A-E), cholelithiasis, alcohol, other drugs 
both prescribed and over-the-counter herbs and supplements.  
Source: Adapted from Regev A, Palmer M, Avigan MI, et al. Consensus: guidelines: best practices for 
detection, assessment and management of suspected acute drug-induced liver injury during clinical trials 
in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2019;49:702-713. 
Guidelines for close observation for potential drug induced liver injury:  
Within 72 hours, perform a complete history, physical, and liver biochemistries, including 
evaluation of: 
• New or worsening signs and symptoms of clinical hepatitis such as fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia  
• Concomitant medications, including acetaminophen, dietary supplements, herbal 
remedies, OTC medications, recreational drug use, and special diets  
• Alcohol consumption  
• Exposure to environmental chemical agents  
• Past medical history  
• Complete review of systems  
• Liver biochemistries including ALT, AST, alkaline phosphatase, total bilirubin, and INR.  
Evaluate participants 2 or 3 times a week for signs and symptoms of clinical hepatitis and obtain 
liver biochemistries until biochemistries stabilize. 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 83 of 85 
If biochemistries stabilize and the participant is asymptomatic, monitor liver biochemistries once 
a week until they return to baseline. 
Participants who live far from study sites may be evaluated locally for history, physical exam, 
and laboratories, if the results are communicated promptly to the site Investigator. 
 
 


 
Protocol Number: AROANG3-2001 
Protocol Amendment 3: 22NOV2022 
 
 
Confidential 
Page 84 of 85 
18 Appendix 2 
Table 9: 
Local Injection Site Reactions (LISRS) 
The following MedDRA Preferred Terms determined by the Sponsor’s pharmacovigilance 
personnel represent the local injection site reaction: 
Injection site discomfort 
Injection site abscess 
Injection site discoloration 
Injection site abscess sterile 
Injection site erythema 
Injection site atrophy 
Injection site irritation 
Injection site calcification 
Injection site inflammation 
Injection site cellulitis 
Injection site induration 
Injection site dermatitis 
Injection site paint 
Injection site erosion 
Injection site edema 
Injection site fibrosis 
Injection site pruritus 
Injection site indentation 
Injection site rash 
Injection site necrosis 
Injection site urticaria 
Injection site nodule 
Injection site reaction 
Injection site ulcer 
Injection site swelling 
 
 
Local injection-site reactions will only include events that start on the day of injection and persist 
for at least 48 hours post injection (ie, event onset date on the day of injection and resolution date 
not on the day of injection or the day after the injection) will be included. Events with onset date 
on the day of injection and missing resolution date will also be included in the summary. 
The following calculation will be utilized to determine the percentage of injections leading to 
local injection site reactions: 
(A/B)*, where A = number of injections with a local injection site reactions, and B = total 
number of injections. 
 
 




Arrowhead Pharmaceuticals  
Confidential 
Page 1 of 2 
Protocol No.: AROANG3-2001 
 
PROTOCOL AMENDMENT SUMMARY OF CHANGES 
 
PROTOCOL 
NUMBER: 
AROANG3-2001 
STUDY TITLE: 
A Double-blind, Placebo-controlled Phase 2b Study to 
Evaluate the Efficacy and Safety of ARO-ANG3 in Adults 
with Mixed Dyslipidemia 
 
 
 
Protocol Amendment 1, Dated 1-March-2021 
− Established minimum time on stable statin regimen to >4 weeks 
− Revised treatment stopping rules due to liver transaminase elevations 
− Revised possible outcomes of Data Safety Committee meetings 
− Revised key inclusion criteria relating to triglyceride (TG) level upper limit, refined 
restrictions on lipid lowering medicadtion and other background therapies; 
− Extended duration of contraceptive use by 12 weeks and requires minimum hormonal 
contraceptive use duration for women of child-bearing potential prior to enrollment 
− Revised exclusion criterion related to medical history and laboratory signs; 
− Removed PK sample collection timepoint at Week 36/EOS and revised associated 
secondary endpoint 
− Removed TG stratification and associated prespecified subgroup analyses 
− Extended contraception requirement to 24 weeks after last administration of 
investigstional product   
− Revised the Schedule of Assessments (Table 1) to: 
o include three distinct screening visits  
o add pregnancy testing for women of childbearing potential at each study visit 
o add urine protein dipstick test 
o clarify fasting requirements relative to assessments and timepoints 
o separate TG, LDL-C, HDL-C and non-HDL-C  testing and clarify timepoints 
o require waiing at least 15 minutes prior to postdose Sparse sample PK collection 
− Removed option for home study visit at Week 12 dosing 
− Clarified baseline values for TG, HDL-C, and non-HDL-C   
− Revised restrictions on concomitant medications during treatment period 
 
 
Protocol Amendment 2, Dated 11-November-2021 
− Added the 24-month Open-Label Extension (OLE) Treatment Period with quarterly 
dosing (Q3M) following the Blinded Treatment Period for a total study duration of 
approximately 35 months and clarified plans for dose level assignment in the OLE 
Treatment Period  
− Updated Treatment Stopping Rules 
− Updated eligibility criteria:  
a) Updated requirement for prior evidence of fasting TG  


Arrowhead Pharmaceuticals  
Confidential 
Page 2 of 2 
Protocol No.: AROANG3-2001 
b) Allowed for participants documented as statin interolerant  
c) Extended time between qualifying TG collections during Screening  
d) Added anticoagulation therapy, testoerone replacement therapy, and thyroid 
hormone replacement therapy to the list of restricted medications  
e) Clarified hypertension exclusion criterion  
f) Replaced urine protein exclusion with spot urine protine/spot urine creatinine 
ratio  
g) Revised alcohol unit definitions and allowable daily consumption limit  
h) Added eligibility criterion for OLE Treatment Period 
− Updated Table 1, 36-Week Double-Blind Period Schedule of Assessments as follows:  
a) Adjusted Screening Visit (S1) window to permit overlap with S2 Visit  
b) Allowed flexibility to combine S1 and S2 where permitted  
c) Clarified collection timing of second lipid collection after Week 24 and Week 36  
−  Added Table 2: Open-Label Extension Treatment Period Schedule of Assessments  
− Clarified that qualifying LDL-C value at Screening may be based on either Martin-
Hopkins method or ultracentrifiguation method.  
− Updated lipid monitoring parameters for increased LDL-C results following the Week 24 
visit from baseline to notify the investigator and Medical Monitor and unblind LDL-C 
participant values as needed to provide appropriate medical follow-up  
−  Revised lipid testing restrictions to allow for provision of lipid results to Investigator in 
the OLE Treatment Period 
− Updated Statisticial section to include interim analysis at Week 36  
−  Added secondary endpoints in the OLE portion of the study  
−  Updated exploratory endpoints to include both blinded and OLE portions of the study  
− 
Clarified that the mean of the two fasting screening values together with the fasting Day 
1 TG value will serve as the baseline value for the primary endpoint analysis 
− Updated the circumstances under which the sponsor may terminate the study  
−  Revised pregnancy reporting and collection of information for up to 1 year  
−  Updated Liver Related Study Modification and Follow-Up Guidelines for Participants 
(Appendix 1) 
 
 
Protocol Amendment 3, Dated 22-November-2022 
− Removed 200 mg dose from the 24-Month OLE treatment period  
− Speified plan to transition subjects assigned to the 200 mg dose cohort to the 100 mg 
dose cohort in the OLE 
− Added guidelines for new study drug discontinuation critieris in response to HbA1c 
elevation 
− Added HbA1c laboratory test at Month 1 and Month 2 of the OLE treatment period 
− Updated risk assessment for study participants in response to HbA1c elevation 
 
 

SAP_001.pdf: 
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
Arrowhead Pharmaceuticals, Inc.
Protocol #: AROANG3-2001
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy 
and Safety of ARO-ANG3 in Adults with Mixed Dyslipidemia
Statistical Analysis Plan
Version 2.0
'RFXPHQWODVWVDYHG 2FW$0
Prepared by:
Approved by:


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
CONTENTS
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQVRI7HUPV  
,,QWURGXFWLRQ   
$ %DFNJURXQG   
% 3URWRFRODQG$PHQGPHQW+LVWRU\  
& &KDQJHVIURP3ODQQHG$QDO\VHVLQWKH3URWRFRO  
,,3URWRFRO2EMHFWLYHV   
$ 3ULPDU\2EMHFWLYH  
,,,6WXG\(QGSRLQWV   
$ 3ULPDU\  
% 6HFRQGDU\   
& ([SORUDWRU\   
,96WXG\'HVLJQ   
$ 'HVLJQ2YHUYLHZ   
% 6WXG\3RSXODWLRQ   
& 6DPSOH6L]H3UHGLFWLRQV  
' 7UHDWPHQW5DQGRPL]DWLRQ  
( $VVHVVPHQW6FKHGXOH  
9*HQHUDO$QDO\WLFDO&RQVLGHUDWLRQV   
$ 'DWD6RXUFHV   
% %DVHOLQHDQG6WXG\'D\  
& $QDO\VLV9LVLW:LQGRZ  
' 0LVVLQJ'DWD   
( 0XOWLSOH6WXG\&HQWHUV   
) &RYDULDWH$GMXVWPHQWLQ3ULPDU\$QDO\VLV  
* 6DPSOH6L]H5HDVVHVVPHQW  
+ ,QWHULP$QDO\VHVRU7LPLQJRI$QDO\VHV   
, 'DWD6DIHW\&RPPLWWHH'6&  
- 7HVW6L]HV  
. 0XOWLSOH&RPSDULVRQV  
/ $QDO\VLV3RSXODWLRQV  
0 6XEJURXSVRI$QDO\VLV3RSXODWLRQV  
1 'DWD'LVSOD\&KDUDFWHULVWLFV   
9,3DUWLFLSDQW$FFRXQWDELOLW\  
$ 3DUWLFLSDQW&KDUDFWHULVWLFV  
% 'LVSRVLWLRQDQG3RSXODWLRQ,QFOXVLRQV   
& 3URWRFRO'HYLDWLRQV  
' 9LVLW$WWHQGDQFHDQG&29,',PSDFW$VVHVVPHQW   
9,,(IILFDF\$QDO\VHV  
$ 3ULPDU\(IILFDF\2XWFRPH$QDO\VLV   


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
% 6HFRQGDU\(IILFDF\2XWFRPH$QDO\VHV  
& ([SORUDWRU\(IILFDF\2XWFRPH$QDO\VHV   
' (IILFDF\$QDO\VLVRQ6XEJURXSVRI3DUWLFLSDQWV 
9,,,6DIHW\$QDO\VHV  
$ ([SRVXUHDQG&RPSOLDQFH  
% $GYHUVH(YHQWV  
& &OLQLFDO/DERUDWRU\5HVXOWV  
' 9LWDO6LJQV  
( (OHFWURFDUGLRJUDP(&*  
) 3K\VLFDO([DPLQDWLRQ   
* 3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV   
+ 2WKHU6DIHW\$QDO\VHV  
,;,PPXQRJHQLFLW\$QWLGUXJ$QWLERGLHV$QDO\VLV   
;3KDUPDFRNLQHWLFV$QDO\VHV  
;,5HIHUHQFHV  
;,,$SSHQGL[  
$ 1RQFRPSDUWPHQWDO3KDUPDFRNLQHWLF$QDO\VLV  


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
List of Abbreviations and Definitions of Terms
Abbreviation
Term
$'$
$QWLGUXJ$QWLERGLHV
$(
$GYHUVHHYHQW
$/3
$ONDOLQHSKRVSKDWDVH
$/7
$ODQLQHDPLQRWUDQVIHUDVH
$1&29$
$QDO\VLVRIFRYDULDQFH
$1*37/
$QJLRSRLHWLQOLNHSURWHLQ
$SR%
$SROLSRSURWHLQ%
$SR%
$SROLSRSURWHLQ%
$SR%
$SROLSRSURWHLQ%
$SR$,
$SROLSRSURWHLQ$,
$SR$9RU$SR$
$SROLSRSURWHLQ$9
$SR&,,RU$SR&
$SROLSRSURWHLQ&,,
$SR&,,,RU$1*
$SROLSRSURWHLQ&,,,
$52$1*,QMHFWLRQ
&OLQLFDOGUXJSURGXFWVROXWLRQUHDG\IRU6&LQMHFWLRQ
$52$1*
6KRUWQDPHIRU$52$1*,QMHFWLRQ
$6&9'
$WKHURVFOHURWLFFDUGLRYDVFXODUGLVHDVH
$67
$VSDUWDWHDPLQRWUDQVIHUDVH
$7&
$QDWRPLFDO7KHUDSHXWLF&KHPLFDO
$8&
$UHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYH
%/4
%HORZWKHOLPLWRITXDQWLILFDWLRQ
%0,
%RG\PDVVLQGH[
&,
&RQILGHQFHLQWHUYDO
&0
&RQFRPLWDQWPHGLFDWLRQ
&29,'
&RURQDYLUXVGLVHDVH
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
&6
&OLQLFDOO\VLJQLILFDQW
&9
&RHIILFLHQWRIYDULDWLRQ
'%
'RXEOH%OLQG
'%3
'LDVWROLFEORRGSUHVVXUH
'6&
'DWD6DIHW\&RPPLWWHH
(&
(WKLFV&RPPLWWHH
(&*
(OHFWURFDUGLRJUDP
H&5)
(OHFWURQLF&DVH5HSRUW)RUP
(26
(QGRI6WXG\
(7
(DUO\7HUPLQDWLRQ
)$6
)XOO$QDO\VLV6HW
)&6
)DPLOLDO&K\ORPLFURQHPLD6\QGURPH
)6+
)ROOLFOHVWLPXODWLQJKRUPRQH
*0
*HRPHWULFPHDQ
*3,+%3
*O\FRV\OSKRVSKDWLG\OLQRVLWRODQFKRUHGKLJKGHQVLW\
OLSRSURWHLQELQGLQJSURWHLQ
+E$F
*O\FRV\ODWHGKHPRJORELQ
+'/
+LJKGHQVLW\OLSRSURWHLQ
+'/&
+LJK GHQVLW\OLSRSURWHLQFKROHVWHURO
+20$,5
+RPHRVWDWLFPRGHODVVHVVPHQWIRULQVXOLQUHVLVWDQFH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
+5
+HDUWUDWH
,'/
,QWHUPHGLDWHGHQVLW\OLSRSURWHLQ
,15
,QWHUQDWLRQDOQRUPDOL]HGUDWLR
,3
,QYHVWLJDWLRQDOSURGXFW
,5%
,QVWLWXWLRQDO5HYLHZ%RDUG
,:56
,QWHUDFWLYH:HE5HVSRQVH6\VWHP
/'/
/RZGHQVLW\OLSRSURWHLQ
/'/&
/RZGHQVLW\OLSRSURWHLQFKROHVWHURO
/'/5
/RZGHQVLW\OLSRSURWHLQUHFHSWRU
/)7
/LYHUIXQFWLRQWHVW
/,65
/RFDOLQMHFWLRQVLWHUHDFWLRQ
//24
/RZHUOLPLWRITXDQWLILFDWLRQ
/0)
/LSDVHPDWXUDWLRQIDFWRU
/SD
/LSRSURWHLQD
/3/
/LSRSURWHLQOLSDVH
/6
/HDVWVTXDUHV
0$5
0LVVLQJDWUDQGRP
0&0&
0DUNRY&KDLQ0RQWH&DUOR
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
0,
0XOWLSOHLPSXWDWLRQ
0050
0L[HGPRGHOUHSHDWHGPHDVXUHV
01$5
0LVVLQJQRWDWUDQGRP
05,
0DJQHWLFUHVRQDQFHLPDJLQJ
05,3'))
0DJQHWLFUHVRQDQFHLPDJLQJSURWRQGHQVLW\IDWIUDFWLRQ
1&$
1RQFRPSDUWPHQWDODQDO\VLV
QRQ+'/&
1RQORZGHQVLW\OLSRSURWHLQFKROHVWHURO
2&
2EVHUYHGFDVHV
2/(
2SHQ/DEHO([WHQVLRQ
3'
3KDUPDFRG\QDPLF
3.
3KDUPDFRNLQHWLF
336
3HUSURWRFROVHW
37
3UHIHUUHG7HUP
47
47LQWHUYDO DPHDVXUHRIWKHWLPHEHWZHHQWKHVWDUWRI
WKH4ZDYH DQGWKHHQGRIWKH7ZDYH LQWKHKHDUW
V
HOHFWULFDOF\FOH
6$(
6HULRXVDGYHUVHHYHQW
6&
6XEFXWDQHRXV
6'
6WDQGDUGGHYLDWLRQ
62$
6FKHGXOHRI$VVHVVPHQWV
62&
6\VWHP2UJDQ&ODVV
6%3
6\VWROLFEORRGSUHVVXUH
7($(
7UHDWPHQWHPHUJHQWDGYHUVHHYHQW
7*
7ULJO\FHULGHV
7/)
7DEOHVOLVWLQJVDQGILJXUHV
75/
7ULJO\FHULGHULFKOLSRSURWHLQ
8/1
8SSHUOLPLWRIQRUPDO
9/'/
9HU\ORZGHQVLW\OLSRSURWHLQ
9/'/&
9HU\ORZGHQVLW\OLSRSURWHLQFKROHVWHURO


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
,
Introduction
A.
Background
3DWLHQWV ZLWKPL[HGG\VOLSLGHPLDDUHDWKLJKULVNRIDWKHURVFOHURWLF
FDUGLRYDVFXODUGLVHDVH$6&9'WKHOHDGLQJFDXVHRIPRUWDOLW\ZRUOGZLGH
WKDWLVDVVRFLDWHGZLWKVXEVWDQWLDOPRUELGLW\DQGKHDOWKFDUHFRVWV$6&9'LV
FRPPRQO\DVVRFLDWHGZLWKHOHYDWHGFRQFHQWUDWLRQVRIORZGHQVLW\OLSRSURWHLQ
FKROHVWHURO/'/&EXWHYHQLQWKHVHWWLQJRIDGHTXDWH/'/&FRQWURO
FRQVLGHUDEOHUHVLGXDOFDUGLRYDVFXODUGLVHDVHULVNUHPDLQVGXHWRHOHYDWHG
WULJO\FHULGHV7*DQG7*ULFKOLSRSURWHLQOHYHOV75/V
1RQ+'/&FRPSULVHV WKHFKROHVWHUROFDUULHGE\DOOSRWHQWLDOO\DWKHURJHQLF
SDUWLFOHVLQFOXGLQJORZGHQVLW\OLSRSURWHLQ/'/LQWHUPHGLDWHGHQVLW\
OLSRSURWHLQ,'/YHU\ORZGHQVLW\OLSRSURWHLQ9/'/DQG9/'/UHPQDQWV
FK\ORPLFURQSDUWLFOHVDQGFK\ORPLFURQUHPQDQWVDQGOLSRSURWHLQD/S>D@
(SLGHPLRORJLFVWXGLHVKDYHVKRZQWKDWQRQ+'/&LVDVWURQJHUSUHGLFWRURI
$6&9'PRUELGLW\DQGPRUWDOLW\WKDQ/'/&
B.
Protocol and Amendment History
7KLV6WDWLVWLFDO$QDO\VLV3ODQ6$3LVEDVHGRQ3URWRFRO$52$1*
$PHQGPHQWGDWHGWK 1RYHPEHU
7KLV6$3ZLOOQRWUHSHDWDOOWKHGHILQLWLRQVJLYHQLQWKHSURWRFROEXWZLOOSURYLGH
IXUWKHUGHWDLOVRIWKHVXPPDULHVDQGDQDO\VHVSODQQHGWKHUHLQ7KHSODQPD\
EHPRGLILHGXQWLOWKHWLPHRIWUHDWPHQWXQEOLQGLQJ$Q\GHYLDWLRQVIURPWKH
DQDO\VLVSODQLQFOXGLQJDQ\WLPHDIWHUWKHWLPHRIWUHDWPHQWXQEOLQGLQJZLOOEH
GRFXPHQWHGDVVXFKLQWKHVWXG\UHSRUW
C.
Changes from Planned Analyses in the Protocol
1RGHYLDWLRQVIURPWKHSODQQHGDQDO\VHV LQWKHSURWRFRO KDYHEHHQQRWHG
,,
Protocol Objectives
A.
Primary Objective
7KHSULPDU\REMHFWLYHRIWKHVWXG\LVWRHYDOXDWHWKHVDIHW\DQGHIILFDF\RI
$52$1*LQ DGXOWVZLWKPL[HGG\VOLSLGHPLDDQGWRVHOHFWDGRVLQJUHJLPHQ
IRUODWHUVWDJHFOLQLFDOVWXGLHVLQWKLVSDWLHQW SRSXODWLRQ
7KLVVWXG\ZLOODOVRHYDOXDWHWKHHIILFDF\VDIHW\DQGWROHUDELOLW\RIORQJWHUP
GRVLQJRI$52$1*LQDPRQWK2/(7UHDWPHQW3HULRGIROORZLQJWKH
'RXEOH%OLQG7UHDWPHQW3HULRG


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
,,,
Study Endpoints
A.
Primary
7KHSULPDU\HQGSRLQWLV SHUFHQWFKDQJHIURPEDVHOLQHDW:HHNLQIDVWLQJ
7*
B.
Secondary
7KHIROORZLQJVHFRQGDU\HQGSRLQWVZLOOEHHYDOXDWHG GXULQJWKHZHHN
'RXEOH%OLQG'%7UHDWPHQW3HULRG
x
3HUFHQWFKDQJHIURPEDVHOLQHLQIDVWLQJ7*RYHUWLPHWKURXJK:HHN
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJQRQ+'/&
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJWRWDO DSROLSRSURWHLQ$SR%
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJ /'/&
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQDQJLRSRLHWLQOLNHSURWHLQ$1*37/
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJ+'/&
x
3ODVPDFRQFHQWUDWLRQVRI$52$1*RYHUWLPHWKURXJK:HHN
x
7KHIUHTXHQF\DQGVHYHULW\RI$(VDQG6$(VRYHUWLPHWKURXJK:HHN

/'/& ZLOO XVH )ULHGHZDOG IRUPXOD0DUWLQ+RSNLQVPHWKRGRORJ\DQG
XOWUDFHQWULIXJDWLRQ
7KHIROORZLQJVHFRQGDU\HQGSRLQWVZLOOEHHYDOXDWHGLQWKHRSHQODEHO
H[WHQVLRQ2/(7UHDWPHQW3HULRG
x
3HUFHQWFKDQJHIURPEDVHOLQHLQIDVWLQJ7*QRQ+'/&WRWDO
DSROLSRSURWHLQ$SR%/'/&$1*37/+'/&DQGSODVPD$52
$1*DWDOOVFKHGXOHGYLVLWV
x
7KHIUHTXHQF\DQGVHYHULW\RI$(VDQG6$(VWKURXJK0RQWK
/'/& ZLOO XVH )ULHGHZDOG IRUPXOD0DUWLQ+RSNLQVPHWKRGRORJ\DQG
XOWUDFHQWULIXJDWLRQ
C.
Exploratory
7KHIROORZLQJH[SORUDWRU\HQGSRLQWVDUHGHILQHGLQWKLVVWXG\
x
&KDQJHIURPEDVHOLQHRYHUWLPHGXULQJ'% 7UHDWPHQW3HULRGDVZHOODV
RYHUWLPHGXULQJ2/(7UHDWPHQW3HULRGLQRWKHUIDVWLQJOLSLG
SDUDPHWHUVWRWDOFKROHVWHURO/'/+'/UDWLRYHU\ORZGHQVLW\


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
OLSRSURWHLQFKROHVWHURO>9/'/&@$SR%OLSRSURWHLQ>/3@D$SR%
$SR&,,,$SR&,,$SR$,$SR$9DQG$SR$
x
&KDQJHIURPEDVHOLQHWR:HHN DQGRYHUWLPHWKURXJK:HHN
GXULQJ'%7UHDWPHQW 3HULRGDVZHOORYHUWLPHLQWKH2/(7UHDWPHQW
3HULRGLQIDVWLQJVHUXPEORRGJOXFRVH+E$&KRPHRVWDWLFPRGHO
DVVHVVPHQWIRULQVXOLQUHVLVWDQFH+20$,5DQG&SHSWLGH
x
3URSRUWLRQRISDUWLFLSDQWVUHTXLULQJHPHUJHQWDSKHUHVLVRYHUWLPH
GXULQJ'%7UHDWPHQW3HULRGDVZHOODVGXULQJWKH2/(7UHDWPHQW
3HULRG
x
&KDQJH DQGSHUFHQWFKDQJH IURPEDVHOLQHWR:HHNLQOLYHUIDW
FRQWHQWXVLQJPDJQHWLFUHVRQDQFHLPDJLQJSURWRQGHQVLW\IDWIUDFWLRQ
05,3')) RQO\ LQ SDUWLFLSDQWV ZLWK D OLYHU IDW IUDFWLRQ RI  DW
6FUHHQLQJ
x
(PHUJHQFHRIDQGOHYHOVRIDQWLGUXJDQWLERGLHVWR $52$1*LQWKRVH
UHFHLYLQJ $52$1*RYHUWLPHGXULQJ'%7UHDWPHQW3HULRGDVZHOODV
RYHUWLPHGXULQJWKH2/(7UHDWPHQW3HULRG
,9
Study Design
A.
Design Overview
7KLVLVDUDQGRPL]HGGRXEOHEOLQGSODFHERFRQWUROOHG3KDVHEFOLQLFDO
VWXG\ ZLWK2/(7UHDWPHQW3HULRG 3DUWLFLSDQWVZKR KDYHVLJQHGDQ(WKLFV
&RPPLWWHH (&,QVWLWXWLRQDO5HYLHZ%RDUG,5%DSSURYHGLQIRUPHG FRQVHQW
IRUPPD\LQLWLDWHVFUHHQLQJGXULQJZKLFKHOLJLELOLW\DVVHVVPHQWVZLOOEH
FRPSOHWHG
3DUWLFLSDQWVPXVWPDLQWDLQDVWDEOHGLHWDQGVWDEOHOLSLGORZHULQJWKHUDS\
LQFOXGLQJVWDWLQV XQOHVVFRQVLGHUHGVWDWLQLQWROHUDQWSHUSURWRFROVHFWLRQ
DQGRWKHUUHOHYDQWEDFNJURXQGPHGLFDWLRQVDVDSSOLFDEOHWKURXJKRXWWKH
6FUHHQLQJ3HULRG
$WRWDO RIDSSUR[LPDWHO\ SDUWLFLSDQWVZLOOEHHQUROOHGLQWKHVWXG\$OOGRVH
FRKRUWV ZLOO HQUROOLQSDUDOOHOZLWK SDUWLFLSDQWVSHUGRVHFRKRUWUDQGRPO\
DVVLJQHGLQDUDWLRWR UHFHLYH$52$1* PJPJRUPJ RU
PDWFKHGSODFHER(DFKSDUWLFLSDQWZLOOUHFHLYH6XEFXWDQHRXV6& LQMHFWLRQV
 RQ'D\DQGDW:HHN IRUDWRWDORILQMHFWLRQVGXULQJWKH:HHN
'RXEOH%OLQG7UHDWPHQW3HULRGDVIROORZV


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
)ROORZLQJFRPSOHWLRQRIWKH:HHN9LVLWHOLJLEOHSDUWLFLSDQWVZLOOEHLQYLWHG
WRFRQWLQXHLQWKH0RQWK2/(7UHDWPHQW3HULRG3DUWLFLSDQWVLQWKH2/(
ZLOOEHGRVHGTXDUWHUO\DQGZLOOUHFHLYHWKHVDPHGRVHOHYHOWRZKLFKWKH\
ZHUHUDQGRPL]HGLQWKH'% 7UHDWPHQW3HULRGXQWLODVLQJOHGRVHKDVEHHQ
VHOHFWHGE\WKH6SRQVRU$IWHUWKHODVWVXEMHFWLQWKH'% 7UHDWPHQW3HULRG
FRPSOHWHVWKH:HHN9LVLWDQGDILQDOGRVHKDVEHHQVHOHFWHGE\WKH
6SRQVRUDOOVXEMHFWVLQWKH2/(7UHDWPHQW3HULRGZLOOEHWUDQVLWLRQHGWR
UHFHLYH$52$1*DWWKHVHOHFWHGGRVHIRUWKHUHPDLQGHURIWKHLUGXUDWLRQRQ
WKH2/(


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
B.
Study Population
7KLVVWXG\ZLOOEHFRQGXFWHGLQDGXOWVZLWKPL[HGG\VOLSLGHPLD/'/&  
PJG/>PPRO/@25QRQ+'/&  PJG/>PPRO/@DIWHUDWOHDVW
ZHHNVRIVWDEOHRSWLPDOVWDWLQWKHUDS\ XQOHVVGRFXPHQWHGDVVWDWLQ
LQWROHUDQWSHUSURWRFROVHFWLRQ$1'PHDQIDVWLQJ7* PJG/>
PPRO/@EXW PJG/>PPRO/@DW6FUHHQLQJ$WRWDORI
DSSUR[LPDWHO\SDUWLFLSDQWVZLOOEHHQUROOHGLQWKHVWXG\ LQFHQWHUV
JOREDOO\UHFHLYLQJ $52$1*RUSODFHERLQUDWLR SHUGRVLQJUHJLPHQ
C.
Sample Size Predictions
:LWKDWRWDORISDUWLFLSDQWVUDQGRPO\DVVLJQHGWRWUHDWPHQWLQDDFWLYH
WRSODFHERUDWLRZLWKLQHDFKGRVLQJFRKRUWWKHVWXG\ZLOOKDYHJUHDWHUWKDQ
SRZHUWRGHWHFWDWOHDVWDFWLYHWUHDWPHQWGRVHFRKRUWZKLFKLV
VLJQLILFDQWO\GLIIHUHQWIURPSODFHERDQGDWOHDVWSRZHUWRGHWHFWDOO
WUHDWPHQWGRVHFRKRUWVZKLFKDUHVLJQLILFDQWO\GLIIHUHQWIURPSODFHERXVLQJD
WZRVLGHG WHVWZLWKOHYHORIVLJQLILFDQFHDGMXVWHGIRUPXOWLSOLFLW\7KHVH
HVWLPDWHVDUHEDVHGRQWKHDVVXPSWLRQRIWRUHGXFWLRQIURP
EDVHOLQHLQIDVWLQJ7*LQWKHDFWLYHWUHDWPHQWGRVHFRKRUWVDQGQRFKDQJH
LQIDVWLQJ7*LQWKHSRROHGSODFHERFRKRUW7KH6'LVDVVXPHGWREHLQ
WKHSRROHGSODFHERJURXSDQGWRLQWKHDFWLYHWUHDWPHQWJURXSV
D.
Treatment Randomization
(OLJLEOHSDUWLFLSDQWVZLOOEHUDQGRPO\DVVLJQHGWRHLWKHUDFWLYH $52
$1*WUHDWPHQWLQRIGRVHJURXSV RU PJRUWRSODFHER
WUHDWPHQW VWUDWLILHGEDVHGRQ OHYHORI/'/& DW6FUHHQLQJPJG/
YHUVXVPJG/ 7UHDWPHQWVZLOOEHDGPLQLVWHUHGSHUWKHUDQGRPL]HG
VHTXHQFHJHQHUDWHGE\DQ,QWHUDFWLYH:HE 5HVSRQVH6\VWHP,:56
7KHDOORFDWLRQRIDFWLYHWUHDWPHQWRUSODFHERZLOOEHSHUIRUPHGXVLQJ D
PLQLPL]DWLRQ UDQGRPL]DWLRQ DOJRULWKP LQLWLDOO\DQGXVLQJEORFNUDQGRPL]DWLRQ
IRUVXEMHFWUHSODFHPHQW DVGHWDLOHGLQ WKH,:56YHQGRU¶V5DQGRPL]DWLRQ
5HTXLUHPHQWV 6SHFLILFDWLRQ
E.
Assessment Schedule
7KHWRWDOHVWLPDWHGGXUDWLRQRIWKHVWXG\LQFOXGLQJ'% 7UHDWPHQW3HULRGDQG
WKH2/(7UHDWPHQW3HULRGLVDSSUR[LPDWHO\PRQWKV
7KHWRWDOGXUDWLRQRIWKH'% 7UHDWPHQW3HULRGLVDSSUR[LPDWHO\ZHHNV
PRQWKVIURP6FUHHQLQJWRWKH:HHN9LVLW
'XULQJWKH:HHN'% 7UHDWPHQW3HULRG SDUWLFLSDQWV ZLOODWWHQGVWXG\YLVLWV
RQ 'D\ WR'D\ 6FUHHQLQJ  'D\ WR'D\6FUHHQLQJ 'D\
 WR'D\ 6FUHHQLQJ  GXULQJVFUHHQLQJSKDVH 'D\ZHHNZHHN


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
ZHHN KRXUSRVWZHHN ZHHNZHHNZHHNZHHNDQG
ZHHN  HDUO\WHUPLQDWLRQ 'HWDLOHG6FKHGXOHRI$VVHVVPHQWVLV LQFOXGHGLQ
FOLQLFDOVWXG\SURWRFRO7DEOH
'XULQJWKH0RQWK2/(7UHDWPHQW3HULRG SDUWLFLSDQWVZLOODWWHQGVWXG\
YLVLWVRQ'D\PRQWKPRQWKPRQWKPRQWKPRQWKPRQWK
PRQWKPRQWKPRQWKDQGPRQWKHQGRIVWXG\HDUO\
WHUPLQDWLRQ'HWDLOHG6FKHGXOHRI$VVHVVPHQWVLVLQFOXGHGLQFOLQLFDOVWXG\
SURWRFRO7DEOH
9
General Analytical Considerations
A.
Data Sources
6WDWLVWLFDODQDO\VLVZLOOEHSHUIRUPHGIROORZLQJ,49,$%LRWHFKVWDQGDUG
RSHUDWLQJSURFHGXUHVDQGRQWKH,49,$%LRWHFKFRPSXWHUQHWZRUN$OO
VWDWLVWLFDODQDO\VLVZLOOEHSHUIRUPHGXVLQJ6$69HUVLRQ ZLWKSURJUDP
FRGHSUHSDUHGVSHFLILFDOO\IRUWKHSURMHFWE\TXDOLILHG,49,$%LRWHFK
VWDWLVWLFLDQVDQG6$6SURJUDPPHUV 1RUPDOLW\DQGRWKHUVWDWLVWLFDO
DVVXPSWLRQVIRUVWDWLVWLFDODQDO\VHVZLOOEHHYDOXDWHGDVDSSURSULDWH
$OOREVHUYHGDQGGHULYHGYDULDEOHV HJFKDQJHIURPEDVHOLQHSHUFHQWDJH
FKDQJHIURPEDVHOLQHDQGUHVSRQVHVWDWXVWKDWDUHDQDO\]HGRUVXPPDUL]HG
ZLOOEHOLVWHGE\SDUWLFLSDQW DVDSSURSULDWH'HVFULSWLYHVWDWLVWLFVZLOOSURYLGHDQ
RYHUYLHZRIWKHVDIHW\DQGHIILFDF\ UHVXOWV)RUFDWHJRULFDOSDUDPHWHUVWKH
QXPEHUDQGSHUFHQWDJHRISDUWLFLSDQWVLQHDFKFDWHJRU\ZLOOEHSUHVHQWHG
)RUFRQWLQXRXVSDUDPHWHUVGHVFULSWLYHVWDWLVWLFVZLOOLQFOXGHQXPEHURI
SDWLHQWVPHDQVWDQGDUGGHYLDWLRQ6'PHGLDQPLQLPXP DQGPD[LPXP
$VVHVVPHQWVIRUIDVWLQJOLSLGDQGRWKHUODESDUDPHWHUVGRQHXQGHUQRQ
IDVWLQJVWDWXVZLOOEHH[FOXGHGIURPVXPPDU\DQGDQDO\VLV
'DWDZLOOEHDQDO\]HGE\WUHDWPHQWJURXSVRI$52$1*  DQG
PJ $52$1* SRROHG DQG3ODFHER SRROHG
B.
Baseline and Study Day
'D\
'D\LVGHILQHGDVWKHGDWHRIILUVWDGPLQLVWUDWLRQRIVWXG\GUXJ,IWKHGDWHRI
ILUVWVWXG\GUXJ DGPLQLVWUDWLRQLVPLVVLQJGDWHRIUDQGRPL]DWLRQZLOOEHXVHG
DV'D\ 6WXG\GD\LVFDOFXODWHGUHODWLYHWRWKHGDWHRI'D\ DVIROORZV
x
)RUDQ\HYHQWVRQRUDIWHUWKHILUVWDGPLQLVWUDWLRQRIWKHVWXG\GUXJ
VWXG\GD\LVFDOFXODWHGDVHYHQWGDWH± GDWHRIILUVWDGPLQLVWUDWLRQRI
VWXG\GUXJ


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
)RUDQ\HYHQWVEHIRUHWKHILUVWDGPLQLVWUDWLRQGDWHVWXG\GD\LV
FDOFXODWHGDV HYHQWGDWH± GDWHRIILUVWDGPLQLVWUDWLRQRIVWXG\GUXJ$V
VXFKRQHGD\EHIRUHWKHILUVWDGPLQLVWUDWLRQGDWHLVVWXG\GD\± 
%DVHOLQH
8QOHVVRWKHUZLVHVSHFLILHGEDVHOLQH2YHUDOO%DVHOLQH LVGHILQHGDVWKHODVW
REVHUYHGYDOXHRIWKHSDUDPHWHURILQWHUHVWSULRUWRWKHILUVWDGPLQLVWUDWLRQ RI
VWXG\WUHDWPHQWWKLVLQFOXGHVXQVFKHGXOHGYLVLWV
x
,QSDUWLFXODUIRUIDVWLQJ7* EDVHOLQHLVGHILQHGDVWKHJHRPHWULFPHDQ
RI'D\SUHGRVHDVVHVVPHQWDQGWZRIDVWLQJ7*YDOXHVFROOHFWHG
GXULQJWKH6FUHHQLQJSHULRG ,IIHZHUWKDQSUHGRVHDVVHVVPHQWVDUH
DYDLODEOHWKHJHRPHWULFPHDQZLOOEHWDNHQIURPWKHDYDLODEOHUHVXOWV
)RURWKHUHIILFDF\YDULDEOHV EDVHOLQHLVGHILQHGDVWKHSUHGRVHYDOXH
RQ'D\
:KHUHDSSOLFDEOHEDVHOLQHLVIXUWKHUGHILQHGIRUWKH2/(7UHDWPHQW3HULRG
2/(%DVHOLQHDV WKHODVW REVHUYHGYDOXHRIWKHSDUDPHWHURILQWHUHVWSULRUWR
WKHILUVWDGPLQLVWUDWLRQRIVWXG\WUHDWPHQWLQ2/(7UHDWPHQW3HULRG2/('D\

)RUHDFKW\SHRI%DVHOLQHFKDQJHIURPEDVHOLQH LVFDOFXODWHGDVSRVW
EDVHOLQHYDOXHVPLQXVEDVHOLQHYDOXHV 3HUFHQWDJHFKDQJHIURPEDVHOLQH LV
FDOFXODWHGDVUDWLRRIFKDQJHIURPEDVHOLQHDQGEDVHOLQHH[SUHVVHGDVD
SHUFHQWDJH
3HUFHQWFKDQJHIURPEDVHOLQH SRVWEDVHOLQH± EDVHOLQHEDVHOLQH
(QGRIWUHDWPHQW(27
(27LVWKHGDWHRIWUHDWPHQWFRPSOHWLRQRUGLVFRQWLQXDWLRQDV UHFRUGHGLQWKH
H&5)
(QGRIVWXG\(26
(26LVWKHGDWHRIVWXG\FRPSOHWLRQRUGLVFRQWLQXDWLRQDV UHFRUGHGLQWKH
H&5)
C.
Analysis Visit Window
$OOHIILFDF\DQGVDIHW\HQGSRLQWVZLOOEHDQDO\]HGDFFRUGLQJWRWKHQRPLQDO
YLVLWVLHDVVLJQHG YLVLWH[FHSWIRUDVVHVVPHQWVFROOHFWHGRQHDUO\
WHUPLQDWLRQDQGXQVFKHGXOHGYLVLWV(DUO\WHUPLQDWLRQDQGXQVFKHGXOHGYLVLWV
ZLOOEHUHQXPEHUHGWRDQDQDO\VLVYLVLWEDVHGRQWKHLUZLQGRZHGYLVLWVGHILQHG
E\DFWXDOVWXG\GD\,IPRUHWKDQRQHYLVLW RUDVVHVVPHQW VFKHGXOHGRU
XQVFKHGXOHGRFFXUVZLWKLQDVLQJOHYLVLWZLQGRZWKHQWKHDQDO\VLVZLOOWDNH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
WKHRQHFORVHVWWRWKHWDUJHWGD\,IWKHYLVLWVDUHHTXLGLVWDQWIURPWKHWDUJHW
GD\WKHYLVLWZLWKODWHUGDWHDQGWLPHZLOOEHXVHG
$W:HHNDQG:HHN IDVWLQJOLSLGSKDUPDFRG\QDPLFHQGSRLQWVZLOOEH
FROOHFWHGWZLFHVHSDUDWHGE\DWOHDVWGD\VDQGQRPRUHWKDQGD\VDIWHUD
KRXUIDVW )RUIDVWLQJ7*WKHJHRPHWULFPHDQRIWZRYDOXHVZLOOEHXVLQJ
IRUDQDO\VLV,IRQO\RQHYDOXHLVDYDLODEOHWKHQWKLVYDOXH ZLOOEHXVHGIRU
HQGSRLQWDQDO\VLV DWWKDWYLVLW )RURWKHUHQGSRLQWVWKHVFKHGXOHG:HHN
DQG:HHNYDOXHVZLOOEHXVHG IRUDQDO\VLV
7KHIROORZLQJDQDO\VLVYLVLWZLQGRZVZLOODSSO\WRHDUO\WHUPLQDWLRQDQG
XQVFKHGXOHGYLVLWV
'% 7UHDWPHQW3HULRG
Visit
Target Day
Analysis Window
'D\

2QRUSULRUWR'D\
:HHN

3RVWILUVWGRVH± 'D\
:HHN

'D\± 'D\
:HHN

'D\± 'D\
:HHN

'D\± 'D\
:HHN

'D\± 'D\
:HHN

'D\± 'D\
:HHN

'D\± 'D\
:HHN

 'D\ 
2/( 7UHDWPHQW3HULRG
Visit
Target Day
Analysis Window
'D\

1RPLQDORQO\  GD\V
DIWHUZHHNYLVLWLQ
'RXEOH7UHDWPHQW3HULRG
0RQWK

3RVW'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

'D\± 'D\
0RQWK

 'D\ 
&HUWDLQ HIILFDF\DQGVDIHW\HQGSRLQWVDUHQRWVFKHGXOHGWREHDVVHVVHGDW
HDFKSRVWEDVHOLQHYLVLWVXFKDVWKH(&*V,IWKHGDWHRIDQHDUO\WHUPLQDWLRQ
RUXQVFKHGXOHGYLVLWGRHVQRWIDOOLQWR WKHDQDO\VLVZLQGRZ RIDQ\VFKHGXOHG
YLVLWWKHDVVHVVPHQW ZLOO EHPDSSHGWR WKHVFKHGXOHGSRVWEDVHOLQHYLVLW
FORVHVWWRWKHDVVHVVPHQWGDWH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
D.
Missing Data
3DUWLFLSDQWVPD\EHPLVVLQJVSHFLILFGDWDSRLQWVIRUYDULRXVUHDVRQV4XHULHV
ZLOOEHPDGHWRWKHVLWHVWRGLVWLQJXLVKWUXHPLVVLQJYDOXHVIURPRWKHU
XQNQRZQYDOXHVHJGXHWRPHDVXUHPHQWRIVDPSOHSURFHVVLQJHUURU$OO
DWWHPSWVZLOOEHPDGHWRFDSWXUHPLVVLQJRUSDUWLDOGDWDIRUWKHVWXG\SULRUWR
GDWDEDVHORFN
0LVVLQJYDOXHVZLOOQRWEHLPSXWHGH[FHSWIRUPLVVLQJRUSDUWLDOGDWHVRI$(V
FRQFRPLWDQWVWDWXVIRUPHGLFDWLRQDQGSURFHGXUHVDQGIRUPLVVLQJRUSDUWLDO
GDWHVZKHUHDFRPSOHWHGDWHLVUHTXLUHGIRUFDOFXODWLRQV :KHQUHOHYDQW
VHFWLRQVEHORZZLOODGGUHVVKRZPLVVLQJGDWDZLOOEHKDQGOHGIRUWKHSDUWLFXODU
DQDO\VHV
1RQFDOFXODEOHRUPLVVLQJYDOXHVIRU/'/&XVLQJ)ULHGHZDOGIRUPXOD ZLOOEH
LPSXWHGZLWK/'/&XVLQJXOWUDFHQWULIXJDWLRQ
Adverse events (AEs):
x
$(V ZLOOEHIODJJHGDVWUHDWPHQWHPHUJHQW $(V7($(V XVLQJYDOLG
DQVZHUVWRWKHTXHVWLRQV³)RUHYHQWVWKDWRFFXUUHGRQ'D\GLGWKH
HYHQWRFFXUEHIRUHVWDUWRIVWXG\GUXJDGPLQLVWUDWLRQ"´RQWKHH&5)
UHJDUGOHVVRIZKHWKHURUQRWWKH$(RQVHWGDWHLVFRPSOHWH$(V WKDW
FDQQRWEHGHILQLWHO\GHWHUPLQHGDVRFFXUULQJSULRUWRVWXG\GUXJ
DGPLQLVWUDWLRQZLOOEHFRXQWHGDV7($(V XQOHVVHLWKHUWKHSDUWLDOVWDUW
GDWHWLPHRUDSDUWLDORUFRPSOHWHHQGGDWHWLPHGRFXPHQWVWKH$(DV
RFFXUULQJSULRUWRWUHDWPHQW
x
7($(VWDUWGDWH
o
7($(LPSXWHGGDWHVZLOOQRWEHHDUOLHUWKDQWKHSDUWLFLSDQW
V'D\
GDWH
o
,IDOO\HDUPRQWKDQGGD\DUHPLVVLQJWKHQXVHWKHSDUWLFLSDQW
V'D\
GDWH
o
,I\HDULVDYDLODEOHEXWGD\DQGPRQWKDUHPLVVLQJWKHGD\DQG
PRQWKIRUWKHVWDUWGDWHZLOOEHVHWWRWKHVWRI-DQXDU\RIWKHRQVHW
\HDU
o
,I\HDUDQGPRQWKDUHDYDLODEOHEXWGD\LVPLVVLQJWKHGD\ZLOOEH
VHWWRWKHVWRIWKHPRQWKRIWKHRQVHW\HDU
x
(QGGDWHZLOOQRWEHLPSXWHG
Concomitant medications (CM):
x
0HGLFDWLRQVZLWKPLVVLQJRUSDUWLDOHQGGDWHVZLOOEHDVVXPHGWREH
FRQFRPLWDQWXQOHVVDSDUWLDOHQGGDWHGRFXPHQWVLWDVHQGLQJSULRUWR
WUHDWPHQW


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
&0VWDUWGDWH
o
,IDOO\HDUPRQWKDQGGD\DUHPLVVLQJWKHQXVHWKHSDUWLFLSDQW
V'D\
GDWH
o
,I\HDULVDYDLODEOHEXWGD\DQGPRQWKDUHPLVVLQJWKHGD\DQG
PRQWKIRUWKHVWDUWGDWHZLOOEHVHWWRWKHVWRI-DQXDU\RIWKHRQVHW
\HDU
o
,I\HDUDQGPRQWKDUHDYDLODEOHEXWGD\LVPLVVLQJWKHGD\ZLOOEH
VHWWRWKHVWRIWKHPRQWKRIWKHRQVHW\HDU
x
(QGGDWHZLOOQRWEHLPSXWHG
Procedures
x
3URFHGXUHVZLWKPLVVLQJRUSDUWLDOHQGGDWHVZLOOEHFRXQWHGDV
FRQFRPLWDQWXQOHVVDSDUWLDOHQGGDWHGRFXPHQWVLWDVHQGLQJSULRUWR
WKHSDUWLFLSDQW
V'D\GDWH
7KHRULJLQDOPLVVLQJRUSDUWLDOGDWHWKHLPSXWHGFRPSOHWHGDWHDQGDQ
LQGLFDWRUYDULDEOH WKDWLQGLFDWHVZKLFKGDWHVZHUHLPSXWHGZLOOEHUHWDLQHGLQ
WKHGDWDEDVH
E.
Multiple Study Centers
'HVFULSWLYHVXPPDULHVRIWKHSULPDU\HIILFDF\HQGSRLQWZLOOEHSUHVHQWHGIRU
HDFKLQGLYLGXDOVWXG\FHQWHUWRH[SORUHDQ\ SRWHQWLDOKHWHURJHQHLW\DFURVV
VLWHV
F.
Covariate Adjustment in Primary Analysis
7KHSULPDU\DQGVHFRQGDU\HIILFDF\DQDO\VHVZLOOEHDGMXVWHGIRUVWUDWLILFDWLRQ
IDFWRUOHYHORI/'/& DW6FUHHQLQJ > PJG/ YHUVXV PJG/@DQG WKH
UHOHYDQW EDVHOLQHYDOXHV
$GGLWLRQDOFRYDULDWHVWKDWPD\EHFRQVLGHUHGDUH
x
$JH \HDUV
x
6H[ PDOHIHPDOH
x
5DFH :KLWH$VLDQDOORWKHUUDFHV
x
%0, NJP
'HWDLOVZLOOEHSURYLGHGDVGHVFULEHG LQUHOHYDQWVHFWLRQVEHORZ
G. Sample Size Reassessment
1RWDSSOLFDEOH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
H.
Interim Analyses or Timing of Analyses
$IWHUWKHODVWVXEMHFWLQWKH'% 7UHDWPHQW3HULRGFRPSOHWHVWKHZHHNYLVLW
DQLQWHULPDQDO\VLVZLOOEHFRQGXFWHGWRUHYLHZWKHHIILFDF\DQGVDIHW\GDWDLQ
RUGHUWRVHOHFWDVLQJOHGRVHOHYHOIRUDOOVXEMHFWVLQ2/(7UHDWPHQW3HULRG
DQGIRUWKHUHPDLQGHURIWKHLUSDUWLFLSDWLRQLQWKHWULDO
I.
Data Safety Committee (DSC)
$QLQGHSHQGHQW'6&ZLOOEHDVVHPEOHGWRUHYLHZVDIHW\GDWDDIWHUKDOIRIWKH
WRWDOQXPEHURI SDUWLFLSDQWVSODQQHGIRUHQUROOPHQWKDYHUHFHLYHGDWOHDVW
GRVHRI,37KLVJURXSPD\DOVREH DVNHGE\WKHVWXG\6SRQVRUWRPHHWRQDQ
DGKRFEDVLVWRUHYLHZVDIHW\GDWDDQGPDNH UHFRPPHQGDWLRQVUHODWHGWRWKH
VWXG\ 3ODQQHGVDIHW\UHYLHZVZLOOLQFOXGHHYDOXDWLRQVIRU LPEDODQFHVEHWZHHQ
DFWLYHDQGSODFHERJURXSVIRU$(VDQG6$(V 7KH'6&PD\EHDVNHGWR
UHYLHZVDIHW\GDWDDWDGGLWLRQDOXQVFKHGXOHGPHHWLQJVVKRXOGDSRWHQWLDO
VDIHW\VLJQDOEH GHWHFWHG7KH'6&PD\DOVRPDNHUHFRPPHQGDWLRQVWRWKH
6SRQVRUIRUPRGLI\LQJVWRSSLQJRU FRQWLQXLQJWKHVWXG\DVSODQQHG
%OLQGHGGDWDZLOOEHUHYLHZHGLQLWLDOO\DQGLIWKHUHDUHDQ\ FRQFHUQVRU
XQEOLQGHGUHYLHZLVZDUUDQWHGEDVHGRQEOLQGHGUHYLHZWKH'6&PD\UHYLHZ
XQEOLQGHGGDWDLQDFORVHGVHVVLRQ
)XUWKHUGHWDLOVHJIUHTXHQF\RIGDWDUHYLHZVDQGVWXG\FRPPLWWHH
FRPSRVLWLRQDQGPHPEHUVKLSZLOOEHSURYLGHGLQWKH'6& FKDUWHU7KH
FKDUWHUZLOOGHILQHWKHFULWHULDIUHTXHQF\RIUHYLHZVGDWDDQGVRXUFH
GRFXPHQWDWLRQUHTXLUHGWRDGMXGLFDWHDOOHYHQWV
J.
Test Sizes
$Q\WHVWHGK\SRWKHVHVZLOOEHWHVWHGDJDLQVWWZRVLGHG DOWHUQDWLYHVXVLQJ
SURFHGXUHV WKDW SURYLGH DQ H[SHFWHG SUREDELOLW\ RI 7\SH , HUURU Į RI  $OO
LQIHUHQWLDOVWDWLVWLFVLHSYDOXHVZLOOEHFRQVLGHUHGDVH[SORUDWRU\
K.
Multiple Comparisons
:KHQSHUIRUPLQJWKH SULPDU\DQDO\VLVWKHDGMXVWPHQWIRUPXOWLSOLFLW\RI
WHVWLQJ$52$1* DUPVYHUVXVSODFHERZLOOEH FDUULHGRXWXVLQJ+ROP¶VVWHS
GRZQSURFHGXUH
$VLGHIURPWKHFRQWURORI7\SH,HUURULQWKHSULPDU\DQDO\VLVRIWKHSULPDU\
HQGSRLQWQRFRQWUROIRUWKHHIIHFWRIPXOWLSOHFRPSDULVRQVLVSODQQHG $Q\
LQIHUHQWLDOVWDWLVWLFVLHSYDOXHVIRUVHFRQGDU\DQGH[SORUDWRU\HQGSRLQW
DQDO\VHVZLOOEHFRQVLGHUHGRQO\DVH[SORUDWRU\
L.
Analysis Populations 
7KHIROORZLQJVWXG\SRSXODWLRQVDUHGHILQHGLQWKLVVWXG\


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
1. Full Analysis Set Overall (FAS Overall)
$OOUDQGRPL]HGSDUWLFLSDQWVZKRUHFHLYHDWOHDVWGRVHRI,3 GXULQJWKH
VWXG\SHULRG $OO'%7UHDWPHQW3HULRGHIILFDF\DQDO\VHVZLOOEHSHUIRUPHG
XVLQJ)$63DUWLFLSDQWVZLOOEHDQDO\]HG DFFRUGLQJWRWKHWUHDWPHQW
DVVLJQHGDWUDQGRPL]DWLRQ
2. Safety Analysis Set
$OOSDUWLFLSDQWVZKRUHFHLYHDWOHDVWGRVHRI,3 GXULQJWKHVWXG\SHULRG
$OORYHUDOODQG'%7UHDWPHQW3HULRGVDIHW\DQG WROHUDELOLW\DQDO\VHVZLOO
EHSHUIRUPHGXVLQJWKLVVHW 3DUWLFLSDQWVZLOOEHDQDO\]HG DFFRUGLQJWRWKH
WUHDWPHQWWKH\DFWXDOO\UHFHLYHG
3. Full Analysis Set OLE (FAS OLE)
$OOUDQGRPL]HGSDUWLFLSDQWVZKRUHFHLYHDWOHDVWGRVHRI,3 GXULQJWKH
2/(7UHDWPHQW3HULRG $OO2/(7UHDWPHQW3HULRGHIILFDF\ VDIHW\DQG
WROHUDELOLW\ DQDO\VHVZLOOEHSHUIRUPHGXVLQJWKLVVHW
4. Per-protocol Population (PPS)
$OOSDUWLFLSDQWVLQWKH)$6SRSXODWLRQZKRKDYHFRPSOHWHGWKH:HHN
YLVLWZLWKRXWDQ\PDMRUSURWRFROYLRODWLRQVWKDWFRXOGLQIOXHQFHWKHYDOLGLW\
RIWKHGDWDIRUWKHSULPDU\DQGVHFRQGDU\HIILFDF\HYDOXDWLRQV$OOFULWHULD
WRH[FOXGHSDUWLFLSDQWVIURPWKH336ZLOOEHPDGHEDVHGRQDEOLQGHG
UHYLHZRIWKHGDWDSULRUWRWKHXQEOLQGLQJRIWKHVWXG\
$SDUWLFLSDQWPD\EHH[FOXGHGIURPWKH336LIDQ\RIWKHIROORZLQJFULWHULD
DUHPHW
x
1RWPHHWLQJ,QFOXVLRQ([FOXVLRQFULWHULD
x
8VDJHRIUHVWULFWHGPHGLFDWLRQVWUHDWPHQWV
x
1RQFRPSOLDQFHZLWKWKHWULDOWUHDWPHQWUHJLPHQ
$QDO\VHVRQ336ZLOOEHRIVXSSRUWLYHSXUSRVHDQGOLPLWHGWRWKHSULPDU\
HQGSRLQW DQGWKHVHFRQGDU\HQGSRLQWV
5. PK Analysis set
3.$QDO\VLV6HWLQFOXGHVDOOSDUWLFLSDQWVZKR KDYHUHFHLYHG DWOHDVWRQH
GRVHRIDFWLYHGUXJDQGKDYHDWOHDVWRQH3.FRQFHQWUDWLRQGDWD
3DUWLFLSDQWVDUHDVVLJQHGWR³)XOO3.$QDO\VLV6HW´RU³6SDUVHVDPSOH3.
$QDO\VLV6HW´DVGHILQHGLQWKHVWXG\SURWRFRO


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
6. MRI-PDFF Analysis Set
)$6SDUWLFLSDQWVZLWKEDVHOLQHOLYHUIDWIUDFWLRQ ZKRKDYHDWOHDVWRQH
DVVHVVPHQWIRU05,3'))
M. Subgroups of Analysis Populations    
'DWDIURPVXEJURXSVRISDUWLFLSDQWVLQWKH)$6 ZLOOEHDQDO\]HGDVVSHFLILHG
EHORZ7KHVHDQDO\VHVZLOOFRPSULVHGHVFULSWLYHVXPPDULHVWKHJRDOZLOOEH
WRLGHQWLI\VLJQDOVRIDGGLWLRQDOHIIHFWVWKDWWKHSULPDU\DQDO\VLVGRHV QRW
FRQVLGHU6XFKDQDO\VHVZLOOEHFRQVLGHUHGH[SORUDWRU\ DQG ZLOOQRWLQYROYH
K\SRWKHVLVWHVWLQJ
3UHVSHFLILHGVXEJURXSDQDO\VHVZLOOEHEDVHGRQ
x
6WUDWLILFDWLRQIDFWRURI/'/&OHYHO DW 6FUHHQLQJ  PJG/ 
PJG/,IOHYHORI/'/&DW6FUHHQLQJLVGLIIHUHQWWKDQWKHFDWHJRU\
DFWXDOO\XVHGLQWKHUDQGRPL]DWLRQGXHWRHUURUVWKHDFWXDOFDWHJRU\
XVHGLQ,;56ZLOOEHXVHG
x
$JH DW6FUHHQLQJ 
x
6H[IHPDOHPDOH
x
5DFH:KLWH$VLDQDOORWKHU UDFHV
x
%DVHOLQH%0, NJP  NJP
x
5HJLRQ1RUWK$PHULFD$VLD3DFLILF RWKHU
x
5HSRUWHGKLVWRU\RI$6&9'<HV1R
x
*HQRW\SHFRQVLVWHQWZLWK)&6LQFOXGLQJEXWQRWOLPLWHGWR
KRPR]\JRXVFRPSRXQGKHWHUR]\JRXVRUGRXEOHKHWHUR]\JRXVORVV
RIIXQFWLRQRURWKHUZLVHLQDFWLYDWLQJPXWDWLRQVLQJHQHVDIIHFWLQJ
OLSRSURWHLQOLSDVH/3/DFWLYLW\LQFOXGLQJ/3/$32&$32$
*3,+%3/,3**3'RU/0)
x
&RQFRPLWDQW 6WDWLQ8VH KLJKLQWHQVLW\ PRGHUDWHLQWHQVLW\ORZ
LQWHQVLW\QRQH
6WDEOHVWDWLQUHJLPHQLVDOORZHGIRULQGLFDWHGSDUWLFLSDQWVIURPSULRUWR
6FUHHQLQJDQGWKURXJKRXWWKH7UHDWPHQW3HULRG&RQFRPLWDQWVWDWLQ
XVHDQGLWVLQWHQVLW\ZLOOEHLGHQWLILHGIURPOLSLGPDQDJHPHQW
PHGLFDWLRQVVHHEHORZ UHFRUGHGRQWKHH&5)WKDWVWDUWEHIRUH'D\
DQGFRQWLQXHLQWR7UHDWPHQW3HULRGUHJDUGOHVVRIHQGGDWH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
,QWHQVLW\RI VWDWLQWKHUDS\ZLOOEHGHWHUPLQHGEDVHGRQWRWDOGDLO\GRVH
DFFRUGLQJWRWKH EHORZ JXLGHOLQH
Statin
Low Intensity
Moderate Intensity
High Intensity
$WRUYDVWDWLQ/LSLWRU
1$
WRPJ
WRPJ
)OXYDVWDWLQ/HVFRO
WRPJ
PJ
1$
/RYDVWDWLQ0HYDFRU
PJ
PJ
1$
3LWDYDVWDWLQ/LYDOR
PJ
WRPJ
1$
3UDYDVWDWLQ3UDYDFKRO
WRPJ
WRPJ
1$
5RVXYDVWDWLQ&UHVWRU
1$
WRPJ
WRPJ
6LPYDVWDWLQ=RFRU
PJ
WRPJ
1$
N.
Data Display Characteristics
'DWDGLVSOD\VSURGXFHGIRUWKLVVWXG\ZLOOLQFOXGHWKUHHW\SHV²VXPPDU\
WDEOHVGDWDOLVWLQJVDQGILJXUHV8QOHVVVWDWHGRWKHUZLVHGDWDOLVWLQJVZLOOEH
SURGXFHGIRUDOOUHFRUGHGGDWD6XPPDU\WDEOHVZLOOEHSURGXFHGDVVSHFLILHG
LQIROORZLQJ
VHFWLRQV $GGLWLRQDOGDWDOLVWLQJVZLOOEHSURGXFHGIRURXWFRPH
PHDVXUHVWKDWLQYROYHH[WHQVLYHSURFHGXUHVWRGHULYHWKHDQDO\]HGRXWFRPHV
'DWDOLVWLQJVZLOOVLPSO\OLVWWKHGDWDUHFRUGHGRQWKHH&5)RUGHULYHGIRUHDFK
SDWLHQW7KH\ZLOOEHRUGHUHGE\ UDQGRPL]HG WUHDWPHQWLQWKH'%7UHDWPHQW
3HULRG$52$1* GRVHJURXS> DQG PJ@DQG SRROHGSODFHER
JURXS SDUWLFLSDQW QXPEHUDQGWLPHRIDVVHVVPHQW
,QJHQHUDOIRUWKH'% 7UHDWPHQW3HULRGVXPPDU\WDEOHVZLOOGLVSOD\VXPPDU\
VWDWLVWLFVFDOFXODWHGIRUHDFKRIWKH$52$1* GRVHJURXS  DQG
PJDSRROHG$52$1* JURXS DQGDSRROHGSODFHERJURXSXQOHVV
GHVFULEHGRWKHUZLVHLQIROORZLQJVHFWLRQV )RUWKH2/(7UHDWPHQW3HULRG
VXPPDU\WDEOHVZLOOGLVSOD\ WKH$52$1*GRVHJURXS DQG
PJEHIRUHWKHGHWHUPLQDWLRQRIDVLQJOH$52$1*GRVHDQGDSRROHG
$52$1* JURXS
'HVFULSWLYHVWDWLVWLFVZLOOEHSUHVHQWHGXQOHVVRWKHUZLVHVSHFLILHG)RU
FRQWLQXRXVYDULDEOHVGDWDZLOOEHSUHVHQWHGDV QXPEHUQPHDQPHGLDQ
VWDQGDUGGHYLDWLRQ6'PLQLPXPDQGPD[LPXP'LVFUHWHYDULDEOHV ZLOOEH
SUHVHQWHGDVIUHTXHQFLHVDQGSURSRUWLRQVRUSHUFHQW
7KH6WDQGDUG'LVSOD\RIWDEOHVOLVWLQJV DQGILJXUHV7/)VDQG3UHFLVLRQRI
'DWD'LVSOD\HGDUHGRFXPHQWHGLQWKHDSSHQGL[RI6$37/)VKHOO
9,
Participant Accountability
7KHSDUWLFLSDQW FKDUDFWHULVWLFVGHILQHGEHORZZLOOEHSUHVHQWHGLQVXPPDU\
WDEOHVDQGGDWDOLVWLQJVIRUSDUWLFLSDQWV LQWKH)$6 VHSDUDWHO\ 1RIRUPDO
VWDWLVWLFDOFRPSDULVRQVZLOOEHSHUIRUPHG
A.
Participant Characteristics


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
Demography:
x
$JH \HDUV $JHDWWLPHRIFRQVHQWFDOFXODWHGDVWKHGLIIHUHQFH
EHWZHHQELUWK\HDUDQGWKH\HDURILQIRUPFRQVHQWGDWH
x
$JHJURXS  \HDUV
x
6H[ 0DOH)HPDOH
x
5DFH$PHULFDQ,QGLDQRU$ODVND1DWLYH $VLDQ %ODFNRU$IULFDQ
$PHULFDQ1DWLYH +DZDLLDQRU2WKHU3DFLILF,VODQGHU :KLWH8QNQRZQ
2WKHU
x
5DFHJURXS:KLWH$VLDQDQGDOORWKHUUDFHV
x
(WKQLFLW\+LVSDQLFRU/DWLQR1RW+LVSDQLFRU/DWLQR1RWUHSRUWHG
8QNQRZQ
x
5HJLRQ1RUWK$PHULFD$VLD3DFLILFRWKHU
Baseline Characteristics 
x
+HLJKWFP
x
:HLJKWNJ
x
%0,NJP
x
%0,JURXSNJP   NJP
x
0HDQYDOXH RI7*DWEDVHOLQHPJG/
x
0HDQOHYHORI 7*DWEDVHOLQHFDWHJRU\ PJG/DQGPJG/
x
9DOXHRI/'/&DWEDVHOLQHPJG/
x
/HYHORI/'/&DWEDVHOLQHFDWHJRU\ PJG/PJG/
 PJG/
x
/HYHORI/'/& DWVFUHHQLQJFDWHJRU\ XVHGDVVWUDWLILFDWLRQIDFWRUIURP
,:56 PJG/  PJG/
x
9DOXHRI+'/&DWEDVHOLQHPJG/
x
9DOXHRIQRQ+'/&DWEDVHOLQHPJG/
x
9DOXHRI5HPQDQW&KROHVWHURODWEDVHOLQHPJG/A
x
/HYHORI5HPQDQW&KROHVWHURODWEDVHOLQHFDWHJRU\A PJG/
PJG/
x
9DOXHRI$SR%DWEDVHOLQHPJG/
x
9DOXHRI$1*37/DWEDVHOLQHPJG/
x
9DOXHRI$SR$DWEDVHOLQHPJG/
x
3DUWLFLSDWLQJLQ)XOO3.VXEVWXG\ <HV1R


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
3DUWLFLSDWLQJLQ05,3'))VXEJURXS <HV1R
x
&RQFRPLWDQW 6WDWLQ8VHKLJKLQWHQVLW\PRGHUDWHLQWHQVLW\ORZ
LQWHQVLW\QRQH
x
&RQFRPLWDQW$QWL3&6.,QKLELWRU8VH<HV1R
x
5HJXODU8VHRI$OFRKRO<HV1R
x
5HJXODU8VHRI7REDFFR<HV1R
A5HPQDQW&KROHVWHURO 7RWDOFKROHVWHURO± +'/& ± /'/&
/'/&XVLQJ)ULHGHZDOG IRUPXOD 0DUWLQ+RSNLQV PHWKRGRORJ\ DQG
XOWUDFHQWULIXJDWLRQZLOOEHVXPPDUL]HGVHSDUDWHO\
Medical History: 0HGLFDOKLVWRU\ZLOOEHFRGHGXVLQJ0HG'5$ YHUVLRQ
RUKLJKHU 0HGLFDO +LVWRULHVZLOOEHVXPPDUL]HGIRUWKH)$6 XVLQJV\VWHP
RUJDQFODVV62&DQGSUHIHUUHGWHUP37 6XEMHFWVZLWK$6&9'
$WKHURVFOHURWLFFDUGLRYDVFXODUGLVHDVHKLVWRU\ ZLOODOVREHVXPPDUL]HGZLWK
IUHTXHQFLHVDQGSURSRUWLRQV
Genotype: *HQRW\SHUHVXOWVZLOOEHVXPPDUL]HGIRUKLVWRULFUHVXOWVDQGQHZ
VDPSOHVFROOHFWHGDWYLVLW'D\ DW'%7UHDWPHQW3HULRG6XPPDULHVZLOOEH
SURYLGHGIRUWKHIROORZLQJ
x
3DUWLFLSDQWVZLWKPXWDWLRQV IRUWKHIROORZLQJJHQHV/3/OLSRSURWHLQ
OLSDVH*3' $32( *3,+%3 $SR& $SR$ /0) /'/5$32%
3&6./'/5$3/,3$$%&* $%&* <HV1R
x
3RVWKHSDULQ/3/DFWLYLW\QRUPDODEQRUPDO
x
3DUWLFLSDQWVZLWKDJHQRW\SHFRQVLVWHQWZLWK )DPLOLDO&K\ORPLFURQHPLD
6\QGURPH )&6 <HV1R
B.
Disposition and Population Inclusions
3DUWLFLSDQW GLVSRVLWLRQZLOOEHVXPPDUL]HG E\HDFK$52$1* GRVHOHYHO
WRJHWKHUZLWKDSRROHG$52$1* JURXSDQGHDFK SODFHERGRVHJURXS
WRJHWKHUZLWKDSRROHGSODFHERJURXS DVWKHQXPEHUDQGSHUFHQWDJHRI
SDWLHQWVZKRZHUH
x
6FUHHQHG
x
)DLOHGVFUHHQLQJWRJHWKHUZLWKUHDVRQIRUVFUHHQIDLOXUH
x
5DQGRPL]HG
x
&RPSOHWLQJWUHDWPHQW DW'%7UHDWPHQW3HULRG
x
'LVFRQWLQXHGWUHDWPHQWDW'%7UHDWPHQW3HULRG WRJHWKHUZLWKWKH
UHDVRQVIRUGLVFRQWLQXDWLRQ
x
&RPSOHWLQJ'%7UHDWPHQW3HULRG
x
'LVFRQWLQXHG VWXG\DW '%7UHDWPHQW3HULRG WRJHWKHUZLWKWKHUHDVRQV
IRUGLVFRQWLQXDWLRQ
x
(QWHULQJ2/(7UHDWPHQW3HULRG


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
&RPSOHWLQJWUHDWPHQWDW2/(7UHDWPHQW3HULRG
x
'LVFRQWLQXHGWUHDWPHQWDW2/(7UHDWPHQW3HULRGWRJHWKHUZLWKWKH
UHDVRQVIRUGLVFRQWLQXDWLRQ
x
&RPSOHWLQJ2/(7UHDWPHQW3HULRG
x
'LVFRQWLQXHG VWXG\DW 2/(7UHDWPHQW3HULRG WRJHWKHUZLWKWKH
UHDVRQVIRUGLVFRQWLQXDWLRQ
3DUWLFLSDQWVZKRZHUHLQHDFKDQDO\VLVSRSXODWLRQDQGZKRZHUH H[FOXGHG
IURPWKH336 DQGUHDVRQIRUH[FOXVLRQZLOOEHOLVWHGDQGVHSDUDWHO\
VXPPDUL]HGLQWKHGLVSRVLWLRQWDEOH
(QUROOPHQWDQGGLVSRVLWLRQZLOOEHOLVWHGE\ VWXG\SHULRG FRKRUWWUHDWPHQW DQG
SDUWLFLSDQW$OOHQUROOHGSDUWLFLSDQWV ZLOOEHGLVSOD\HGLQDOLVWLQJWKDWLQFOXGHV
WKHSURWRFROYHUVLRQXQGHUZKLFKWKH\HQUROOHG WRHDFKVWXG\SHULRGDQG
ZKHWKHURUQRWDOOLQFOXVLRQH[FOXVLRQFULWHULDZHUHVDWLVILHG6FUHHQIDLOXUHV
DQG SDUWLFLSDQWV QRWUDQGRPL]HG ZLOODOVREHOLVWHG
C.
Protocol Deviations 
3URWRFROGHYLDWLRQOLVWLQJZLOOEHSUHVHQWHGE\SDUWLFLSDQW
D.
Visit Attendance and COVID-19 Impact Assessment 
'XHWRWKHRXWEUHDNRI&29,'SDQGHPLF&29,'UHODWHGYLVLW
DWWHQGDQFHDQGGLVSRVLWLRQHYHQWVZLOOEHVXPPDUL]HGIRUWKHIROORZLQJ
x
1XPEHURISDUWLFLSDQWV ZKRGLVFRQWLQXHGWUHDWPHQWIRUUHDVRQVUHODWHG
WR&29,'
x
1XPEHURISDUWLFLSDQWV ZKRGLVFRQWLQXHGVWXG\IRUUHDVRQVUHODWHGWR
&29,'
x
$WHDFKVFKHGXOHGYLVLWWKHQXPEHURISDUWLFLSDQWVDWWHQGLQJWKHYLVLW
IRURYHUDOODQGE\W\SHRIYLVLWFOLQLFUHPRWHDQGSHUIRUPHURIWKHYLVLW
VLWHVWDIIKRPHKHDOWK
x
$W HDFKVFKHGXOHGYLVLWQXPEHURISDUWLFLSDQWVZLWKYLVLWVPLVVHGIRU
UHDVRQVUHODWHGWR&29,'
9,,
Efficacy Analyses 
$OOHIILFDF\DQDO\VHVZLOOEHSHUIRUPHGXVLQJ)$6 2YHUDOO '%7UHDWPHQW3HULRG
RU)$62/( 2/(7UHDWPHQW3HULRG3DUWLFLSDQWVZLOOEHDQDO\]HG DFFRUGLQJWR
WKHWUHDWPHQWDVVLJQHGDWUDQGRPL]DWLRQ IRUWKH'%7UHDWPHQW3HULRG
A.
Primary Efficacy Outcome Analysis
7KHSULPDU\DQDO\VLVRIWKHSULPDU\HQGSRLQWZLOOHYDOXDWHWKHGLIIHUHQFHLQ
PHDQVEHWZHHQHDFK$52$1* GRVHFRKRUWDQGSRROHGSODFHERFRKRUW


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
1.
Primary Estimand
7KHSULPDU\ HVWLPDQGRILQWHUHVWLV WKHGLIIHUHQFHLQPHDQVRISHUFHQWFKDQJH
IURPEDVHOLQHLQIDVWLQJ7*DW:HHNLQSRSXODWLRQRIDGXOWVZLWKPL[HG
G\VOLSLGHPLDUHJDUGOHVVRIWUHDWPHQWFRPSOLDQFHRU RWKHULQWHUFXUUHQWHYHQWV
SRVWEDVHOLQH GHILQHGE\WKHIROORZLQJDWWULEXWHV
Attribute
Description
7UHDWPHQW
$52$1* GRVHOHYHOV DQG PJYV
SODFHER
3RSXODWLRQ
3RSXODWLRQRIDGXOWVZLWKPL[HGG\VOLSLGHPLDDVGHILQHGE\
WKHLQFOXVLRQH[FOXVLRQFULWHULDLQWKHSURWRFRO
(QGSRLQW
)DVWLQJVHUXP7*DW:HHN
,QWHUFXUUHQW
HYHQWV
1RQFRPSOLDQFHZLWKWUHDWPHQWDQGXVHRISURKLELWHG
PHGLFDWLRQV
7KHRFFXUUHQFHRILQWHUFXUUHQWHYHQWVLVFRQVLGHUHG
LUUHOHYDQWLQGHILQLQJWUHDWPHQWHIIHFWWKHYDOXHVRIWKH
HQGSRLQWZLOOEHXVHGUHJDUGOHVVRIZKHWKHUVXEMHFW
H[SHULHQFHVDQLQWHUFXUUHQWHYHQW 7KLVFRUUHVSRQGVWRD
treatment policy strategy
3RSXODWLRQ
OHYHOVXPPDU\
'LIIHUHQFHLQWKHPHDQSHUFHQWFKDQJHIURPEDVHOLQHDW
:HHN
VHUXP7*DW:HHNFROOHFWHGXQGHUQRQIDVWLQJVWDWXVDVLQGLFDWHGE\
GLHWDU\DQG IDVWLQJIRUPZLOOEHFRQVLGHUHGDVPLVVLQJ
2.
Primary Efficacy Analysis
7KHȝ ȝ ȝ DQGȝ EHWKHSRSXODWLRQPHDQVRIWKHSHUFHQWFKDQJHIURP
EDVHOLQHDW:HHNLQIDVWLQJ7*OHYHOVXQGHUSRROHGSODFHER$52$1*
 PJPJ DQGPJGRVHOHYHOVUHVSHFWLYHO\
7KHQXOOK\SRWKHVLV++ + JLYHEHORZZLOOEHWHVWHGDJDLQVWWKH
DOWHUQDWLYHK\SRWKHVLV+$+$ +$
+ȝ ȝ YV+$ȝ ȝ
+ȝ ȝ YV+$ȝ ȝ
+ȝ ȝ YV+$ȝ ȝ
7KHSULPDU\DQDO\VLVZLOOEHSHUIRUPHGEDVHGRQDOOREVHUYHGFDVHV2&
IURPEDVHOLQHWKURXJK:HHN XVLQJDPL[HGPRGHOUHSHDWHGPHDVXUHV
0050 DSSURDFKZLWKWUHDWPHQWVWXG\YLVLWVWUDWLILFDWLRQIDFWRU OHYHORI
/'/& DW6FUHHQLQJ>PJG/YHUVXVPJG/@DQGEDVHOLQH7*
YDOXH LQFOXGHGDV PRGHOWHUPV$GGLWLRQDOFRYDULDWHVDJHVH[UDFHDQG
%0,DVGHVFULEHGLQ6HFWLRQ9)ZLOOEHLQFOXGHG DVDSSURSULDWH 7KHPRGHO


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
ZLOODOVRLQFOXGHWUHDWPHQWE\YLVLWDQGWUHDWPHQWE\EDVHOLQHLQWHUDFWLRQ WHUPV
$QXQVWUXFWXUHG81FRYDULDQFHVWUXFWXUHZLOOEHDSSOLHGIRU0050,QFDVH
WKHPRGHOZLOOQRWFRQYHUJHZLWKWKH81FRYDULDQFHVWUXFWXUHWKHDSSURSULDWH
FRYDULDQFHVWUXFWXUHZLOOEHXVHGLQVWHDG VXFKDVWKH7RHSOLW]DQG$5
FRYDULDQFHVWUXFWXUHV
,IWKHUHDUHFRQYHUJHQFHRUHVWLPDWLRQLVVXHVGXHWRWKHQXPEHURI
SDUWLFLSDQWVDWFHUWDLQFRYDULDWHOHYHOVHJUDFHWKHQWKDWFRYDULDWHPD\EH
SRROHGRUUHPRYHGIURPWKHPRGHO$GGLWLRQDOFRYDULDWHVRUIDFWRUVPD\EH
UHPRYHGLIWKHUHDUHVWLOOLVVXHV HJVWURQJFROOLQHDULW\
&RQWUDVWVZLOOEHFRQVWUXFWHGWRFRPSDUHHDFKRIWKHWKUHH$52$1*
WUHDWPHQWJURXSVWRWKHSODFHERJURXSDWHDFKYLVLW7KHOHDVWVTXDUHV/6
PHDQ SHUFHQW FKDQJHIURPEDVHOLQHZLWKWKHDVVRFLDWHGVWDQGDUGHUURUVZLOO
EHGLVSOD\HGIRUHDFKWUHDWPHQWJURXS(VWLPDWHGWUHDWPHQWGLIIHUHQFHV
$52$1*YV 3ODFHERDORQJZLWKFRUUHVSRQGLQJWZRVLGHG &,VDQGS
YDOXHVZLOODOVREHSUHVHQWHG IRU:HHN
:KHQSHUIRUPLQJWKH SULPDU\DQDO\VLVDIDPLO\ZLVHHUURUUDWHZLOOEH
FRQWUROOHG DWDOSKD  7KHDGMXVWPHQW IRU PXOWLSOLFLW\RIWHVWLQJPXOWLSOH
DUPV $52$1*PJPJPJ YHUVXVSODFHERZLOOEH FDUULHGRXW
XVLQJ+ROP¶VVWHSGRZQSURFHGXUH
6XSSRUWLYHDQDO\VHVZLOOEHSHUIRUPHGIRU336SRSXODWLRQLQDVLPLODUPDQQHU
WRWKHSULPDU\HIILFDF\DQDO\VLVXVLQJ0050DSSURDFK
1RDGMXVWPHQWVIRUPXOWLSOLFLW\ZLOOEHFRQVLGHUHGIRU DQ\ RWKHUHIILFDF\
DQDO\VHV
&KDQJHIURPEDVHOLQH DQGSHUFHQWFKDQJHIURPEDVHOLQH LQIDVWLQJ7*ZLOO
DOVREHSORWWHGE\YLVLW
3.
Sensitivity Analyses Using Multiple Imputation (MI)
7KHSULPDU\DQDO\VLVRI0050XVLQJ2&RIWKHGDWDLVEDVHGRQWKH
DVVXPSWLRQRIPLVVLQJDWUDQGRP0$5DQGWKDWSDUWLFLSDQWVZKRGURSRXW
ZRXOGEHKDYHVLPLODUO\WRWKRVHLQWKHVDPHWUHDWPHQWJURXSZKRGRQRW
0XOWLSOHLPSXWDWLRQ0,EDVHG VHQVLWLYLW\DQDO\VHVPD\EHSHUIRUPHG ZKHQ
WKHDPRXQWRIPLVVLQJGDWDIRUWKHSULPDU\HQGSRLQWDWDQ\YLVLWLVGHHPHG
VXEVWDQWLDOHJH[FHHGLQJDWHQWDWLYHWKUHVKROGRI  7KHVHQVLWLYLW\
DQDO\VHVZLOO DVVHVVWKHUREXVWQHVVRI WKHSULPDU\DQDO\VLVFRQVLGHULQJWKH
GDWDDV PLVVLQJQRWDWUDQGRP01$5XVLQJWKH0,SURFHGXUHLQ6$6
7ZR0,DQDO\VHVZLOOEHSHUIRUPHGDVIROORZV
5HIHUHQFHGSODFHEREDVHGPXOWLSOH LPSXWDWLRQ


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
 ,QWHUPLWWHQWPLVVLQJYDOXHVZLOOEHLPSXWHGXVLQJWKH0DUNRY&KDLQ
0RQWH&DUOR 0&0&PHWKRGRORJ\ZKLFKDVVXPHVDPXOWLYDULDWH
QRUPDOGLVWULEXWLRQRYHUDOOYDULDEOHVLQFOXGHGLQWKHLPSXWDWLRQPRGHO
 LPSXWHGGDWDVHWV ZLWKPRQRWRQHPLVVLQJSDWWHUQZLOOEHJHQHUDWHG
7KHYDULDEOHVWREHXVHGLQWKHLPSXWDWLRQPRGHODUHWUHDWPHQW
EDVHOLQH 7* YDOXHV EDVHOLQHQRQ+'/& YDOXHVEDVHOLQH+'/&
YDOXHVEDVHOLQH/'/& YDOXHV DQG7*YDOXHVREVHUYHGDWSRVW
EDVHOLQH YLVLWV
proc mi data = indata out = mono nimpute = 100 seed = &seed;
var trt01pn basetgc basenh baseh basel base w4 w8 w12 w16 w20 
w24;
mcmc impute = monotone;
run;
 7KHQDOOWKHPRQRWRQHPLVVLQJYDOXHVZLOOEHPXOWLSO\LPSXWHGXVLQJ
WKHLPSXWDWLRQPRGHOEXLOWIURPWKHFRQWUROJURXSLHDVVXPLQJWKH
PLVVLQJGDWDLQWKHWUHDWPHQWJURXSV ZLOOKDYHDSURILOHWKDWHTXDOVWKH
SURILOHRIWKHFRQWUROJURXSIRUDOOWLPHSRLQWV7KHPLVVLQJGDWD
LPSXWDWLRQZLOOEHLPSOHPHQWHGXVLQJ352&0,LQ6$6ZLWKWKH
01$5VWDWHPHQW
proc mi data= mono seed=&seed nimpute=1 out= outdata;
by
imputation ;
class trt01pn basetgc;
monotone reg(/details);
mnar model(base w4 w8 w12 w16 w20 w24/ 
modelobs=(trt01pn='0'));
var basetgc basenh baseh basel base w4 w8 w12 w16 w20 w24;
run;
1RWHtrt01pn='0' LQGLFDWHVSODFHERVXEMHFWV
2QFHWKHFRPSHWHGGDWDVHWVDUHIRUPHGWKHVDPH0050DQDO\VLVPRGHODV
VSHFLILHGIRUWKHSULPDU\DQDO\VLVZLOOEHDSSOLHGWRHDFKFRPSOHWHGVHWDQG
LQIHUHQFHGUDZQ XVLQJ352&0,$1$/<=(
0XOWLSOH LPSXWDWLRQ ZLWKWLSSLQJSRLQWDSSURDFK
$WLSSLQJSRLQWDQDO\VLVZLOOEHSHUIRUPHGWRLQYHVWLJDWHWKHUREXVWQHVVRI
GHSDUWXUHVIURPWKH0$5DVVXPSWLRQLQWKH0,PRGHOE\DSSO\LQJDVSHFLILHG
VHTXHQFHRI VKLIWSDUDPHWHUVWKDWPRGLI\WKHLPSXWHG7* YDOXHVDVIROORZV
 0LVVLQJYDOXHVZLOOEHLPSXWHGXVLQJWKH0&0&PHWKRGRORJ\
³FRPSOHWH´GDWDVHWVZLOOEHJHQHUDWHG7KHYDULDEOHVWREHXVHGLQWKH
LPSXWDWLRQPRGHODUHWUHDWPHQWEDVHOLQH7*YDOXHVEDVHOLQHQRQ
+'/&YDOXHVEDVHOLQH+'/&YDOXHVEDVHOLQH/'/&YDOXHVDQG7*
YDOXHVREVHUYHGDWSRVWEDVHOLQHYLVLWV
proc mi data = indata out = mcmc nimpute = 100 seed = &seed;


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
var trt01pn basetgc basenh baseh basel base w4 w8 w12 w16 w20 
w24;
mcmc;
run;
 )RUHDFKRIWKHFRPSOHWHGGDWDVHWVDSSO\DVKLIWSDUDPHWHU6 LQ
WKH$52$1* JURXSVRQO\$SRVLWLYHDGMXVWPHQWDVVXPHVD
ZRUVHQHGRXWFRPH IRUWKHLPSXWHGYDOXHVLQWKH$52$1* JURXSV
7KH01$5VWDWHPHQWZLWKWKH$'-867RSWLRQLQ352&0,ZLOOEH
XVHGWRDSSO\WKHVKLIWSDUDPHWHU
 (DFKRIWKHFRPSOHWHGGDWDVHWVDSSO\LQJWKHVKLIWSDUDPHWHUZLOO
EHDQDO\]HGXVLQJDQ0050DQDO\VLVDVGHVFULEHGDERYH
 7KHUHVXOWVRIWKHFRPSOHWHGGDWDVHWVZLOOEHFRPELQHGIRU
LQIHUHQFHXVLQJ352&0,$1$/<=(
 5HSHDW6WHSVZLWKDGMXVWPHQWE\DGLIIHUHQWVKLIWSDUDPHWHUWRWKH
LPSXWHG7*YDOXHVLQWKH$52$1* JURXSVRQO\DVIROORZV6  
QRVKLIW«DQGPJG/
 7KHVKLIWSDUDPHWHUWKDWUHVXOWLQDUHYHUVHGVWXG\FRQFOXVLRQLHS
YDOXHLQFUHDVHVIURPWRıZLOOEHIODJJHG
 $OWHUQDWHVHULHVRIVKLIWSDUDPHWHUVPD\EHDSSOLHGEDVHGRQWKHDFWXDO
GDWD $OWHUQDWHWLSSLQJDSSURDFKPD\EHH[SORUHGEDVHGRQ WKHDFWXDO
GDWDHJDSSO\LQJVKLIWSDUDPHWHUVWRWKHSODFHERJURXSLQDGGLWLRQWR
DSSO\LQJWKRVHWRWKH$52$1* JURXSV
$SUHVSHFLILHGVHHGQXPEHURI ZLOOEHXVHGLQDOOLPSXWDWLRQ
SURFHGXUHVDVGHVFULEHGDERYH$OWHUQDWLYHPRGHOVSHFLILFDWLRQVPD\EHXVHG
EDVHGRQWKHDFWXDOGDWDLIWKHUHLVDQLVVXHLQPRGHOFRQYHUJHQFH
B.
Secondary Efficacy Outcome Analyses
'% 7UHDWPHQW3HULRG
7KHIROORZLQJ FRQWLQXRXVVHFRQGDU\HQGSRLQWVZLOOEHDQDO\]HG LQDVLPLODU
PDQQHUWRWKHSULPDU\ HQGSRLQW XVLQJ0050 DSSURDFK
x
3HUFHQWFKDQJHIURPEDVHOLQHLQIDVWLQJ7*RYHUWLPHWKURXJK:HHN
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJQRQ+'/&
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJWRWDO DSROLSRSURWHLQ$SR%
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJ /'/&


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQDQJLRSRLHWLQOLNHSURWHLQ$1*37/
x
3HUFHQWFKDQJHIURPEDVHOLQHDW:HHNDQGRYHUWLPHWKURXJK:HHN
 LQIDVWLQJ+'/&
/'/&XVLQJ)ULHGHZDOG IRUPXOD 0DUWLQ+RSNLQVPHWKRGRORJ\DQG
XOWUDFHQWULIXJDWLRQZLOOEHVXPPDUL]HGVHSDUDWHO\
7KH 0050 PRGHOZLOOEHEDVHGRQ2&RIWKHGDWDIURPEDVHOLQHWKURXJK
:HHN LQFOXGLQJ WUHDWPHQWVWXG\YLVLWVWUDWLILFDWLRQIDFWRUDQGWKH
FRUUHVSRQGLQJEDVHOLQHOHYHO$GGLWLRQDOFRYDULDWHVDVGHVFULEHGLQ6HFWLRQ
9)ZLOOEHLQFOXGHGDVDSSURSULDWH7KHPRGHOZLOODOVRLQFOXGHWUHDWPHQWE\
YLVLWDQGWUHDWPHQWE\EDVHOLQHLQWHUDFWLRQ WHUPV7KH/6PHDQFKDQJHIURP
EDVHOLQHZLWKWKHDVVRFLDWHGVWDQGDUGHUURUVZLOOEHGLVSOD\HGIRUHDFK
WUHDWPHQWJURXS(VWLPDWHGWUHDWPHQWGLIIHUHQFHV$52$1*YV 3ODFHER
DORQJZLWKFRUUHVSRQGLQJWZRVLGHG &,VDQGSYDOXHVZLOODOVREH
SUHVHQWHGDWHDFKSRVWEDVHOLQHWLPHSRLQW ZHHNV DQG

6XSSRUWLYHDQDO\VHVZLOOEHSHUIRUPHGIRU336SRSXODWLRQ IRUDOOVHFRQGDU\
HQGSRLQWVXVLQJ0050DSSURDFK
'HVFULSWLYHVXPPDU\VWDWLVWLFVIRUVHFRQGDU\YDULDEOHVZLOOEHSURYLGHGE\
WUHDWPHQWDQGYLVLW 6HFRQGDU\HIILFDF\HQGSRLQWVZLOODOVREHSORWWHGE\YLVLW
2/(7UHDWPHQW3HULRG
'HVFULSWLYHVXPPDU\VWDWLVWLFVZLOOEHSURYLGHGIRUWKHIROORZLQJFRQWLQXRXV
VHFRQGDU\HQGSRLQWVE\WUHDWPHQWDQGYLVLW 3ORWVZLOODOVREHSURYLGHG
x
3HUFHQWFKDQJHIURPEDVHOLQHLQIDVWLQJ7*QRQ+'/&WRWDO
DSROLSRSURWHLQ$SR%/'/&$1*37/DQG+'/&DWDOOYLVLWV
/'/&XVLQJ)ULHGHZDOG IRUPXOD0DUWLQ+RSNLQVPHWKRGRORJ\DQG
XOWUDFHQWULIXJDWLRQZLOOEHVXPPDUL]HGVHSDUDWHO\
C.
Exploratory Efficacy Outcome Analyses
'%7UHDWPHQW3HULRG
)RUWKHDQDO\VLVRIH[SORUDWRU\HQGSRLQWVGHVFULSWLYHVXPPDULHVZLOOEH
SURYLGHG E\WUHDWPHQWDQGYLVLWDVDSSOLFDEOH DQGDQ\LQIHUHQWLDOVWDWLVWLFVLH
SYDOXHVZLOOEHFRQVLGHUHGRQO\DVH[SORUDWRU\ 7KHIROORZLQJ HQGSRLQWVZLOO
EHDQDO\]HG LQDVLPLODUPDQQHUWRWKHSULPDU\ HQGSRLQW XVLQJ0050
x
&KDQJH DQGRUSHUFHQWFKDQJH IURPEDVHOLQHRYHUWLPHLQRWKHUIDVWLQJ
OLSLGSDUDPHWHUVWRWDOFKROHVWHURO/'/+'/UDWLRYHU\ORZGHQVLW\
OLSRSURWHLQFKROHVWHURO>9/'/&@$SR%OLSRSURWHLQ>/3@D$SR%
$SR&,,,$SR&,,$SR$,$SR$9DQG$SR$


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
x
&KDQJHIURPEDVHOLQHWR:HHNDQGRYHUWLPHWKURXJK:HHNLQ
IDVWLQJVHUXPEORRGJOXFRVH+E$&KRPHRVWDWLFPRGHODVVHVVPHQW
IRULQVXOLQUHVLVWDQFH+20$,5DQG&SHSWLGH
7KHH[SORUDWRU\HQGSRLQWRISURSRUWLRQRISDUWLFLSDQWVUHTXLULQJHPHUJHQW
DSKHUHVLVRYHUWLPHGXULQJWKHGRXEOHEOLQGVWXG\SHULRGZLOOEH VXPPDUL]HG
E\WUHDWPHQWDUPV&KLVTXDUHWHVWZLOOEHXVHGIRUWKHDQDO\VLV2GGVUDWLR
$52$1*YV3ODFHERDORQJZLWKFRUUHVSRQGLQJWZRVLGHG&,VDQG
SYDOXHVZLOODOVREHSUHVHQWHG
7KHIROORZLQJZLOOEHDQDO\]HGEDVHGRQWKH05,3',))$QDO\VLV6HW XVLQJDQ
DQDO\VLVRIFRYDULDQFH$1&29$PRGHOLQFOXGLQJWUHDWPHQWVWUDWLILFDWLRQ
IDFWRUDQGEDVHOLQHOHYHO DVFRYDULDWH
x
&KDQJH DQGRU SHUFHQWFKDQJH IURPEDVHOLQHWR:HHNLQOLYHUIDW
FRQWHQWXVLQJPDJQHWLFUHVRQDQFHLPDJLQJSURWRQGHQVLW\IDWIUDFWLRQ
05,3')) RQO\ LQ SDUWLFLSDQWV ZLWK D OLYHU IDW IUDFWLRQ RI  DW
6FUHHQLQJ
7KH/6PHDQHVWLPDWHVIRUHDFKWUHDWPHQWDUPZLOOEHGLVSOD\HGWRJHWKHUZLWK
VWDQGDUGHUURUVDQGWKHLUFRUUHVSRQGLQJ&,V7UHDWPHQWGLIIHUHQFHVZLWK
&,VZLOODOVREHSURGXFHG
([SORUDWRU\HIILFDF\HQGSRLQWVZLOODOVREHSORWWHGE\YLVLW
2/(7UHDWPHQW3HULRG
)RUWKHDQDO\VLVRIH[SORUDWRU\HQGSRLQWVGHVFULSWLYHVXPPDULHVZLOOEH
SURYLGHG E\WUHDWPHQWDQGYLVLW
x
&KDQJH DQGRUSHUFHQWFKDQJH IURPEDVHOLQHRYHUWLPHLQRWKHUIDVWLQJ
OLSLGSDUDPHWHUVWRWDOFKROHVWHURO/'/+'/UDWLRYHU\ORZGHQVLW\
OLSRSURWHLQFKROHVWHURO>9/'/&@$SR%OLSRSURWHLQ>/3@D$SR%
$SR&,,,$SR&,,$SR$,$SR$9DQG$SR$
x
&KDQJH DQGRUSHUFHQWFKDQJH IURPEDVHOLQHRYHUWLPHLQIDVWLQJ
VHUXPEORRGJOXFRVH+E$&KRPHRVWDWLFPRGHODVVHVVPHQWIRU
LQVXOLQUHVLVWDQFH+20$,5DQG&SHSWLGH
([SORUDWRU\HIILFDF\HQGSRLQWVZLOO DOVREHSORWWHGE\YLVLW
D.
Efficacy Analysis on Subgroups of Participants
6XPPDU\VWDWLVWLFVZLOOEHSUHVHQWHGIRUWKHSULPDU\HIILFDF\HQGSRLQW LQHDFK
VXEJURXSE\WUHDWPHQWDUP 7KHVDPH0050DQDO\VLVDVGHVFULEHGIRUWKH
SULPDU\DQDO\VLVZLOOEHDSSOLHGLQHDFKVXEJURXS
'HWDLOVRIVXEJURXSLQJDUHGHVFULEHGLQ6HFWLRQ90


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
9,,, Safety Analyses
6DIHW\DQDO\VHVZLOOXVHGDWDIURPWKH6DIHW\$QDO\VLV6HW LIDQDO\]LQJWKHZKROH
VWXG\RU'%7UHDWPHQW3HULRG DQG)$6 2/( LIDQDO\]LQJ2/(7UHDWPHQW3HULRG
A.
Exposure and Compliance
6WXG\GUXJDGPLQLVWUDWLRQ GDWDZLOOEHOLVWHGE\SDUWLFLSDQW 7KHQXPEHUDQG
SHUFHQWDJHRISDUWLFLSDQWVZLOOEHVXPPDUL]HGE\QXPEHURIGRVHVRIWKH
VWXG\GUXJUHFHLYHGWUHDWPHQWDUPDQGVWXG\SHULRG3DUWLFLSDQWVQRW
UHFHLYLQJSODQQHGYROXPH ZLOODOVREHVXPPDUL]HGDWHDFKYLVLWIRURYHUDOO
DQGE\UHDVRQ$(GRVLQJHUURURWKHU
%HFDXVHVWXG\GUXJZLOOEHDGPLQLVWHUHGVXEFXWDQHRXVO\ WRWKHSDUWLFLSDQWVLQ
DFFRUGDQFHZLWKWKHSURWRFROFRPSOLDQFHZLOOQRWEHDVVHVVHG
'LHWDU\FRXQVHOOLQJDQGIDVWLQJVWDWXVGDWDZLOOEHVXPPDUL]HGDWHDFKYLVLW
IRU
x
3DUWLFLSDQWVZKRKDYHPDLQWDLQHGDVWDEOHGLHW<HV1R
x
3DUWLFLSDQWVZKRKDYHEHHQRQDVWDEOHGRVLQJUHJLPHQIRUDSSOLFDEOH
&0<HV1R
B.
Adverse Events
$(WHUPVZLOOEHFRGHGXVLQJWKH0HG'5$GLFWLRQDU\YHUVLRQ  RUKLJKHU$
WUHDWPHQWHPHUJHQW$(7($(LVGHILQHGDVDQ$(WKDWRFFXUV IROORZLQJ
LQYHVWLJDWLRQDOSURGXFW,3DGPLQLVWUDWLRQRUDSUHH[LVWLQJFRQGLWLRQ
H[DFHUEDWHGIROORZLQJ,3DGPLQLVWUDWLRQ )XUWKHU7($(VZLOOEHFDWHJRUL]HG
E\VWXG\ SHULRG'%7UHDWPHQW3HULRG 2/(7UHDWPHQW3HULRG DVIROORZV
x
7($(VWKDWRFFXUEHIRUHWKHILUVW DGPLQLVWUDWLRQRI,3LQWKH2/(
7UHDWPHQW3HULRG2/('D\DUHFRQVLGHUHGWREHLQWKH'%
7UHDWPHQW3HULRG
x
7($(VWKDWRFFXU RUH[DFHUEDWH DIWHU WKHILUVWDGPLQLVWUDWLRQRI,3LQWKH
2/(7UHDWPHQW3HULRGDUHWREHLQWKH2/(7UHDWPHQW3HULRG
7KHVHYHULW\RIDOO$(VZLOOEHJUDGHGXVLQJWKHODWHVW YHUVLRQRI WKH1DWLRQDO
&DQFHU,QVWLWXWH&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(
YHUVLRQ ,IDQ$(FDQQRWEHJUDGHGXVLQJWKH&7&$(FULWHULDLWVKRXOGEH
JUDGHGDVPLOGPRGHUDWH VHYHUHOLIHWKUHDWHQLQJRUGHDWK
,IUHODWLRQVKLSWRWUHDWPHQWLVPLVVLQJWKHHYHQWZLOOEHFRQVHUYDWLYHO\WUHDWHG
DVUHODWHGWRVWXG\GUXJ0LVVLQJVHYHULW\ZLOOEHVXPPDUL]HGDVVHSDUDWH
FDWHJRU\


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
$OO$(VZLOOEHOLVWHGE\ VWXG\SHULRG WUHDWPHQWDQGSDUWLFLSDQWGHWDLOLQJWKH
YHUEDWLPWHUPJLYHQE\WKHLQYHVWLJDWRUWKHSUHIHUUHGWHUP37V\VWHPRUJDQ
FODVV62&RQVHWGDWHDQGWLPHHQGGDWHDQGWLPHVHYHULW\JUDGH
RXWFRPHUHODWLRQVKLSWRVWXG\GUXJDFWLRQWDNHQZLWKVWXG\GUXJRWKHUDFWLRQ
WDNHQWRWUHDWWKHHYHQW DFXWHSDQFUHDWLWLVHYHQW VHULRXVQHVVDQGFULWHULDIRU
VHULRXVQHVV 6HULRXV$(V6$(V7($(VOHDGLQJWRVWXG\ GUXJ
GLVFRQWLQXDWLRQ7($(VUHODWHGWRVWXG\GUXJDQGORFDOLQMHFWLRQVLWHUHDFWLRQV
/,65ZLOODOVREHOLVWHGVHSDUDWHO\
$QRYHUDOO$(VXPPDU\ ZLOO EHSUHVHQWHGE\VWXG\SHULRGDQGRYHUDOO E\WKH
QXPEHUDQGSHUFHQWRISDWLHQWVZLWKWKHIROORZLQJ
x
$OO7($(V
x
7UHDWPHQWUHODWHG7($(V
x
6HULRXV7($(V
x
7($(VOHDGLQJWRVWXG\GUXJGLVFRQWLQXDWLRQ
x
'HDWKV
x
/,65
7KHIROORZLQJ$(VXPPDULHVZLOOEHSURGXFHGE\VWXG\SHULRGDQGRYHUDOO E\
62& DOSKDEHWLFDORUGHUDQG37 GHVFHQGLQJRUGHURIWKHRYHUDOOIUHTXHQF\
x
$OO7($(V
x
6HULRXV7($(V
x
7($(VOHDGLQJWRVWXG\GUXJGLVFRQWLQXDWLRQ
x
7UHDWPHQWUHODWHG7($(V
x
7($(VE\PD[LPXPVHYHULW\JUDGH
x
7($(VE\PD[LPXPUHODWLRQVKLSWRWKHVWXG\GUXJ
$WHDFKOHYHORIVXPPDUL]DWLRQDSDUWLFLSDQW ZLOOEHFRXQWHGRQFHLIKHVKH
UHSRUWHGRQHRUPRUHHYHQWV7KHVHYHULW\JUDGHDQGUHODWLRQVKLSWRVWXG\
GUXJZLOOEHVXPPDUL]HGLQDVLPLODUPDQQHU
Local injection site reactions (LISR)
/,65VZLOORQO\LQFOXGHHYHQWVWKDWVWDUWZLWKLQKRXUV RILQMHFWLRQDQGSHUVLVW
IRUDWOHDVWKRXUV SRVWLQMHFWLRQ (YHQWVZLWKRQVHWGDWHRQWKHGD\RI
LQMHFWLRQDQGPLVVLQJUHVROXWLRQGDWHZLOODOVREHLQFOXGHGLQWKHVXPPDU\
7KHIROORZLQJ0HG'5$37V GHWHUPLQHGE\WKH6SRQVRU¶VSKDUPDFRYLJLODQFH
SHUVRQQHOUHSUHVHQWWKHORFDOLQMHFWLRQVLWHUHDFWLRQ
,QMHFWLRQVLWHGLVFRPIRUW
,QMHFWLRQVLWHDEVFHVV
,QMHFWLRQVLWHGLVFRORUDWLRQ
,QMHFWLRQVLWHDEVFHVVVWHULOH


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
,QMHFWLRQVLWHHU\WKHPD
,QMHFWLRQVLWHDWURSK\
,QMHFWLRQVLWHLUULWDWLRQ
,QMHFWLRQVLWHFDOFLILFDWLRQ
,QMHFWLRQVLWHLQIODPPDWLRQ
,QMHFWLRQVLWHFHOOXOLWLV
,QMHFWLRQVLWHLQGXUDWLRQ
,QMHFWLRQVLWHGHUPDWLWLV
,QMHFWLRQVLWHSDLQW
,QMHFWLRQVLWHHURVLRQ
,QMHFWLRQVLWHHGHPD
,QMHFWLRQVLWHILEURVLV
,QMHFWLRQVLWHSUXULWXV
,QMHFWLRQVLWHLQGHQWDWLRQ
,QMHFWLRQVLWHUDVK
,QMHFWLRQVLWHQHFURVLV
,QMHFWLRQVLWHXUWLFDULD
,QMHFWLRQVLWHQRGXOH
,QMHFWLRQVLWHUHDFWLRQ
,QMHFWLRQVLWHXOFHU
,QMHFWLRQVLWHVZHOOLQJ
7KHQXPEHUDQGSHUFHQWDJHRISDUWLFLSDQWVUHSRUWLQJ/,65VDVZHOODVWKH
QXPEHURI/,65VZLOOEHVXPPDUL]HG E\ VWXG\SHULRG 37DQGPD[LPXP
VHYHULW\JUDGH7KHSHUFHQWDJHRILQMHFWLRQVOHDGLQJWR/,65ZLOOEH
VXPPDUL]HGDVIROORZV
$%ZKHUH$ QXPEHURILQMHFWLRQVZLWKD/,65DQG% WRWDO QXPEHURI
LQMHFWLRQVHDFKGRVHZLOOEHDGPLQLVWHUHGDVDVLQJOHLQMHFWLRQ
C.
Clinical Laboratory Results
/DERUDWRU\WHVWUHVXOWVKHPDWRORJ\FKHPLVWU\FRDJXODWLRQXULQDO\VLV
VHURORJ\ DQGDEQRUPDOODERUDWRU\YDOXHVZLOOEHSUHVHQWHGLQGDWDOLVWLQJV E\
SDUWLFLSDQW6XPPDULHVRIDFWXDOYDOXHV DQG FKDQJHVIURPEDVHOLQH LQWKH'%
7UHDWPHQW3HULRG ZLOOEHSUHVHQWHGE\ GRVHOHYHO DQG WKHSRROHG$52$1*
DQG SRROHGSODFHER JURXSIRU HDFKDVVHVVPHQWWLPHSRLQW EHJLQQLQJZLWKWKH
6FUHHQLQJ YLVLW7KHVDPHVXPPDULHVZLOODOVREHSUHVHQWHG IRUWKH2/(
7UHDWPHQW3HULRGZLWKEDVHOLQHGHILQHGERWKDVWKH2YHUDOO%DVHOLQHDQG2/(
%DVHOLQH
/DEVKLIWWDEOHVXVLQJWKH&7&$(JUDGLQJZLOOEHXVHGIRUVHOHFWHGDQDO\WHVRI
LQWHUHVWZKHQDSSOLFDEOHIRUHDFKVWXG\SHULRG
,QDGGLWLRQDOOLYHUIXQFWLRQWHVW/)7DEQRUPDOLWLHVZLOOEHDVVHVVHGE\WKH
LQFLGHQFHRYHUDOOE\VWXG\SHULRG DQGE\YLVLWVRIWKHIROORZLQJFDWHJRULHV
x
$/7RU$67!î8/1
x
$/7RU$67!î8/1
x
7RWDOELOLUXELQ!î8/1
x
$/7RU$67!î8/1DQG7RWDOELOLUXELQ!î8/1
x
$/7RU$67!î8/1DQG ,15!
D.
Vital Signs


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
9LWDOV6LJQVUHVXOWVV\VWROLFEORRGSUHVVXUH>6%3@GLDVWROLFEORRGSUHVVXUH
>'%3@SXOVHUDWHUHVSLUDWLRQUDWHDQGWHPSHUDWXUHDQGFKDQJHIURPEDVHOLQH
YDOXHVZLOOEHSUHVHQWHGLQGDWDOLVWLQJVE\VWXG\SHULRGDQGSDUWLFLSDQW
6XPPDULHVRIDFWXDOYDOXHV DQG FKDQJHVIURPEDVHOLQHIURPEDVHOLQH ZLOOEH
SUHVHQWHGE\VWXG\SHULRGWUHDWPHQWDQGYLVLWDWVFKHGXOHGWLPHSRLQW
E.
Electrocardiogram (ECG)
(&*SDUDPHWHUVKHDUWUDWH>+5@35554564747F)DQG47F%
LQWHUYDOVZLOOEHVXPPDUL]HGGHVFULSWLYHO\LQVXPPDU\WDEOHVDVDFWXDO DQG
FKDQJHIURPEDVHOLQH E\VWXG\SHULRGWUHDWPHQWDQGWLPHSRLQWV
(&*UHVXOWV+5355545647 47F) 47F%DQGFODVVLILFDWLRQRI
1RUPDOLW\$EQRUPDOLW\ZLWK&OLQLFDO6LJQLILFDQFHRU$EQRUPDOLW\ZLWKRXW
&OLQLFDO6LJQLILFDQFHZLOOEHSUHVHQWHGLQGDWDOLVWLQJV E\SDUWLFLSDQW
F.
Physical Examination
&OLQLFDOO\LPSRUWDQWDEQRUPDOSK\VLFDOH[DPLQDWLRQUHVXOWVZLOOEHUHFRUGHGDV
0+RU$(VDQGDQDO\]HGDFFRUGLQJO\
G. Prior and Concomitant Medications
3ULRUDQG&RQFRPLWDQW0HGLFDWLRQVZLOOEHFRGHGXVLQJWKH:RUOG+HDOWK
2UJDQL]DWLRQ'UXJ'LFWLRQDU\YHUVLRQ%*OREDO6HSWHPEHULQWRGUXJ
FODVV$QDWRPLFDO7KHUDSHXWLF&KHPLFDOOHYHODQG SUHIHUUHGWHUP
3ULRUPHGLFDWLRQVDUHGHILQHGDVPHGLFDWLRQVZLWKVWDUWDQGVWRSWLPHVSULRUWR
WKHWLPHRIVWXG\GUXJDGPLQLVWUDWLRQ
&RQFRPLWDQWPHGLFDWLRQVDUHGHILQHGDVPHGLFDWLRQVZLWKDVWDUWWLPHDWRU
DIWHUWKHWLPHRIVWXG\GUXJDGPLQLVWUDWLRQ RUPHGLFDWLRQVZLWKDVWDUWWLPH
SULRUWRVWXG\GUXJDGPLQLVWUDWLRQEXWFRQWLQXLQJDIWHUWUHDWPHQW
7KHQXPEHUDQGSHUFHQWDJHRISDUWLFLSDQWVZLWKSULRURUFRQFRPLWDQWZLOOEH
VXPPDUL]HG E\:+2''$QDWRPLFDO7KHUDSHXWLF&KHPLFDO$7&
FODVVLILFDWLRQDQG SUHIHUUHGWHUP37IRUHDFK$52$1*GRVH OHYHOD
SRROHGSODFHERJURXSDQGRYHUDOO7KHVXPPDU\WDEOHZLOOGLVSOD\FRXQWVDQG
SHUFHQWDJHVRISDUWLFLSDQWVZKRUHSRUWHGXVLQJDWOHDVW&0LQHDFK
UHSUHVHQWHGSKDUPDFRORJLFDO VXEJURXS
7KHGDWDZLOOEHOLVWHGE\ SDUWLFLSDQW
H.
Other Safety Analyses
Pregnancy and FSH Results:


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
)HPDOHSDUWLFLSDQWVRIFKLOGEHDULQJSRWHQWLDOZLOOKDYHXULQHSUHJQDQF\WHVWV
DWHDFK6FUHHQLQJ YLVLW66'D\EDVHOLQH GXULQJWKH:HHN'RXEOH
%OLQG7UHDWPHQW3HULRGDQGDWVXEVHTXHQWVWXG\YLVLWVSULRUWRGRVLQJ
WKURXJKRXWWKH VWXG\ DVLQGLFDWHGLQWKHVFKHGXOHRIDVVHVVPHQW7DEOHDQG
7DEOHRISURWRFRO
3UHJQDQF\DQG)6+WHVWUHVXOWVZLOOEHOLVWHGVHSDUDWHO\E\WUHDWPHQWDQG
YLVLWWLPHSRLQW
Substance use:
6XEVWDQFHXVHUHVXOWVFROOHFWHGDW6FUHHQLQJZLOOEHOLVWHG
,;
Immunogenicity (Anti-drug Antibodies) Analysis
$OOLPPXQRJHQLFLW\GDWDZLOOEHOLVWHGE\SDUWLFLSDQWIRU6DIHW\$QDO\VLV6HWZKLFK
KDVDWOHDVWRQH$'$GDWDUHSRUWHG
)RUHDFK VWXG\SHULRGIRUVXEMHFWVWKDWZHUH$'$QHJDWLYHDWEDVHOLQH 2YHUDOO
%DVHOLQH2/(%DVHOLQHWUHDWPHQWHPHUJHQW$'$LQFLGHQFHZLOOEHVXPPDUL]HG
QXPEHUDQGSHUFHQWRIVXEMHFWZLWK SRVLWLYH$'$DWHDFKWLPHSRLQWIRUHDFK
WUHDWPHQWJURXSSRROHGSODFHER DQGSRROHGWUHDWPHQW$OVRWKHWLWHUYDOXHVZLOO
EH VXPPDUL]HGGHVFULSWLYHO\IRUHDFKWLPHSRLQWE\WUHDWPHQWLIGDWDDYDLODEOH,I
$'$SRVLWLYHZHUHREVHUYHGDWEDVHOLQHWKHSRVWGRVHWLWHUYDOXHVZLOOEH
FRPSDUHGZLWKEDVHOLQHDQGSORWWHGYVWLPHSRLQWWRVHHLIDWUHDWPHQWERRVWHG
$'$KDSSHQLQJWRWKHVXEMHFW
,I DQ\$'$SRVLWLYHREVHUYHG GXULQJWKHVWXG\ VSDJKHWWLSORWVRILQGLYLGXDOSODVPD
FRQFHQWUDWLRQV YHUVXVDFWXDOWLPHZLOOEHSUHVHQWHGE\$'$FDWHJRU\IRUHDFK
WUHDWPHQWJURXSIRU3.DQDO\VLVVHW
;
Pharmacokinetics Analyses
)RUWKH3.DQDO\VLVVHWZKLFKLQFOXGHVIXOO3.DQDO\VLVVHWDQGVSDUVH3.
DQDO\VLVVHWDOOWKH3.FRQFHQWUDWLRQGDWDZLOOEHOLVWHG$OO3.GDWDPD\EHXVHG
IRU3RSXODWLRQ3.DQDO\VLVDQGRU3.3'DQDO\VLVODWHUZKLFKZLOOEHVXSSRUWHG
E\VHSDUDWHDQDO\VLVSODQDQGFRPELQHGZLWK3.DQG3'GDWDIURPRWKHUFOLQLFDO
VWXGLHV
)RU)XOO3.$QDO\VLVVHWWKH3.FRQFHQWUDWLRQGDWDZLOODOVREHVXPPDUL]HGDQG
SORWWHG
&RQFHQWUDWLRQVEHORZWKHOLPLWRITXDQWLILFDWLRQ%/4ZLOOEHVHWWR]HURIRU
VXPPDU\VWDWLVWLFV3ODVPD3.FRQFHQWUDWLRQV IRU$52$1* ZLOO EH VXPPDUL]HG
E\WUHDWPHQWGHVFULSWLYHO\LQFOXGLQJQDULWKPHWLFPHDQ6'PLQLPXPPHGLDQ


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
PD[LPXPFRHIILFLHQWRIYDULDWLRQ>&9@JHRPHWULFPHDQ*0DQGJHRPHWULF
&9
)RUHDFKGRVHPHDQSODVPDFRQFHQWUDWLRQV6'ZLOOEHSORWWHGRQDOLQHDUDQG
VHPLORJDULWKPLFVFDOHYHUVXVQRPLQDOWLPHSRLQWVE\WUHDWPHQW,QGLYLGXDOSODVPD
FRQFHQWUDWLRQVZLOOEHSORWWHGRQVHPLORJDULWKPLFVFDOHYHUVXVDFWXDOVDPSOLQJ
WLPHVE\WUHDWPHQW)RUHDFKWUHDWPHQWVSDJKHWWLSORWVRILQGLYLGXDOSODVPD
FRQFHQWUDWLRQVRQVHPLORJDULWKPLFVFDOHZLOODOVREHSUHVHQWHG$UHIHUHQFHOLQH
LQGLFDWLQJWKHORZHUOLPLWRITXDQWLILFDWLRQ//24ZLOOEHLQFOXGHGLQSORWVDV
DSSURSULDWH
7KHIROORZLQJ3.SDUDPHWHUVZLOOEHFDOFXODWHGXVLQJ1RQFRPSDUWPHQWDODQDO\VLV
1&$IRU)XOO3.$QDO\VLV6HWZKHQHYHUGDWDDSSOLFDEOH
$8&±
7KHDUHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPH
FXUYHIURPWKH]HURWRKRXUV
$8&ODVW
7KHDUHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPH
FXUYHIURP]HURWRWKHWLPHRIWKHODVWTXDQWLILDEOH
FRQFHQWUDWLRQ
&PD[
PD[LPXPREVHUYHGFRQFHQWUDWLRQ
7PD[
WLPHWRUHDFKPD[LPXPSODVPDFRQFHQWUDWLRQ
7
WHUPLQDOHOLPLQDWLRQKDOIOLIH
9])
DSSDUHQWYROXPHRIGLVWULEXWLRQGXULQJWHUPLQDOSKDVH
DIWHUH[WUDYDVFXODUGRVLQJ
&/)
DSSDUHQWV\VWHPLFFOHDUDQFHDIWHUH[WUDYDVFXODUGRVLQJ
$GGLWLRQDO3.3DUDPHWHUVPD\DOVREHFDOFXODWHGDVDSSURSULDWH
7KH6SRQVRU$+&OLQSKDUPZLOOSURYLGH1&$IRU)XOO3.$QDO\VLV6HWDQG
GHWDLOVDERXW1&$DUHLQ$SSHQGL[$
3ODVPD3.SDUDPHWHUVIRU$52$1* ZLOOEHOLVWHGDQGVXPPDUL]HGE\
WUHDWPHQWGHVFULSWLYHO\LQFOXGLQJQDULWKPHWLFPHDQ6'PLQLPXPPHGLDQ
PD[LPXPFRHIILFLHQWRIYDULDWLRQ>&9@JHRPHWULFPHDQ*0DQGJHRPHWULF
&9)RU7PD[RQO\QPLQLPXPPHGLDQDQGPD[LPXPZLOOEHUHSRUWHG
;,
References
*DXGHW'$OH[DQGHU9-%DNHU%)%ULVVRQ'7UHPEOD\.6LQJOHWRQ:HWDO
$QWLVHQVH ,QKLELWLRQRI$SROLSRSURWHLQ&,LLLQ3DWLHQWVZLWK +\SHUWULJO\FHULGHPLD
N Engl J Med 


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
+DUULVRQ6$%DVKLU05*X\&'=KRX50R\ODQ&$)ULDV-3HWDO
5HVPHWLURP0*/ IRUWKHWUHDWPHQWRIQRQDOFRKROLFVWHDWRKHSDWLWLVD
PXOWLFHQWUHUDQGRPLVHGGRXEOHEOLQG SODFHERFRQWUROOHGSKDVHWULDOLancet

6KDQNDU*$UNLQ6&RFHD/'HYDQDUD\DQ9.LUVKQHU6 .URPPLQJD$
4XDUPE\95LFKDUGV 66FKQHLGHU&.6XEUDPDQ\DP06ZDQVRQ69HUWKHO\L
'<LP6American Association of Pharmaceutical Scientists$VVHVVPHQWDQG
UHSRUWLQJRIWKHFOLQLFDOLPPXQRJHQLFLW\RI WKHUDSHXWLFSURWHLQVDQGSHSWLGHV
KDUPRQL]HGWHUPLQRORJ\DQGWDFWLFDOUHFRPPHQGDWLRQV$$36 -
-XOGRLV(SXE$SU30,'
30&,'30&
6WRQH1-5RELQVRQ-*/LFKWHQVWHLQ$+HWDO$&&$+$JXLGHOLQHRQWKH
WUHDWPHQWRIEORRGFKROHVWHUROWRUHGXFHDWKHURVFOHURWLFFDUGLRYDVFXODUULVNLQ
DGXOWVDUHSRUWRIWKH$PHULFDQ&ROOHJHRI&DUGLRORJ\$PHULFDQ+HDUW
$VVRFLDWLRQ7DVN)RUFHRQ3UDFWLFH*XLGHOLQHV>-@-RXUQDORIWKH$PHULFDQ
&ROOHJHRI&DUGLRORJ\3DUW%


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
;,,
Appendix
A.
Noncompartmental Pharmacokinetic Analysis
Handling Missing or Non-Quantifiable Data
)RU1RQFRPSDUWPHQWDODQDO\VLV1&$SODVPDFRQFHQWUDWLRQVEHORZWKHOLPLWRI
TXDQWLILFDWLRQ%/4ZLOOEHDVVLJQHGDYDOXHRI7KHIROORZLQJUXOHVDSSO\ZLWK
VSHFLDOVLWXDWLRQVGHILQHGEHORZ
x
,IDQHQWLUHFRQFHQWUDWLRQWLPHSURILOHLV%/4LWZLOOEHH[FOXGHGIURP3.
DQDO\VLV
x
:KHUHRUPRUHFRQVHFXWLYHFRQFHQWUDWLRQVDUH%/4DWWKHHQGRID
SURILOHWKHSURILOHZLOOEHGHHPHGWRKDYHWHUPLQDWHGDQG DQ\IXUWKHU
TXDQWLILDEOHFRQFHQWUDWLRQVZLOOEHVHWWRPLVVLQJIRUWKHFDOFXODWLRQRIWKH
3.SDUDPHWHUVXQOHVVWKH\DUHFRQVLGHUHGWREHDWUXHFKDUDFWHULVWLFRI
WKHSURILOHRIWKHGUXJ
x
,IDSUHGRVHSODVPDFRQFHQWUDWLRQLVPLVVLQJLWPD\EHVHWWR]HURE\
GHIDXOWIRUILUVWGRVHRQO\
x
,IDQHPEHGGHG%/4YDOXHLVFRQVLGHUHGDQRPDORXVZLWKLQWKH
FRQFHQWUDWLRQWLPHSURILOHWKLVYDOXHZLOOEHVHWDVPLVVLQJDQGH[FOXGHG
IURPWKHVXPPDU\VWDWLVWLFV
Pharmacokinetic Parameter Calculation 
6WDQGDUG3.SDUDPHWHUVZLOOEHGHWHUPLQHGZKHUHSRVVLEOHIURPWKHSODVPDDQG
XULQHFRQFHQWUDWLRQVRI$52$1* XVLQJQRQFRPSDUWPHQWDOPHWKRGV1&$LQ
YDOLGDWHGVRIWZDUHSURJUDP3KRHQL[:LQ1RQOLQ&HUWDUD86$,QFYHUVLRQ RU
KLJKHU
3KDUPDFRNLQHWLFDQDO\VLVZLOOEHFDUULHGRXWZKHUHSRVVLEOHXVLQJDFWXDOEORRG
VDPSOLQJWLPHVSRVWGRVH,IDQDFWXDOWLPHLVPLVVLQJWKHVDPSOHFRQFHQWUDWLRQ
UHVXOWZLOOEHWUHDWHGDVPLVVLQJXQOHVVWKHUHLVVFLHQWLILFMXVWLILFDWLRQWRLQFOXGHWKH
UHVXOWXVLQJWKHQRPLQDOWLPH
&PD[DQG WPD[ZLOOEHREWDLQHGGLUHFWO\IURPWKHFRQFHQWUDWLRQWLPHSURILOHV)RU
PXOWLSOHSHDNVWKHKLJKHVWSRVWGRVHFRQFHQWUDWLRQZLOOEHUHSRUWHGDV&PD[,Q
WKHFDVHWKDWPXOWLSOHSHDNVDUHRIHTXDOPDJQLWXGHWKHHDUOLHVWWPD[ZLOOEH
UHSRUWHG
$8&ZLOOEHHVWLPDWHGXVLQJWKHOLQHDUWUDSH]RLGDOUXOHIRULQFUHDVLQJ
FRQFHQWUDWLRQVDQGWKHORJWUDSH]RLGDOUXOHIRUGHFUHDVLQJFRQFHQWUDWLRQVLH
³OLQHDUXSORJGRZQ´WUDSH]RLGDOUXOHLQ3KRHQL[:LQ1RQOLQ


$UURZKHDG 3URWRFRO $52$1*
,49,$%LRWHFK&RQILGHQWLDO3URMHFW6=$
7HPSODWH1R 19$B73B&55HYLVLRQ
CONFIDENTIAL
7HPSODWH (IIHFWLYH'DWH$XJ
5HIHUHQFH623&5:3&5
3DJH RI
Criteria for Calculation and Reporting of Area Under the Concentration-time 
Curve
7KHPLQLPXPUHTXLUHPHQWIRUWKHFDOFXODWLRQRIDUHDXQGHUWKHFRQFHQWUDWLRQWLPH
FXUYH$8&ZLOOEHWKHLQFOXVLRQRIDWOHDVWFRQVHFXWLYHFRQFHQWUDWLRQVDERYH
WKHORZHUOLPLWRITXDQWLILFDWLRQ,IWKHUHDUHRQO\FRQVHFXWLYHFRQFHQWUDWLRQVDW
OHDVWVKRXOGIROORZ&PD[
Treatment of Outliers in Pharmacokinetic Analysis
,IDYDOXHLVFRQVLGHUHGWREHDQRPDORXVGXHWREHLQJLQFRQVLVWHQWZLWKWKH
H[SHFWHG3.SURILOHLWPD\EHDSSURSULDWHWRH[FOXGHWKHYDOXHIURPWKH3.
DQDO\VLV+RZHYHUWKHH[FOXVLRQRIDQ\GDWDPXVWKDYHVWURQJMXVWLILFDWLRQDQG
ZLOOEHGRFXPHQWHGLQWKH&65
$Q\TXDQWLILDEOHSUHGRVHFRQFHQWUDWLRQYDOXHEHIRUHWKHILUVWGRVHZLOOEH
FRQVLGHUHGDQRPDORXVDQGVHWWRPLVVLQJIRUWKH3.DQDO\VLV


Arrowhead Pharmaceuticals  
Confidential 
Page 1 of 2 
Protocol No.: AROANG3-2001 
Statisitcal Analysis Plan Summary of Changes Version 1 to Version 2 
 
STATISICAL ANALYSIS PLAN SUMMARY OF 
CHANGES VERSION 1 TO VERSION 2 
 
PROTOCOL 
NUMBER: 
AROANG3-2001 
STUDY TITLE: 
A Double-blind, Placebo-controlled Phase 2b Study to 
Evaluate the Efficacy and Safety of ARO-ANG3 in Adults 
with Mixed Dyslipidemia 
 
 
 
 
− Updated definition of “baseline” for TG value from “average” to “geometric mean” of 
Day 1 predose assessment and two fasting TG values collected during the screening 
period.  
− Clarified that the geometric mean of the two collection timepoints associated with Week 
24 and Week 36 will be used for the analysis.  Further clarified that for all other 
lipid/pharmacodynamic endpoints, the analysis will be based on the reported value for the 
Week 24 and Week 36 visit. 
− Clarified that non-calculable or missing values for LDL-C using Friedewald formula will 
be imputed with LDL-C using ultracentrifugation. 
− Clarified the definition of Full and Sparse PK analysis will align with study protocol 
definitions 
− Updated Baseline Characteristics to be presented in summary tables and listings as 
follows: 
− Added level of LDL-C baseline category of <70 mg/dL, 70-<100 mg/dL and ≥100 
mg/dL 
− Added value of Remnant Cholesterol at baseline  
− Added level of Remnant Cholesterol at baseline category of <39 mg/dL, ≥39 
mg/dL 
− Added value of ApoB at baseline 
− Added value of ANGPTL3 at baseline 
− Added value of ApoA1 at baseline 
− Added concomitant use of PCSK9 inhibitor: Yes, No 
− Removed level of LDL-C at screening and screening category of <100 mg/dL, 
≥100 mg/dL 
− Removed level of non-HDL-C at screening and screening category of <100 
mg/dL, ≥100 mg/dL 


Arrowhead Pharmaceuticals  
Confidential 
Page 2 of 2 
Protocol No.: AROANG3-2001 
Statisitcal Analysis Plan Summary of Changes Version 1 to Version 2 
− The Exploratory Efficacy Outcome Analyses section was updated to add the proportion 
of subjects requiring emergent apheresis during the double-blind treatment period. 
− Updated the analyses of clinical laboratory results, vital signs, and electrocardiogram by 
removing the percent change from baseline for the summaries. 
− The Pharmacokinetics Analyses section was updated to: 
− Include PK samples collected outside the sampling window in the PK parameters 
calculation. 
− Add the following PK parameters: 
− Terminal elimination half-life (T 1/2) 
− Apparent volume of distribution during terminal phase after extravascular 
dosing (Vz/F) 
− Apparent systemic clearance after extravascular dosing (CL/F)